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Introduction: Human Immunodeficiency Virus (HIV), Tuberculosis (TB) and malaria 
remain a major threat to the Ethiopian population. In the past decades, substantial gains 
have been achieved in reducing morbidity and mortality caused by HIV, TB and malaria 
diseases. Despite this progress, the coverage of essential health services for these 
diseases is far below the global targets. The health financing model in Ethiopia heavily 
relies on out-of-pocket (OOP) spending, which predisposes households to financial 
hardship. Therefore, high disease burden along with economic barriers have prohibitive 
consequences on accessing quality health services in the country. In addition, the 
allocation of scarce healthcare resources needs to be rationed appropriately to improve 
the health of the population in fair and efficient ways. Furthermore, in Ethiopia, like 
most low-income countries, apart from the health benefit of interventions to control 
major communicable diseases, the interventions’ importance in greater household 
economic returns, financial risk protection (FRP) and distributional consequences has 
not been fully recognised. Hence, evaluation of patient costs and benefits of the scale-
up of HIV, TB and malaria interventions through universal public financing on health, 
equity and FRP domains are essential for priority setting and resource allocation 
decisions in Ethiopia. 
Objectives: This thesis aims to provide evidence on the patient cost, health gains and 
financial risk protection of HIV, TB and malaria interventions across socio-economic 
groups in Ethiopia. 
Methods: This thesis comprises of three interrelated studies. In Paper-I, a nationwide 
household survey (for HIV) and a separate cross-sectional survey collected from health 
facilities selected from Oromia and Afar regions (for TB) was used to estimate the 
magnitude of patient costs, catastrophic health expenditure (CHE) and its determinants 
for households affected by these diseases. Patient costs and CHE were used as a primary 
outcome measure in Paper-I. In Paper-II, an Extended Cost-Effectiveness Analysis 
(ECEA) method was used to estimate the impact of the universal public finance of 
selected malaria interventions on health benefits and FRP domains across income 




the universal public finance of selected TB interventions on mortality and financial risk 
reduction across income groups over the period 2018-35. The main outcomes were death 
averted and CHE in Papers II and III, including private expenditure averted and net 
government costs for Paper-II. 
Results: The mean patient cost was $ 78 per year for HIV care and $ 115 per TB episode. 
Direct patient costs of HIV and TB account for 69% and 46% of the total costs, 
respectively. The overall incidence of CHE among HIV patients was 20% (43% for the 
poorest quintile and 4% for the richest quintile) and that of the TB household was 40% 
(ranging from 58% to 20%, between the poorest and richest income quintiles, 
respectively). The incidence of CHE is higher in patients with frequent healthcare visits, 
TB/HIV co-infection, drug-resistant TB and hospitalisation. Inequality in financial risk 
was present across the different income quintiles, where the lower quintile suffers most. 
Increasing coverage (by 10%) of artemisinin combination therapy (ACT), long-lasting 
insecticide-treated bed nets (LLIN), indoor residual spraying (IRS) and malaria vaccines 
among the population at risk would avert 358, 188, 107, and 38 malaria deaths per year 
in Ethiopia. The four malaria interventions would avert 440, 220, 125, and 18 cases of 
CHE, respectively. Similarly, among the four interventions, malaria treatment (ACT) 
averts approximately $4,277,000 in private expenditure. ACT and LLIN interventions 
were linked to the largest number of deaths and cases of CHE averted. Those people in 
the lowest income quintiles have the highest health and FRP benefits. For example, the 
poorest two quintiles accounted for almost half of the deaths averted, compared to one-
third in the richest two quintiles. The government cost of the ACT, LLIN, IRS and 
malaria vaccine interventions is $ 5.7, 16.5, 32.6, and 5.1 million, respectively. 
Implementing active TB case finding from 2018 to 2035 would lead to reductions of 
206,000 (27%) and 193,000 (32%) of the expected TB deaths and CHEs, respectively. 
Similarly, enhancing DOTS for drug-susceptible TB would avert 192,000 (25%) deaths 
and 93,000 (15%) CHEs; and improvements in MDR-TB care would avert up to 6,300 
(1%) and 33,000 (6%) deaths and CHEs, respectively. Both the health and financial risk 




Conclusion: In Ethiopia, spending on HIV and TB care imposes a major economic 
burden on households. Healthcare payments for HIV and TB care have adverse impact 
on equitable access to health services and place the population, especially the poorest, 
at considerable financial risk. The universal public financing of TB and malaria control 
interventions saves patient lives and brings higher FRP benefits, particularly among the 
poorest. Therefore, the Ethiopian Government needs to focus on the universal public 
finance of health intervention to reduce CHE, foster equity and protect households from 
the financial risks posed by these diseases. 
Keywords: HIV, tuberculosis, malaria, economic burden, equity, catastrophic health 
expenditures, financial risk protection, universal health coverage, extended cost-
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1. Introduction  
Globally, health-financing mechanisms include a mix of public (tax-based systems, 
health insurance funds and external funds) and private spending (mainly in a form of out 
of pocket payments), with major variation across countries. Most high-income and 
middle-income countries depend on the former two financing mechanisms and are 
important for FRP that ensures individuals receive health services without exposure to 
financial hardship. In low-income countries, however, such systems are often 
underdeveloped and many rely heavily on out-of-pocket payments, which can predispose 
households to an increased risk of financial hardship and health outcome disparities (1-
4). Hence, ill-health has substantial adverse economic consequences, and its assessment 
provides insight into the impact of diseases on household economy (5). 
Analysis of the economic burden of disease has grown in the last decades (5), though 
considerable gaps still remain. Many of the studies focused on describing disease burden 
at population level with limited disaggregated analysis by disease categories and 
subgroups. Important policy issues, such as the impact of ill health on medical and non-
medical consumptions; on productivity and CHE, are often not addressed in the current 
literature. Moreover, there is limited evidence of policies that reduce service coverage 
gaps and mitigate financial risks. Understanding the variation in economic burden across 
different disease categories and population subgroups is a growing concern for 
policymakers and researchers, which supports prioritising disease-specific health 
services according to the economic opportunities they offer (5-7). Infectious diseases 
such as human immunodeficiency virus (HIV), tuberculosis (TB) and malaria have a 
greater disease burden and economic impact relative to other chronic diseases and 
injuries (e.g. renal diseases, cancers and cardiovascular diseases) in low-income 
countries (6). In such settings, chronic infectious diseases account for the largest 
population with CHE (21.4 million), followed by renal (3.8 million), cardiovascular (0.4 
million) and endocrine (0.3 million) diseases (6). 
This thesis examines the magnitude of the household economic consequences of seeking 




financing of TB and malaria interventions in the domains of both health and non-health 
benefits. Such evidence is of high value for policymakers aiming to identify where the 
greatest gains can be made in mitigating financial risk in accessing healthcare (8, 9). In 
addition, the evidence is important in identifying effective policies that support decision-
makers in equitably allocating limited healthcare resources (5, 10).   
This thesis is structured into eight sections. The first section provides a brief overview 
and literature summary of key topics that include economic burden of HIV, TB and 
malaria (section 1.1), universal health coverage (section 1.2), priority setting (section 
1.3), health financing (section 1.4), a global overview of communicable diseases (section 
1.5), country context covering country profile, healthcare system, and overview of HIV, 
TB and malaria in Ethiopia (section 1.6). In section two, the general and specific 
objectives of this research are presented. Section three describes the overall methodology 
including study setting, methodological and analytical considerations in general, 
followed by detailed elaboration of the method used specifically in the three sub-studies. 
In section four, (sections 4.1-4.3), result of Papers I-III are summarised independently. 
The first result section (Paper-I) presents findings from a cross-sectional survey of HIV 
and TB patient cost, CHE and determinants. The next result section (Paper-II) presents 
the health and non-health benefits of the universal public finance of malaria 
interventions. The third result section (Paper-III) presents expected health and FRP 
benefits of the public financing of selected TB interventions. Section five starts with a 
synthesis of the main findings from the three Papers, followed by discussion with 
relevant literature and a summary of the limitations and strengths. Sections six and seven 
confer key conclusions and recommendations of the three studies. The final section 
(section eight) provides the list of references. 
1.1 Economic burden of HIV, TB and malaria 
HIV, TB and malaria have a profound impact on household earnings and the 
development of national economy, including a high human physical toll (1, 7, 11, 12). 
At the household level, the economic effects include the loss of savings and investments 




diseases drain national resources, adversely impacting investments in physical and 
human capital, which are vital for the economic growth of a country (as measured by, 
i.e., gross domestic product (GDP)) (5). The economic impact of these diseases on 
household can be measured using ‘direct costs’, the expenses related to seeking 
healthcare and ‘indirect costs’, the monetary value of lost time due to decreased 
productivity and health facility visits. Besides direct and indirect costs, these diseases 
impose intangible costs in the form of pain, suffering, other debilitating symptoms, social 
isolation, and death, which are less quantified in many studies. In contrast, these diseases 
are primarily evaluated at population level in terms of their impact on overall economic 
welfare (5). 
HIV, TB and malaria patients face immense pre- and post-diagnosis expenses and 
financial losses of varying degrees (1), despite substantial global and national 
investments in high burden countries and sub-Saharan Africa with policy goals of care 
“free-of-charge” or care at “affordable costs”. In several settings, a national “free-of-
charge” policy exempts only selected disease-specific interventions, including medicines 
and diagnostic tests and do not necessarily cover costs related to items, such as healthcare 
fees for pre-diagnostic services, ancillary medicines, imaging, adverse event monitoring, 
hospitalisation, and non-medical expenses that patients have to pay for (13-16). An 
economic modelling analysis in 106 malaria-endemic countries found that 13% of 
malaria expenditure comes from household payments, which was higher than the OOP 
spending share of HIV, at 4.7% in 2016 (17, 18). The direct cost of malaria care for 
patient was found to be within the range of 2-3% of household incomes, compared to 2-
6% for indirect payments (1). Likewise, 6.5% of total spending on HIV is OOP (18). 
However, the TB related OOP payment remains high and accounts for about 19% of the 
total TB spending in resource-constrained countries (i.e.135 low-income and middle-
income countries) (19). A systematic review found an average direct cost of $ 155 per 
drug-susceptible TB with a two-fold increase of indirect costs (20). However, many 
economic evaluations of HIV, TB and malaria do not fully capture the indirect patient 
and household costs in the form of lost income (1, 20). The indirect costs are a non-




households, although the extent differs across diseases (1, 11, 21). For example, persons 
with HIV and TB have been shown to face higher indirect costs than those with malaria 
due to longer courses of illness and the need for more repeated healthcare visits (1).   
The high direct and indirect care costs can lead to CHE. According to a widely used 
WHO definition, CHE occurs when healthcare costs exceed 10% to 25% of the annual 
household income or consumption (22). In several previous studies, total malaria patient 
cost is less than 10% of household annual income. Households suffer from malaria-
related CHE when a family member has complicated malaria requiring hospital 
admission, recurring episodes, or chronic health effects (e.g. neurological sequelae, 
anemia and death) (1, 6). Unlike malaria, the total costs of HIV and TB care for many 
households have been catastrophic, possibly due to the need for long-term care and loss 
of productive working days due to these diseases (11, 23-25). The adverse health shocks 
due to spending on healthcare affect the consumption of basic necessities such as food, 
housing and education (22). Households attempt to smooth out the consumption of non-
health goods and services using savings, loans, or asset sales. These coping strategies are 
not always sufficient to handle the economic shocks associated with these diseases and 
could potentially lead to the reduction of capital stocks and savings, which increase 
household vulnerability to future crises. Furthermore, because of high healthcare costs, 
households may be compelled to reduce the intake of non-health goods and services. In 
more extreme cases, spending on the care of these diseases may even further impoverish 
affected households by trapping them in the vicious cycle of ill-health and poverty. In 
addition, high patient costs can raise a particular concern as they correlate not only with 
household economic strain but also with deferring health facility visits unless severely 
ill (26).   
The economic consequences of spending on HIV, TB and malaria services are affected 
by various factors, and quantifying the relative importance of these factors informs the 
design of effective strategies to reduce financial risks. Unfortunately, few studies have 
provided adequate detail on factors related to the economic burden of these diseases. 




by the providers or requires hospital admission, resulting in high direct costs and loss of 
income in countries where people lack insurance (1, 6). A national survey of hospitalised 
malaria patients in Malawi revealed that each day spent in the hospital was associated 
with a 2% increase in household costs (27). More generally, households that have 
endured hospitalisation episodes use multiple coping strategies to protect their 
consumption compared to those without hospitalisation (7). Another factor influencing 
the level of household spending on HIV, TB and malaria related care is the baseline 
socio-economic status, where the poorest spend less on healthcare than the better-off. 
However, poor households typically pay a relatively higher proportion of their total 
income and at times can barely afford the services they need (10, 23, 28-30). Thus, the 
poor tend to face a greater financial burden than the better-off when seeking healthcare. 
For instance, diseases like TB and malaria trap the poorest in a cycle of sickness and 
economic hardship. In addition, the poor are more vulnerable to economic shocks caused 
by prohibitive healthcare costs and are more likely to fall into poverty or continue to sink 
into poverty while sick. As result, diseases are more likely to worsen income inequality 
and increase poverty by reducing the per capita income growth for individuals and 
households (6, 10, 28, 29). Therefore, investing in universal public finance of care for 
communicable diseases gives the poorest a better chance in life, breaking the spiral of 
sickness and poverty in order to build a sustainable life and share in the benefits of 
economic progress. 
In endemic countries, the economic impact of HIV, TB and malaria extends from 
households to affect the general population and national economies as a whole (5). The 
impact of these diseases takes place through several mechanisms. Where these diseases 
prevail, the morbidity and mortality burden often falls on children and adults of prime-
age (12). Loss of life from these diseases has a profound effect on population size and 
composition including childbirth. As a result, the diseases have been projected to reduce 
life expectancy in low-income countries by 1.45 years for HIV, 1.35 years for TB, and 
0.96 years for malaria (31). The high mortality rate also results in a marked loss of labour 
and productivity in the national economy. Furthermore, these diseases can divert 




in endemic countries, leading to slow growth of GDP over time (17-19). HIV is estimated 
to reduce national economic growth rates from nil to 2-4% each year (32) and for every 
10% rise in reported new TB cases, the country’s growth rate is estimated to decrease by 
0.2% to 0.4% (33). In malaria-endemic countries, after controlling for other variables, 
GDP grew by 0.25-1.3% less per year than in countries without malaria (34). In addition 
to economic growth and demographic changes, the macroeconomic impact of these 
diseases is expected to accumulate over time and will continue to have long-term 
consequences in the future. Nonetheless, the existing evidence on the macro-economic 
impacts of these diseases typically does not take into account the intimate overlaps 
between the diseases and the loss of social capital or the long-term harm to human 
capital, as children's intellectual development, health and nutrition go far beyond the 
period and scope of most macro-economic forecasts (5, 35).   
In general, the diseases burden and the financial hardship of infectious disease will 
continue to put tremendous pressure on the healthcare systems of low-income and 
middle-income countries (LMICs). This will require policy-makers to improve access to 
care and ensure FRP alongside broader poverty reduction strategies by formulating 
measures that accelerate universal health coverage (UHC) as part of a multi-pronged 
strategy (6). 
1.2 Universal health coverage   
“Universal health coverage ensures that all people receive the needed health services 
without being exposed to financial ruin” (2). UHC ensures people accessing ranges of 
comprehensive services, including prevention, promotion, treatment, rehabilitation and 
palliative care. Such range of services would progressively expand to reduce the unmet 
health needs, as no or few countries can afford to instantly finance a full set of services 
to all people (36, 37). UHC also requires countries to build their health systems in a way 
that guarantees equity, FRP and better health. The lack of physical access, poorly 
equipped health facilities and inadequate quality of care are among the main barriers to 
accessing essential health services in LMICs. Furthermore, socioeconomic factors have 




UHC encompasses different health system components, including service delivery, 
financing policy, information system, infrastructure, health workforce, drug supply 
management, and governance (2).   
The path to UHC is not straightforward; in every country, some systems are in place and 
each country needs to build on the existing systems to progress towards UHC (2, 36). 
However, to achieve the goal of UHC, each country needs to step forward in at least 
three distinct aspects : (a) the proportion of people covered by pooled funds (b) the range 
of available services (expands over time) through UHC policies and (c) the cost required 
from pooled funds to deliver health services (Figure 1) (2). As countries move along 
these dimensions, they will need to make critical policy choices in terms of 
maximisation of benefits, fairness and other concerns (36). These decisions involve 
trading among the fraction of the population reached, the range and types of services 
included, and the cost covered by the pooled funds in order to achieve 100% coverage 
in each dimension.  
 
Figure 1: Three-dimensional framework and critical choices in the path towards UHC. 
Source: The World Health Report 2010. 
UHC is among the priorities of the Sustainable Development Goal (SDG) and is the base 
of SDG 3. SDG 3.8 has two key indicators to track progress towards UHC, namely the 
essential health services coverage (SDG 3.8.1 indicator) and the percentage of 
individuals or households with CHE (SDG 3.8.2 indicator). Both indicators are intended 
to capture effective coverage and FRP dimension of progress towards UHC (38). In 




effective coverage and FRP, respectively, while the population axis is related to both. 
Monitoring financial risks along with access to essential services are very important on 
the path to UHC. In particular, a low incidence of CHE means that either people are 
successfully shielded from financial hardship or are not able to access health services at 
all (i.e. low service coverage). Conversely, even if the service is made available or 
delivered as a result of reforms, it should also be accessible and affordable to all in need 
of care. Hence, a combined analysis of both indicators would provide a more precise 
specification of UHC (4).  
The UHC Service Coverage Index (SCI) is a summary index derived from the coverage 
of 14 tracer indicators and is used to track country progress towards SDG 3.8.1. In 2017, 
close to half of the world’s population is covered by essential health services. This 
achievement is mainly attributed to the performance of the 14 tracer indicators, with the 
greatest contribution to this coverage coming from HIV, TB and malaria services. 
Nevertheless, the rate of progress is still slow for many services and unevenly distributed 
across socio-economic groups requiring the coverage of essential health services to 
double in order to meet UHC's SDG target by 2030. Globally, CHE has been increasingly 
rising and FRP is declining over time as tracked by indicator 3.8.2. Between 2000 and 
2015, the proportion of the world’s population with OOP exceeding 10% of household 
income increased from 9.4% to 12.7% (926.6 million people) and globally an estimated 
1.2% (89.7 million people) are pushed into extreme poverty. Policy implications of UHC 
progress differ across countries as there are large variations in terms of service coverage 
and FRP outcomes that require comprehensive reform of both service delivery and health 
financing systems for low-income countries; and enhancing efficiency, quality and 
equity gains for high-income and upper-middle-income countries (4).  
The Ethiopian Government has continued to develop important strategies to move 
towards UHC. The latest national revision of the essential health services package 
(EHSP) is one of these critical endeavours. The first EHSP was set up in 2005 and revised 
in 2019. The EHSP is not only aimed at ensuring equitable access to high-quality 




as a guiding framework to attain UHC for essential health services in the country. The 
EHSP proposes the types of services offered under the current health service delivery 
system that should be available to all Ethiopians, regardless of income, gender and place 
of residence. The EHSP is defined primarily based on disease burden in Ethiopia, in 
addition to six other relevant criteria (i.e. cost-effectiveness, budget impact, equity, 
public and political acceptability, and FRP). The prevention and control of 
communicable diseases was one of the main components of Ethiopia's EHSP and was 
deemed a high priority based on the above criteria. Thus, the effective implementation 
of the EHSP would strengthen access to affordable care and protection of financial risks 
related to HIV, TB and malaria services in the country from now on and in the future 
(39). For the realisation of the EHSP, a sustainable system of health financing through 
effective and efficient payment modalities is also necessary. In Ethiopia, the EHSP 
financing is organised in three different categories from the patient/client perspective 
and the financing arrangements are assigned on the basis of the priority level of 
intervention. The first category is that high-priority health services are offered with 
universal public finance (e.g. immunisation, malaria, family planning, childbirth services 
and TB at primary health care facilities). The second category includes medium-priority 
services that are financed based on cost-sharing mechanisms where direct OOP payments 
fund a proportion of the provider costs of these interventions. The third category is non-
essential health services provided on a full cost-recovery basis and such services were 
mostly provided in private healthcare settings. However, from the perspective of 
providers, a clear and sustainable funding system must be in place for all programmes 
that would allow health facilities to provide quality health services without financial 
limitations (39).  
The implementation of UHC policies in many developing countries represents an 
important opportunity to address or combat HIV, TB and malaria diseases. UHC ensures 
that all essential services for HIV, TB and malaria are accessible based on the needs of 
individuals, without exposing them to financial hardship, thus mitigating the 
transmission of these diseases. Furthermore, UHC has the potential to accelerate progress 




early access to high-quality HIV, TB and malaria services under UHC is essentially more 
cost-effective than providing low-quality and delayed diagnosis and care. For instance, 
every dollar spent on treating people with HIV, TB and malaria before complications or 
drug resistance occur are estimated to give $ 28, $ 43 and $ 36, respectively, in return 
(40). Even if UHC offers an opportunity to extend service coverage for communicable 
diseases, scarce healthcare resources and increasing population demands push countries 
into priority setting and a discussion about which services should be included in the 
Health Benefits Package (HBP) (36).   
The decision to select the best alternatives and the appropriate mix of interventions to be 
covered by UHC schemes in the light of limited healthcare resources requires appropriate 
and fair priority-setting criteria (for example, priority for services that provide good 
value for money, priority for the worse-off and priority for services providing FRP) that 
are decided through deliberative and consultative processes (36). 
1.3 Priority setting in health care  
Priority setting is an inevitable continuous exercise required at all levels (global, 
national, and local) of the health system and addresses the populations' most critical 
health needs by choosing the appropriate health policy among different alternatives. 
However, priority setting is a difficult and inherently political process that involves 
public debate and negotiation among multiple stakeholders, each with different views, 
values and interests as to who will or will not benefit from public resources and when. 
Effective priority setting addresses these varying views and interests through evidence 
and a transparent approach to determine health policies and services that are most 
appropriate. Priority setting also needs strong political commitment and financial support 
to accomplish its goals (41). 
Priority setting has three main components, namely fact, values and processes (42). Facts 
are mainly empirical evidence on the effectiveness of the intervention to be prioritised. 
Values are grounded in ethical principles and criteria (i.e. utilitarianism, egalitarianism 




related to employing a framework for a rational prioritization process. A systematic 
review indicated that a variety of processes exist in well-functioning health systems. 
Accountability for reasonableness is an ethical framework that focuses on the 
reasonableness of decision-making process, although the approach is not straightforward 
and replicable. Another multi-criteria decision analysis (MCDA) approach is a method 
that simultaneously assesses health policies or interventions in the health sector against 
various criteria. This exploratory analysis defines a range of relevant criteria, including 
both medical and non-medical, and weigh their relative importance in guiding priority 
setting. The method has been widely used in other areas, such as agriculture, energy, etc., 
and experience in other sectors has contributed to the acceptance of this approach for 
public health decision-making. For example, the MCDA is used to assist policy decisions 
in the implementation of a lung health programme in Nepal, and the programme is 
considered one of the priorities based on various relevant criteria (43). Programme 
budgeting and marginal analysis is another method of priority setting process that 
evaluates the costs and benefits of planned investment or disinvestment, using a 
transparent, replicable method and formal participation of stakeholders (panel of 
experts). The exercise has been applied for effective allocation of healthcare resources 
in high-income countries (44). This approach was used in North Wales UK to optimise 
resource allocation alternatives for respiratory care pathways and identified investment 
opportunities such as the management of pharmaceutical wastes and pulmonary 
rehabilitation and disinvestment areas including mucolytic and prescription of high-cost 
antibiotics (45). The priority setting processes mentioned here are not exhaustive and 
others are also available (e.g. marginal budgeting for bottlenecks) but lack a framework 
for decision-making processes, or are not routinely used. A review from 2012 concluded 
that there is no generalisable priority setting process, and each of these approaches 
should be evaluated and adapted to the need and context of each country (44). A list of 
criteria or principles representing the three components (facts, value and process) 
provides an appropriate basis for priority setting decisions (42, 46). In particular, the 




the decisions are based and then gathers clinical facts about the possible effects of 
interventions in terms of 'values' that are supported by fair processes (42). 
Priority setting decisions can also be categorised based on the level of decisions 
addressed by the process. The macro level refers to the global/national level, where 
resource allocation decisions have been made. At the meso-level, this relates to the 
regional/district level, where decisions have been made on the healthcare programme. 
At the micro-level, decisions about patient interactions were made in health facilities 
(47). Each one of these levels affects one another. Macro-level decisions on health 
service resources, for example, affect micro/patient-level decisions (42).  
Priority-setting decisions also consider the transparency of the process and are classified 
as explicit and implicit. Explicit was based on clear and well-defined criteria, 
participatory approach, and fair and accountable processes that are more important 
during priority setting as they prevent the unfair, uninformed and non-functional 
processes. Implicit (ad hoc) is the opposite, which lacks a transparent discussion on the 
criteria and joint evaluation of the evidence during priority setting. When priorities are 
implicitly set they are more prone to pressures and individual interests, and many other 
factors play role that may not be in the interest of the population. Priority setting is often 
implicit (ad hoc) in LMICs, where political pressure accompanied by lack of evidence 
and funding play a more important role than the process evaluation (44, 48). 
Consequently, careful consideration of the systems and other contextual factors are very 
important in LMICs, in addition to an explicit priority setting. In general, when people 
are informed of the decision-making process and its outcome and the consequences, 
priority setting is preferable and acceptable, though may sometimes appear too complex 
or technically challenging to be fully explicit (41, 42).  
Explicit priority setting can be made using a set of well-defined criteria and the process 
may yield evidence-based policies or offer transparent rationale for including or 
excluding interventions. Such criteria can emanate from the health system goal of 
improving population health and fair distribution of health benefits (2, 36). Typically, 




benefits, cost-effectiveness, acceptability and equity (41, 49) (Table 1). The choice of 
the criteria and weight assigned to each of them will differ according to people 
preferences. For example, in the selection of high priority services for the progressive 
realisation of UHC, at least three criteria should be considered, including priority for 
cost-effectiveness, worse-off, and FRP (36).  
Table 1: Example of criteria used in priority setting in various low-income and middle 
income countries. 
Category  Number of 
studies included 
Criteria for Priority setting  
 Overall  42 Cost-effectiveness (52%), health benefits 
(45%), and equity (43%) 
Country region by income 
 Low-income  14 Cost-effectiveness, health benefits, severity 
of disease (50% each); equity (43%) 
 Lower middle-
income  
10 Cost-effectiveness, health benefits (44% 




18 Cost-effectiveness; equity; health benefits 
(47% each) 
Level of priority setting decision 
 National(macro) 35 Cost-effectiveness (54%), health benefits 
(51%), and equity (40%) 
 District(meso) 4 Cost of care, cost-effectiveness, feasibility of 
implementation (50% each) 
 Hospital(micro) 3 Equity (67%) 
Priority setting approaches 
 Accountability for 
reasonableness  
7 Fairness/ethics, equity (50% each); burden of 
disease, severity of disease, health benefits 
(33% each) 
 Health technology 
assessment  
2 Health benefits (100%); cost-effectiveness, 
provider acceptability, legal and regulatory 
framework for implementation (66.7% each) 
 MCDA   8 Health benefits (100%); cost-effectiveness, 
the severity of disease, equity, legal and 
regulatory framework (50% each) 
Source : adapted from a systematic review by Kaur et al (49). 
In summary, priority setting in the three dimensions of UHC may help to identify 
interventions that meet the health needs of the whole population in general, and 




working towards UHC, countries need to determine which package of interventions to 
expand first, how to extend the range of services to disadvantaged groups like poor and 
rural communities and how to switch from OOP to pre-payment mechanisms. Therefore, 
the following section focuses on three important criteria that are considered acceptable 
by all theories of distributive justice (i.e. cost-effectiveness, priority for the worse-off 
and priority for service offering FRP) (50).  
1.3.1 Priority to services providing good value for money  
Cost-effectiveness analysis (CEA) assesses the opportunity cost of investing in 
alternative health interventions by comparing costs and health gains. It aids healthcare 
decision-making by identifying interventions that maximise population health for a given 
level of resources (51). Spending the scarce resources available for interventions that 
provide very little health benefit would result in lost opportunities to avert more deaths 
and prevent serious complications from these diseases/conditions. Thus, cost-
effectiveness analysis provides valuable insights into the economic attractiveness, where 
the intervention with the lowest value for money is placed at the bottom (52).  
To illustrate the opportunity cost involved in deciding between interventions, the CEA 
approach accounts for both the effect and cost of interventions (51). The effect or 
outcome is mainly measured in natural units, ranging from intermediate outcomes such 
as blood pressure reduction to more distal endpoints such as deaths averted, and life-year 
gained, etc. (51). Often, the health effects are difficult to describe in a single effectiveness 
unit and, for example, treatment intervention apart from affecting survival can also affect 
the health status which is often not captured in the above effectiveness measures. 
Therefore, one of the main challenges of the cost-effectiveness approach is to create a 
single outcome measure that summarises the effect on both the quality and quantity of 
life or quantifies the disease burden. A summary measure of health status, like quality-
adjusted life-year (QALY), incorporates preferences for both the quantity of life lived 
and quality of life into a single metric, while disability-adjusted life year (DALY) 
represents a weighted combination of the year lived with the diseases and lives lost as a 




that have been standardised for comparative use (53). The choice of outcome measure 
largely depends on the type of intervention being evaluated or the study context. 
However, the use of distal health outcomes is commonly recommended as a basis for 
cost-effectiveness analysis to allow comparison with various alternatives. Another 
component of the CEA is to identify, measure and valuate resources at their “opportunity 
cost”. Both variable costs and the allocated share of fixed costs are included in the total 
cost, but researchers can limit the scope and concentrate only on variable costs. The CEA 
uses estimates of both the healthcare costs and effects for computing the net or 
incremental cost and effects of mutually exclusive alternatives and presents this result in 
the form of cost-effectiveness ratio (i.e. the cost per unit of health effect or cost per 
DALY averted). When the cost-effectiveness ratio is estimated relative to the next best 
alternatives are referred to as incremental cost-effectiveness ratio, while estimation from 
do-nothing option is described as average cost-effectiveness ratio. The cost-effectiveness 
ratio mainly depends on the perspective of the analysis, the definition of interventions 
and the scope of costs (51, 54). 
The CEA outcome, i.e. the average or incremental cost-effectiveness ratio (ICER) needs 
to be complemented by decision rules to determine the worthiness of the intervention for 
further consideration. Numerous approaches have been suggested to decide on best buys; 
the first approach is to finance interventions starting with the most cost-effective (i.e. the 
goal is to maximise population health under a fixed healthcare budget) and moving down 
a rank-ordered list (i.e. league table) until the budget cap is reached. This approach is 
affected by the availability of cost-effective data and omits other factors influencing 
decision-making. The second approach is to use the cost-effectiveness estimates of a 
benchmark intervention that has already been adopted in the relevant country as a 
threshold to represent good value for money. Although such an approach may have 
greater local relevance, the use of a single benchmark intervention does not answer the 
pressing issue of whether there could be other alternatives that have a greater cost-
effectiveness ratio than benchmark intervention. This may be mitigated by using 
aggregate data on willingness to pay for a unit of health benefit from a wide range of 




income. Generally, costs less than one and three times the national annual GDP per capita 
per DALY averted are considered highly cost-effective and cost-effective, respectively. 
The use of GDP-based per capita thresholds is of concern because it lacks empirical and 
theoretical foundation and ignores budget or affordability issues (55). Indeed, experts 
argue that the benchmark for placing importance on health needs must be firmly situated 
within the notion of resource constraints and the relevant context (55, 56). The proposed 
benchmarks include 1-51% times GDP per capita for both low-income and middle-
income countries and 18-71% times GDP per capita for middle- and high-income 
countries (57). Ideally, context-specific thresholds focused on the opportunity cost of 
financing healthcare better guide resource allocation decisions and promote population 
health (56, 57). 
In practice, CEA is data-intensive and challenging in LMICs and few studies are 
available for LMIC settings. CEA evidence for resource constrained settings are made 
available from the Disease Control Priorities Project, the World Health Organization 
(WHO)-choosing Interventions that are Cost-Effective and Tuft University CEA 
database (58-60). However, the comparison of the CEA ratio estimates or the 
applicability of the result to other settings depends on the contextual factors, in particular, 
local epidemiological conditions, the existing coverages, potential risks and the health 
system performance which are crucial in making use of cost-effectiveness analysis (52).  
In summary, CEA is highly critical in providing valuable information to decision-makers 
about choosing which interventions to prioritise when the concern is to increase 
population health at a low cost. Interventions with low ICER (relatively inexpensive) can 
be financed by re-allocating ineffective or less cost-effective interventions. If it is not 
feasible to shift funds from such interventions, future budgetary increases to the sector 
could be directed to finance these interventions in order to achieve more (54). However, 
in combination with other relevant criteria that include affordability, budget impact, 
fairness and feasibility, CEA effectively guides priority setting decisions for the health 
sector (41). For example, malaria and TB interventions have similar costs per death, but 




FRP benefits from the latter and probably better investment until resources are available 
for both (61). At a given budget, CEA identifies interventions that provide the greatest 
health benefit though does not explicitly address the distribution of health and FRP 
benefits across subgroups that were important in priority setting, which will be the focus 
of the following section. 
1.3.2 Priority to services benefiting the worse-off 
In a perfect health system, available healthcare should be equitably distributed based on 
needs, without any other barriers to access (62). However, health inequities related to 
access, utilisation and health outcomes are evident and largely determined by economic, 
social and individual factors such as sex, age, place of residence, education, income, and 
ethnicity, etc. Worse-off can be defined mainly in two ways. Firstly, individuals who are 
at a lower absolute level in terms of health needs or severity and benefiting this group 
matters more (36). Second, the worse-off also refers to the most disadvantaged groups 
in areas other than health, which includes the poor, the marginalised communities, rural 
residents and migrant workers, etc. (36). As a consequence, disadvantaged groups often 
bear the greatest burden of health problems and receive the least care available where 
they are most in need — the inverse care law (63). Principles of fairness motivate, one 
way or another, priority to services benefiting the worse-off and, as a consequence, 
promote equality in health and access to care (36, 54). Nevertheless, worse-off 
populations may be hard to reach and require innovative strategies that may be costly. 
Often, cost-effectiveness and priority to worse-off are not in conflict. However, in some 
cases, decisions may involve trade-offs between maximising aggregate benefit and 
reducing health inequity. Such trade-offs may occur, for example, in the delivery of 
services that improve the overall well-being of the community but involve additional 
costs to improve access to vulnerable populations due to added infrastructure 
requirements, lack of trained human resources, or other utilisation barriers (64). These 
conflicting concerns require an explicit method for weighing trade-offs between 




Distributional Cost-Effectiveness Analysis (DCEA) is a methodological framework that 
expands the CEA model and incorporates both the objective of maximising the overall 
health and reducing health inequity through healthcare programmes. DCEAs help to 
quantitatively examine the distributional impact of healthcare interventions and whether 
more or less equity may be achieved. DCEA methods can assess equity impact with 
inequality indexes such as the Gini index or concentration index (equity impact analysis) 
and quantify trade-offs between total health and health equity (i.e. equity trade-off 
analysis). The equity trade-off analysis uses indexes including the Atkinson or Wagstaff 
achievement index, where the implications of a broad range of inequality preferences on 
a policy decision are explored (65, 66). Such type of analysis can answer how strong the 
preferences for equity need to be in order to change which policy option is deemed most 
favourable. The equity trade-off analysis was divided into two; an equity constraint 
analysis and equity weighting analysis. An equity constraint analysis counts the cost of 
choosing a fairer but less cost-effective policy. A direct equity weighting analysis is a 
type of multi-criteria decision analysis that adjusts costs and/or effects to the extent to 
which distributive concerns such as severity, poverty or gender inequality are affected 
(64, 66).  
Finally, when selecting which services to expand first, many recommend starting with 
cost-effectiveness evaluations of the interventions of interest, and then continue with the 
assessment of other relevant criteria (36). This is what very often happens in practice, at 
least. 
1.3.3 Priority to services that offer greater financial risk protection 
FRP ensures that people receive the needed health services without financial ruin (2). 
FRP offers an insight into the influence of health systems on the non-health side of 
people’s lives (67). It is more important in countries where prepaid systems are not 
relatively strong and people have incurred high OOP costs (68). 
Out-of-pocket payments often lead to severe financial strain on families and can lead to 




household expenditure or 40% of total annual non-food expenditure is a widely used 
definition of CHE. Impoverishing expenditure is related to healthcare payments causing 
households to fall below a fixed level of absolute poverty (22, 26). Both indices are 
widely used measures of the financial risk associated with healthcare and represent the 
failure of the system to shield people from the economic impacts of accessing health 
services (6). Even though the latter is not, per se, part of the UHC SDG indicators, 
medical impoverishment explicitly ties UHC to the first SDG goal of "ending poverty in 
all its forms everywhere" (69).     
FRP can be used as a relevant criterion for the selection of services for HBP and is 
affected by the choices of services (36). For example, the inclusion of high-cost services 
in the HBP or the lowest-cost but frequently used services provides an efficient way to 
purchase FRP. Verguet and colleagues suggest methods to determine the value of a given 
intervention beyond health benefits that involve FRP benefits (68).  
In light of these concerns, extended cost-effectiveness analysis (ECEA) is a method that 
“was developed by Disease Control Priorities, 3rd edition” to assess FRP benefits along 
with health outcomes and distributional impacts resulting from health policies. ECEA is 
a methodological extension of CEA that independently quantifies the relative importance 
of a health policy instrument for different objectives that enable policymakers to consider 
multiple criteria during priority setting or formulation of HBP. This methodological 
framework is particularly relevant in LMICs, where prevention of CHE is a key concern 
alongside the maximisation of population health. More broadly, the use of ECEA 
techniques quantitatively estimates the impact of health policies on various dimensions 
that enable comparisons with other disciplines, such as agriculture, education, and 
transport. 
One of the main policy instruments is universal public finance, which is “Government 
financing of health intervention irrespective of who is receiving it” (70). The public-
financing policies can improve access to healthcare by implementing effective and 
efficient interventions that otherwise would not be available, thereby providing health 




of use that entails financial gain for the user in terms of cost-saving (i.e. crowding out 
OOP). Finally, public financing offers insurance against financial risks and prevents 
CHE (i.e. a major benefit in countries with less efficient insurance systems). The ECEA 
method quantifies intervention policy impact in three health system outcomes: 1) health 
gain, 2) private expenditure averted and 3) FRP; all disaggregated by relevant subgroups 
in a given policy context (e.g., income quintile, gender, geographic, disadvantaged 
groups). Universal public finance requires additional investments in rural and 
underserved areas, such as training, facilities, infrastructure improvements, etc., and 
expanding health services. Lack of such investments can limit the coverage that universal 
public finance can achieve. The ECEA method helps to identify interventions that are 
cost-effective in reducing mortality alongside FRP benefits, or narrowing the equity gap 
between the poor and rich. The outcomes in the three domains, however, might yield 
contradictory findings; the first category attempts to maximise health by increasing the 
number of deaths or DALYs averted, while the second assesses interventions based on 
the number of catastrophic/poverty cases averted or the decrease in the health equity gap. 
Currently, ECEA does not provide a method to aggregate or rank these diverse benefits. 
However, the right balance usually requires a decision maker to account for health gains, 
FRP and equity benefit trade-offs and weighing each outcome depending on the 
objective of HBP of the country (the detailed methodological aspect of ECEA will be 
discussed in section 3.2.4) (68, 70).  
In summary, protection from financial risks has emerged as an important policy objective 
for national health sector programmes in many countries. The healthcare financing 
arrangement greatly matters for financial protection and countries differ considerably in 
their FRP coverage. In general, countries that rely on the public financing of the health 
system provide better protection against financial risk through diverting OOP payments 
into pooled and compulsory prepayment schemes (9, 36, 71).  
1.4 Health financing 
Health financing plays a vital role in health systems to maintain and enhance human 




mobilisation, accumulation and allocation of money to cover the health needs of the 
people, individually and collectively, in the health system…the purpose of health 
financing is to make funding available, as well as to set the right financial incentives to 
providers, to ensure that all individuals have access to effective public health and 
personal healthcare” (2).     
The health financing system often focuses on three inter-related core functions, which 
include (i) revenue-collection: mobilising sufficient resources from a combination of 
domestic and external sources (i.e. prepayment schemes, government taxes, OOP 
payments, and donor funds) for the health system; (ii) risk-pooling: the accumulation 
and redistribution of prepaid financial resources to provide FRP across all scheme 
members, and pooled funds can be derived from tax and health insurance (i.e. 
compulsory or voluntary prepaid insurance schemes) contributions and come from a mix 
of sources in most countries; (iii) purchasing/provision of services: allocation of 
resources to health service providers so that appropriate and efficient services are 
available to the population (72). Countries’ HBP must be organised under the three core 
functions of the health financing system to realise the defined benefits in practice.  
Notably, countries’ health financing models are a hybrid of public (e.g. tax-based, health 
insurance funds and external aid) and private mechanisms (e.g. private spending mostly 
paid OOP) and the need for coordination between these funding sources is crucial for 
achieving UHC (3, 73). More importantly, relying more on universal public finance (e.g. 
financing from general taxes and obligatory health insurance) plays an important role 
towards UHC. Universal public finance ensures universal coverage of publicly funded 
priority interventions and decreases the payment of healthcare at point of service use. In 
addition, universal public financing would enhances equity by cross-subsidisation from 
the better-off to the worse-off and from the well to the ill. Most countries have recognised 
the importance of public finance, and health-financing reform is being pursued in the 
direction of prepaid sources through general taxation, health insurance, or a mix of 
approaches. However, the progress of countries differs, where public finance is dominant 




health financing reforms towards public finance (i.e. tax and health insurance) are 
important for LMICs to promote equitable use of needed services, quality in service 
delivery and cost efficiency by making the system more accountable and transparent (9, 
73). Therefore, the reforms have a direct impact on the progress of countries towards 
UHC goals by reducing unmet service needs, improving health and FRP (37). 
The Government of Ethiopia has been implementing a healthcare financing (HCF) 
strategy over the past two decades. As part of this strategy, the government has 
introduced a wide range of healthcare financing reforms in the areas of resource 
mobilisation, risk pooling and strategic purchasing for the health system to ensure long-
term financial sustainability (74). Among the reforms introduced are revenue retention 
and use at health facility level, a fee-waiver system for the poor, revision of user fees, 
standardised exemption of services, provision of service through private wings, 
outsourcing non-clinical services, implementation of health insurance, and promoting 
health facility autonomy through the introduction of a governance system (75). As a 
consequence, the period has been characterised by a huge expansion in health 
investment, primary healthcare infrastructure, and human resources development (75).   
The implementation of the HCF policy has led to a rise in the country's overall health 
spending, with increased total health expenditure (all financing sources) from $ 230 
million in 1995/96 to $ 3.1 billion in 2016/17 (i.e. 4.2% as a share of GDP) (76). 
Similarly, the per capita spending on health increased from $ 4.1 to $ 33.2 during the 
same period (76). Nevertheless, this amount is far below the WHO’s recommended $ 
112 per person need to avail essential healthcare services in low-income countries (77). 
The major sources of health system financing in the country are donor grants, OOP 
spending and domestic government expenditure which accounted for 35%, 31%, and 
32% respectively. The share of OOP spending out of the total health expenditure has 
dropped from 53% in 1995/96 to 31% in 2016/17. Approximately 1% of OOP household 
spending was pooled by community-based health insurance (76). While attempts have 
been made to decrease the impact of OOPs overtime, the amount of change was too small 




expenditures (2). In general, health systems requiring lower OOP healthcare costs offer 
greater protection against CHE. In particular, this would be achieved by reducing OOP 
and relying more on prepayment schemes backed by high-quality health services (2). In 
terms of financing health systems, the country still faces various challenges, such as 
reliance on private spending, external support and underdeveloped prepayment schemes, 
which indicate that there is an ongoing need to expand equitable and effective 
prepayment mechanisms and strengthen the shift to domestic financing in the country 
(76, 78).  
Moreover, the prevention and control of these diseases have been largely supported by 
external funding, such as the Global Fund, which covers a resource-intensive portion of 
the programme, in particular for drugs and reagents. The global economic downturn and 
flattening of international funding for HIV, TB and malaria threaten the sustainable 
financing of the diseases. If the momentum of financial aid for HIV, TB and malaria is 
declined or discontinued, these services will be difficult to continue unless substituted 
by domestic sources in the future (79). Generally, countries heavily dependent on aid 
have weaker health systems compared to those that consider aid as complementary to 
government health expenditure. Therefore, increasing government health spending from 
domestic sources is vital for improving the health in low-income countries, including 
Ethiopia. The country remains committed to pursuing initiatives aimed at improving and 
developing more sustainable health financing through the gradual replacement of 
external to domestic sources. Initiatives intended to increase health financing include i) 
scale-up of health insurance schemes ii) improve domestic health financing mechanisms 
(e.g. innovative financing) iii) health facility revenue generation and effective utilisation 
iv) standardised healthcare fee etc. Besides domestic financing mechanisms, improving 
efficiency and effectiveness in the health sector is key to providing more health with as 
little resources as possible (78). 
1.5 Global overview of HIV, TB and Malaria 
HIV, TB and malaria remain major threats to global health (12, 80). In 2018, an estimated 




infections (81). Similarly, 10.4 million new cases of TB were reported and 8.9% were 
co-infected with HIV (82). Malaria is a constant threat in many countries, with an 
estimated 228 million cases occurring worldwide (83). In 2016, approximately 3 million 
people died of these diseases (81-83). The bulk (i.e. two-thirds) of morbidity and 
mortality (i.e. 75%-91%) linked to HIV and malaria occurred in sub-Saharan Africa (84). 
TB, however, is more widespread, where 84% of the burden is contributed by the 30 
high-burden countries, mainly from Southeast Asia and Africa (12, 82).  
The concerted efforts and commitment in improving access to antiretroviral therapy, 
standardised treatment of TB and artemisinin-based combination therapies (ACT) and 
mass bed net distributions have resulted in millions of lives saved over the past two 
decades (12). In the years between 2000 and 2017, new HIV, TB and malaria infections 
fell by 49%, 21% and 37%, respectively (31), with estimated 60 million lives saved 
between 2000-2013 (12, 85-88). Hence, the HIV epidemic is no longer necessarily a life 
sentence, millions of TB deaths were averted and shrinking the malaria map has become 
a realistic goal for many countries (89, 90).    
Despite the major progress made in addressing the three epidemics, global progress is 
precariously at risk. About half of HIV positive people are unaware of their status, one-
third of TB cases have been undetected and half of the world’s population lives in malaria 
at risk areas (82, 83, 85, 91). During the early years of the sustainable development goal 
(SDG) era, a huge gap is observed between reality and the vision of sustainable health 
(83, 92). Recently, the trend towards reducing new adult HIV infections has largely 
stalled worldwide. HIV infection remains a major concern among key populations 
including injecting drug users, transgender people, migrants, mobile populations, 
inmates, sex workers and men having sex with men (93). The overall TB incidence 
reduction between 2015 and 2018, at the current pace of progress, was only 6.3%, 
reflecting a 20% deficit relative to the End TB Strategy milestone by 2020 or later (92). 
In 2018, a global 20% difference in malaria incident cases per 1,000 at-risk population 
was observed to get the world on track for the 2020 milestones. Similarly, in recent years, 




figures for 2016-2019 (83). If the current rate of progress persists, the attainment of 
global milestones for HIV, TB and malaria morbidity and mortality is under doubt. 
Far too often, public health complacency towards the reduction of the disease burden 
causes priority to subside and leads to the emergence of resistant strains and disease 
resurgence. Emergence of drug-resistant strains for malaria preventive interventions, 
HIV and TB medicines pose a big challenge to global health and economic security. If 
these strains are not contained promptly, they will reverse all the gains made so far, with 
further increase in costs of care (90). For example, in relation to the most commonly 
used first-line antiretroviral drugs, the rate of resistant strains exceeded 10% (94). 
Moreover, public health emergencies, such as outbreaks of pandemic diseases like 
COVID 19, Ebola and influenza in endemic countries with communicable diseases, have 
a negative effect on the delivery of basic health services, including the ability to control 
HIV, TB and malaria (79). Hence, stepping up the response to these diseases isn’t a 
choice, and countries need to effectively overcome the challenges to improve population 
health and wellbeing. 
The UN sustainable development goal endorsed in 2015 provides an unprecedented 
opportunity to boost efforts to reduce morbidity and mortality related to these diseases. 
SDG 3 target 3.3 of the plan calls the world to “end the epidemics of acquired 
immunodeficiency syndrome, tuberculosis, malaria and neglected tropical disease by 
2030 and combat hepatitis, water-borne diseases and other communicable diseases” (38). 
Accelerating progress towards this target requires innovative strategies, tools and 
technologies which includes implementation of high-impact interventions, developments 
in new medicines, vaccines and diagnostics (79). This effort and investment in the 
agendas of HIV,TB and malaria are imperative to ensure that the hard-won gains from 
the global community are not lost (79, 90). The achievement of global targets and ending 
the epidemics will not only save millions of lives, but it will also reduce poverty and 
create healthier, more equitable societies (79). Therefore, the fight to end epidemics must 




1.6 Country context   
1.6.1 Country profile, demography and economy  
Ethiopia is Africa’s oldest 
independent country and the second-
most populous nation after Nigeria. 
The country is located on the horn of 
Africa and bordered by six countries – 
Eritrea, Kenya, Djibouti, Somalia, 
South Sudan, and Sudan (Figure 2) 
(95). The country covers an area of 1.1 
million square kilometres. Ethiopia is 
a country of many nations and 
nationalities with diverse cultures and 
heritage. 
The projected total population of Ethiopia was 109 million in 2020 as reported by the 
United Nations Population and Development Division (96). The annual growth rate is 
2.6%, increasing at a high rate like other sub-Saharan African countries. Young people 
constitute the greatest age composition, with 67% of the population under 30 years of 
age, while women in reproductive age comprised 23.4%. The mean fertility rate is 4.6 
child per woman, with considerable differences between rural and urban residents (5.2 
versus 2.3), across different regions, the highest was reported in Somali (7.2) and the 
lowest in Addis Ababa (1.8). The ratio of male to female is almost equal. The majority 
lives in rural areas (78%), yet recent migration to urban areas has been on the rise (97, 
98).  
The country achieved substantial economic growth by formulating and implementing 
ambitious and comprehensive mid-term plans such as the plan for Accelerated and 
Sustained Development to End Poverty (PASDEP) followed by the Growth and 
Transformation Plan (GTPI-II), which resulted in the country's steady GDP growth of 
9.9% per year with a slight deceleration to 7.7% in 2018. The economic growth is mainly 
  






driven by the construction and service sectors, with the agricultural and manufacturing 
industries contributing less as the country shifts the economy from agricultural to 
industrial-led (99). The economic growth, complemented by the Government's pro-poor 
spending policies, is attributed to an increase in per capita income. Ethiopians' per capita 
income grew from $ 396 in 2010/11 to $ 794 in 2015/16, resulting in a reduction of 
population living below the poverty line from 29.6% in 2010/11 to 23.5% in 2015/16 
(100). In addition, there was a massive expansion of access to social services that are 
tied to economic development such as health, sanitation, water and education, as well as 
infrastructure including highways, railways, telecommunications, and power generation 
among others. Access to universal primary education and potential coverage of health 
services exceeded more than 95% and life expectancy exceeded 64 years (78, 101). 
Notwithstanding this, there are still developmental challenges that affect the path to 
building sustainable economic growth and reducing poverty in the country. The progress 
has been challenged by reduced employment opportunities, exports, an under developed 
private sector, governance and reoccurring drought, which require the country to make 
substantial progress in this regard in order to sustain the achievements and realise the 
vision of a middle-income country by 2025 (99). 
1.6.2 The health system of Ethiopia 
The “health policy of the transitional government of Ethiopia” was formulated in 1993 
to expand public access to a core package of primary health services to all segments of 
the population (102). The policy prioritises the provision of preventive and promotive 
components of health services using primary healthcare approaches.  
A three-tier healthcare delivery model is used throughout the country to ensure access to 
health services for all segments of the population. Level one comprises a primary health 
care unit (PHCU) consisting of five satellite health posts, one health centre, and a 
primary hospital serving up to 5,000, 25,000 (40,000 in urban), and 100,000 people, 
respectively. The secondary level is a general hospital that serving 1 million people and 
a tertiary or specialised hospital serves 5 million people (78). Health programmes are 




three decades, four phases of the Health Sector Development Programme (HSDP I-IV) 
followed by the Health Sector Transformation Plan (HSTP) guided the implementation 
and governance of health programmes, which have resulted in improved population 
health outcomes. Among the gains, the maternal mortality ratio decreased from 676 
deaths in 2011 to 401 (per 100,000 live births) in 2017. Similarly, under-five deaths 
declined from 123 in 2005 to 55 (per 1,000 live births) in 2019. HIV, TB and malaria-
related morbidity and mortality have significantly decreased in the country (78, 103). 
The relevant country health performance measures are depicted in Table 2.  
Table 2: Performance of key health indicators, Ethiopia. 
Indicator  Year  Value Source 
Maternal and child health     
Under-five mortality rate (per 1,000 live births) 2019 55   (103) 
Neonatal mortality rate (per 1,000 live births) 2019 30 (103) 
Infant Mortality rate (per 1,000 live births) 2019 43 (103) 
Maternal Mortality Ratio (per 100,000 live births) 2017 401 (78) 
Total fertility rate (per women) 2016 4.6  (97) 
Communicable diseases     
Adult HIV prevalence (%) 2016 0.9 (97) 
HIV mortality rate (per 100,000 population) 2018 10 (104) 
Estimated number of people needing ART 2018 690,000 (104) 
TB incidence rate (per 100,000 population) 2018 151 (82) 
TB mortality rate (per 100,000 population)* 2018 22 (82) 
Prevalence of malaria (by microscopy) 2016 0.5 (105) 
Population at risk 
of malaria   
High, low and free (>1, 0-1 and 0 case 
per 1,000 population) (%) 
2018 27, 41,32 (83) 
Malaria mortality rate (per 100,000 population) 2018 4 (83) 
General health status     
Life expectancy at birth, total (years) 2016 64 (101) 
UHC index 2019 0.43 (78) 
*excludes HIV+TB 
However, Ethiopia is still among the countries with very high morbidity and mortality 
from the triple burden. Preventable communicable diseases, reproductive health-related 
problems, nutritional disorders and currently rising non-communicable diseases and 




1.6.3 Overview of HIV, TB and malaria in Ethiopia 
HIV, TB and malaria remain a major public health problem causing ill health and death 
among tens of thousands of Ethiopians each year. Cognisant of this, the Government has 
given due attention to the prevention and control of HIV, TB and malaria diseases. The 
control of these diseases were included among the priority health programmes in all 
rounds of the country’s HSDP and HSTP. In addition, the country have developed and 
implemented strategies to address these diseases, which are in line with the globally 
recommended strategies. The disease control programme has also benefited from overall 
health sector development, particularly through involvement of health extension workers 
to deliver integrated health promotion and curative services at peripheral health posts 
and community level.  
The country has made substantial gains in reducing the incidence and deaths related to 
HIV, TB and malaria diseases (106-108). The malaria prevalence (by microscopy) in 
Ethiopia has declined from 1.3% in 2011 to 0.5% in 2015 (105, 109). The country have 
a low-intensity generalised HIV-epidemic, where the national adult (age above 15 years) 
prevalence dropped from 3.5% in 2000 to approximately 1% in 2016 (97). At the same 
time, the incidence of TB has decreased from 421 to 151 per 100,000 people in Ethiopia, 
however, the country is still one of the high burdens of TB, TB/HIV and Multi-drug-
resistant (MDR) TB (82). The age-standardised HIV and TB mortality rate decreased by 
54%, with malaria dropping by more than 90% from 1990 to 2015 (110). Figure 3 








Figure 3: Trend of communicable disease control performance over 2000-2018, 
Ethiopia (A: HIV, B: TB, C and D: Malaria). 
Scaling up and continued investment in the control of HIV, TB and malaria pay off and 
saved more lives in the country. In particular, the rise in voluntary counselling and 
testing, targeted HIV interventions and the implementation of the "test and treat" policy 
were among the main contributors to the achievement of the HIV programme. Early case 
detection and expansion of directly observed treatment, short-course (DOTS) and the 
introduction of new or improved laboratory diagnostics have played a major role in the 
achievement of TB programme. The implementation of key malaria strategies such as 
indoor residual spray (IRS), insecticide-treated nets (ITNs), scale-up of rapid malaria 
diagnostics and treatment of malaria species with highly effective drugs are among the 
contributing measures to the success of malaria control in Ethiopia (14-16). 
Despite progress, much needs to be done and newer challenges are emerging in the 
country. An estimated 690,000 people live with HIV, 164,900 with all types of TB cases 




die from HIV, TB and malaria diseases each year (82, 83, 104). HIV and TB remain 
among the top five leading causes of premature death in the country (110). Ethiopia now 
faces many challenges in achieving the 90-90-90 global targets of HIV and TB. The 
treatment coverage of HIV and TB is 65% and 69%, respectively (82, 104). The burden 
of HIV and TB is still high and heterogeneous by sex, agro-ecological areas and 
population groups (15, 111). On the other hand, malaria is endemic with a marked 
seasonal and geographic variability in most parts of the country. More than 60% of the 
total population lives in malaria-risk geographic areas and just 40% of the population 
slept under insecticide-treated nets the previous night, making malaria the main public 
health problem in Ethiopia (16, 105, 112). Malaria transmission is extremely variable 
both spatially and temporally, where areas below 2,000 meters are considered potentially 
malarious (113, 114). Access to both diagnostic and treatment services of HIV, TB and 
malaria diseases is not yet optimal, and provision of the treatment service is more 
provider-centred than person-centred. The impact of these diseases is further exacerbated 
by poverty and poor health systems of the country. 
1.7 Rationale of the study 
Efforts have been made to implement effective health policies and reforms to improve 
the population health in Ethiopia. UHC is seen as an important goal for the health policy 
of the country. Today, the country is far from reaching universal coverage, even for 
priority services (73, 78, 115). Coverage of essential services for high priority 
preventable diseases like HIV, TB and malaria is sub-optimal, resulting in higher 
financial risks and unfavourable health outcomes among affected individuals and 
households (78). Evidence on how to achieve universal coverage of these services 
without financial risk to patients is essential (39). Furthermore, poorer and vulnerable 
groups, often trapped in cycles of CHE and impoverishment, face barriers to accessing 
preventive and curative healthcare that they desperately need (115).  
The assessment of patient costs, economic returns and health benefits with distributional 
consequences of continuous expenditure related to HIV, TB and malaria diseases is very 




Investment in both preventive and curative interventions to reduce communicable 
diseases requires a focused approach, driven by empirical evidence (54). However, in 
most low-income countries, including Ethiopia, the economic burden associated with 
these diseases and the return on investment from the public financing of major 
communicable disease interventions have not been fully recognised (6). This may be 
because the measures of the disease burden have not been complemented by economic 
terms to augment the existing epidemiological evidence. Hence, the economic burden 
assessment of communicable diseases would direct health policy by demonstrating 
where the greatest improvements can be made in ensuring FRP benefits. Health policies 
that protect individuals and households from the economic burden of diseases are crucial 
if the government is to achieve the UHC-related SDG goal. Furthermore, linking the 
evidence of economic burden of these diseases with their potential prevention and 
treatment by health interventions offers a full picture and judgments as to whether the 
investments are appropriate for the goal of disease specific programmes. 
ECEA is a highly relevant methodology for policy guidance in communicable disease 
interventions in Ethiopia (68), where disease distribution differs across socio-economic 
groups, poorer people are disproportionately affected, and often use health services less 
and spend more as a share of income. Evaluation of the universal public finance of 
communicable disease interventions on health benefit, equity and FRP domains are 
essential, especially in Ethiopia, where nearly one-fourth of the population lives below 
the poverty line and 31% of health expenditure is contributed by OOP (76, 100). The 
ECEA result will provide evidence of what it takes to deliver such services free-of-
charge with high coverage as recommended in the latest EHSP (39). In this study, I tried 
to address the gap in evidence related to the economic burden of HIV and TB on 
households, supplemented by evaluating the health gain and FRP benefits of the public 
financing of malaria and TB intervention across population subgroups, which can help 






2 Objectives of the study  
2.1 General objective  
The aim of this thesis is to assess patient cost, health gains and financial risk protection 
of HIV, TB and malaria interventions across socio-economic groups in Ethiopia. 
2.2 Specific objective 
The specific objectives are as follows: 
 To estimate direct cost, indirect cost, catastrophic health expenditures and its 
determinants across socio-economic groups for household affected by HIV and 
TB diseases. 
 To assess the expected health gains and financial risk protection benefits from the 
public financing of selected malaria prevention and treatment interventions across 
socio-economic groups.  
 To assess the expected health gains and financial risk protection benefits from the 


















3 Methods  
This thesis comprises three interrelated studies that address the specific objectives set 
out in section 2.2 above. In Paper-I, a nationwide health service utilization and 
expenditure survey (for HIV) and a health facility-based patient cost survey (for TB) 
were used to measure patient costs, magnitude and CHE determinants for households 
affected by the disease. In Paper II-III, cost and expenditure data were linked with the 
benefits of the universal public finance of communicable disease interventions. 
Specifically, Paper-II uses ECEA methods to estimate the impact of selected malaria 
interventions on health, private health expenditure and FRP benefits along with their 
distributional consequences. Paper-III is based on a modelling study to estimate the 
impact of universal public finance of selected TB interventions on mortality reduction 
and FRP benefits across population subgroups in line with the End TB strategy target 
date (2018-35). This method section initially gives a general description of the study 
setting, methodological and analytic considerations with relevance across the three 
Papers (section 3.1 and 3.2), followed by a summary of the specific methods that are 
unique to each of the Papers (section 3.3). 
3.1 Study setting and data 
In Paper-I, cross-sectional household data from nine regions and two city administrations 
were used for the HIV survey and separate sub-national household data collected (as part 
of this Ph.D. work) from health facilities located in the Oromia and Afar regions were 
used for the TB survey. The study population for the HIV study was a sample of HIV-
positive individuals from all regions and two city administrations. All TB or MDR-TB 
patients (including children) who received treatment for at least one month from 
December 2018 to September 2019 in selected health facilities were included for the TB 
survey. Paper-II employed a static (single year) ECEA model using national malaria 
estimates and inputs from small scale published studies in the country. The model 
constitutes the population at risk of malaria, incident cases and one birth cohort. Paper-




Impact Modelling and Estimate (TIME)), followed by a separate ECEA using inputs 
mainly from the national model and results from Paper-I.  
The data sources for these studies were obtained from representative household surveys 
(e.g. Living Standards Measurement Surveys, Demographic and Health Surveys, 
National Health Account, Malaria Indicator Survey, etc.). Besides the large-scale 
surveys, facility-based surveys (exit polls) among service users were used to measure 
health outcomes. Income/consumption data are collected and used to rank households 
across socio-economic status. The income distribution would be constructed from 
primary data or approximated based on Gamma distribution using country inputs such 
as GDP and Gini coefficient (116). Consumption is based on expenditures on food, non-
food and consumer durables (65). The procedure for construction of income or 
consumption into equal groups or quintiles has been set out in Paper-I: Supplementary 
Appendix 1. The data inputs and interventions considered in Papers II-III were explored 
in the main articles of these studies. The following section gives an overview of the 
methodological and analytical aspects of the three Papers. 
3.2 Methodological and analytic considerations  
3.2.1 Cost of illness  
Assessing the cost of seeking HIV and TB care offers insight into the financial impact 
of these diseases on patients and families. These costs were mainly divided into direct 
and indirect costs. Out-of-pocket payments incurred during the course of the disease 
treatment are considered as direct costs. These costs were further categorised into 
medical costs that are attributable to medical services and non-medical costs classified 
as expenses associated with illnesses that are not connected to the direct purchase of 
medical services (e.g. travel, additional food and miscellaneous costs). Indirect cost is 
the foregone income or opportunity cost arising from the diseases. In most studies, the 





3.2.2 Catastrophic health expenditure    
There are various methods for assessing the burden healthcare costs create for household 
budgets, and this thesis applies metrics and definitions of CHE that have been commonly 
used in previous studies (67). Some define CHE as OOP for healthcare exceeding a 
predefined threshold (i.e. 10% or 25%) of income or consumption in a given period (22). 
Others assess CHE in relation to the available income after fulfilling basic needs such as 
food and accommodation, and defines CHE as OOP exceeding 40% of the capacity to 
pay. The former assumes the whole budget of a household is available for healthcare 
expenses and typically used to measure progress related to the SDGs UHC indicator, 
while the latter is driven by households' ability to pay for healthcare and better 
differentiates between the poor and the rich (26, 72, 117). The proportion of healthcare 
expenses from the total budget illustrates the degree to which individuals lack FRP and 
are influenced by the choice of the threshold used to measure CHE. Specific disease 
programmes, such as TB, use a different approach for estimation of CHE than the SDG 
monitoring framework (SDG 3.8.2). For instance, the TB-specific 'catastrophic total cost' 
is one of the main targets of End TB strategy and its measurement involves inclusion of 
both direct and indirect costs. The measurement of the indicator is confined to a 
population seeking care under the national TB network. Whereas, the CHE measure in 
the SDG monitoring framework mainly focuses on direct medical care expenses and 
excludes loss of earnings due to the disease. The latter indicator incorporate individuals 
who are unable to visit or afford to pay for healthcare (69, 118). For the estimation of 
CHE in Papers I-III, a range of thresholds were used to facilitate comparisons with 
previous studies. In Papers II-III, the impact of the universal public finance of malaria 
and TB interventions on FRP benefits was investigated using the difference in the 
number of CHEs stratified by the income quintiles prior to and after the policy was 
implemented. 
3.2.3 Health equity analysis 
Health equity analysis illustrates the disparities in the health and non-health outcomes 




gaps and progress towards equitable access. This study mainly focuses on equity analysis 
across socio-economic groups, where expected distributive health and FRP benefits of 
interventions are assessed. The analysis demonstrates how the outcome measures such 
as deaths, OOP payment and CHE, are equitably distributed across income quintiles. 
Universal public finance benefits of TB and malaria interventions in preventing these 
outcomes across income quintiles were also estimated. The final health equity result was 
reported using tables and graphs, rate ratios, concentration curves and concentration 
indices. The concentration curve visually maps disparities in outcomes through 
socioeconomic status, and the concentration index numerically estimates the extent of 
health inequality on a scale from 0 (full equality) to 1 (full inequality) (65). 
3.2.4 Extended Cost-Effectiveness Analysis   
The ECEA methods examine both the health and non-health outcome of health policies 
or interventions (of either preventive or curative). The method uses a dashboard approach 
that explicitly quantifies the impact of health policies with respect to health gains, 
crowding out of private spending and FRP. ECEA generates the results using measures 
such as deaths or DALY averted, private expenditures (i.e. OOP) averted and FRP 
offered by the policy (i.e. measured using cases of CHE and poverty cases averted and 
money-metric value of insurance provided). It also illustrates the benefits of investments 
at the national or sub-national level by equity relevant strata (i.e., income quintiles, 
gender, marginalised populations and geography). Furthermore, the provision of public 
finance as a policy instrument entails additional cost or investment that would be 
quantified from a government or provider perspective (i.e. net policy costs). The outputs 
from ECEA provide information to decision-makers on how each policy intervention 
affects different segments of the population (68).   
In pursuing ECEA, the first step is to define the problem of existing inequalities in health 
outcomes or coverage, the extent of spending on OOPs, and impoverishment. The next 
step is to identify a policy or intervention that reduces inequalities in health outcomes 
and reduces financial risks for households. Thirdly, identifying and defining the target 




Finally, identifying the policy instrument (e.g. public finance, cash transfer) which is 
basically intended to improve the uptake of the effective interventions. Each step needs 
inputs disaggregated by population subgroups (i.e. epidemiology/demography, 
interventions, total costs including OOP and income) to assess the aggregate and 














Figure 4: Conceptual structure of the Extended Cost-Effectiveness Analysis. 
3.2.5 Outcome measures  
In Paper-I, patient cost and CHE were used as the main outcome measures. The costs are 
further stratified and reported by the model of care, severity of disease, provider type 
and socio-economic status. The outcome measures in Paper-II are deaths, private 
spending and CHE averted, including net government costs. Similarly, deaths and CHE 
averted were used as an outcome in Paper-III and cumulatively reported over the period 
from 2018 to 2035. 
Examine specific health policy (at a given cost) 
(Public finance for malaria prevention (e.g. LLIN)) 






















3.3 Method used in the specific Papers 
3.3.1 Paper-I: Financial burden of HIV and TB among patients in Ethiopia: a cross-
sectional survey. 
3.3.1.1 Study population, design, and data collection 
In this study, two data sources were used, one for a HIV survey and another for a TB 
survey. For HIV, nationwide (i.e., nine regions and two city administrations) household 
data were employed to estimate direct, indirect costs and CHE among People Living with 
HIV across income quintiles. A total sample size of 4,208 was determined. A two-stage 
stratified cluster sampling approach was employed. In the first stage, out of a total of 588 
associations, a sample of 105 HIV associations was randomly selected and allocated to 
each region proportionally to their population sizes (i.e. number of associations). In the 
second stage, 40 HIV participants per each associations were selected for interview, for 
a total of 4,171. A total of 1,006 participants had HIV-related care and were included in 
this study. The study included individuals older than 18 years. The data were collected 
from mid-September until mid-October 2016.  
The TB survey is carried out in selected zones of the Afar (Zone 3) and Oromia (Adama 
special zone and Jimma zone) regions, representing more than 4 million people. The 
three zones were purposely selected to illustrate the country's geographical and socio-
economic heterogeneity. A systematic random sampling was used to select 27 public 
health facilities from the three zones. The estimated total TB sample size was 818 and 
allocated proportionally to the TB caseload review of selected health facilities. This 
ensured that all TB cases across all eligible health facilities had an equal chance of being 
selected. A total of 787 TB patients receiving at least 1 month of treatment in selected 
health facilities were sampled and interviewed consecutively until the required sample 
size was met. The data collection period was from December 2018 to September 2019 
and the response rate was above 95%. Figure 5 below presents a map of the study area 





Figure 5: Map of the study area for both the HIV and TB surveys. 
A questionnaire adapted from a standard costing tool was used to collect a wide range of 
variables including socio-demographic, clinical information, patient costs, time losses, 
consumptions, income, asset and coping measures (119, 120). The questionnaire was 
translated into local languages, subsequently pre-tested and amended. 
3.3.1.2 Costing 
The healthcare costs of the two diseases were evaluated from the patient perspectives. 
For HIV, mainly expenditure related to routine care, co-morbidities and management of 
opportunistic infection was considered. Expenditure was collected for outpatient and 
inpatient visits covering a period of one month and six months prior to the survey, 
respectively. Whereas, for TB episodes, expenditure from the symptom onset, diagnosis 
and treatment completion has been included. 
The direct cost was measured as expenses covering consultations, medicines, laboratory 
tests and imaging, hospital days and travel, food/nutritional supplements and 
accommodation, etc. excluding reimbursements while seeking HIV and TB care. Indirect 
costs were measured as foregone days due to inability to work, hospitalisation, travel 
to/from the health facility and receiving/waiting for care. In addition, the indirect cost 
contains guardian time for TB. The reported time loss was summed up to obtain the total 
time lost. Finally, the indirect costs were valued by multiplying the total time lost with 




assuming 22 working days per month and 8 hours a day. The combination of direct and 
indirect costs would provide total cost. An average of four HIV outpatient visits and 
single TB episode outpatient visits was considered to annualise the cost. The average 
outpatient HIV visits per year were extrapolated based on per capita healthcare visits an 
individual made over the last month. The cost related to TB care was extrapolated for 
the full duration of the TB episode, based on the treatment they were in, and 
retrospectively reported cost data.  
All costs were collected in local currency (i.e. Ethiopian Birr) and converted to the US $ 
with the 2019 exchange rate of $1= 29.1468 Ethiopian Birr (108). The cost for HIV care 
was first converted to a reference period (2019), using the consumer price index of 
Ethiopia (121). Measurement of living standards depends on the availability of data, 
where household income (in-kind and cash) for HIV and total consumption for TB was 
used and scaled to adult equivalence (see Paper-I: Supplementary appendix 1 for more 
details). 
3.3.1.3 Data analysis  
3.3.1.3.1 CHE incidence and intensity estimation  
This study measured the economic burden related to seeking HIV and TB care. The 
incidence of CHE is estimated by using a cut point of 10% of household income or 
consumption. In addition, further analysis was conducted at a threshold of 20% of both 
OOP and total cost, and also using 40% of non-food spending. Moreover, two other 
indicators "over-shoot" and "mean positive over-shoot" were reported as a metric of CHE 
intensity (depth). Overshoot measures the degree to which the average HIV and TB care 
expenses in the whole sample surpassed the threshold; mean positive overshoot measures 





3.3.1.3.2 Health inequality measures (Concentration curve and index) 
A concentration curve was used to plot the cumulative percentage of people seeking HIV 
and TB care on the x-axis (i.e. ranked from the poorest to the richest) and the cumulative 
percentage of patient cost or share of OOP on the y-axis to assess the health inequality 
across income quintiles. The patient cost or share of OOP is more concentrated among 
the poorest households when the curve lies further above the 45 ° line of equality and 
vice versa. Similarly, the concentration index ranges from -1 to 1. A negative value, at a 
minimum of -1, indicates that the patient cost or share of OOP related to HIV and TB 
service is more concentrated among poor households (i.e. the concentration curve is at 
the top of the equality line), while a positive value indicates the opposite. A value of '0' 
implies independence of inequality. In addition, a pen's parade plots household income 
or consumption before and after HIV and TB related OOP expenditures. Furthermore, 
the interval plot (with 95% confidence interval for the mean) has been used to plot the 
incidence and intensity of HIV and TB-related CHE across income quintiles. 
3.3.1.3.3 Statistical analysis 
Descriptive statistics of demographic, socio-economic, clinically relevant variables, and 
patient costs were reported for HIV and TB participants. The Kruskal-Wallis test was 
employed to assess patient cost disparities across income quintiles. Multivariate logistic 
regression was employed to identify the determinants of CHE by incorporating 
significant variables from the univariate analysis. A stepwise regression method was 
used to construct the final model. The Hosmer-Lemeshow test and receiver operating 
characteristic curve was used to check the goodness of fit and the predictive power of 
the final model (122). A statistical test was conducted at 5% level of significance for all 




3.3.2 Paper-II. Health gains and financial risk protection of selected malaria 
interventions in Ethiopia: an extended cost-effectiveness analysis. 
3.3.2.1 Interventions and data inputs 
In Paper II, ECEA was used to evaluate the health and non-health benefits of selected 
malaria interventions in Ethiopia. The study assessed four malaria disease prevention 
and control interventions, which include i) artemisinin-based combination therapy 
(ACT), ii) long-lasting insecticide-treated bed nets (LLIN), iii) indoor residual spraying, 
and iv) malaria vaccine. Unlike the first three, the last intervention was a hypothetical 
malaria intervention that had not been introduced in the country at that time. An ECEA 
model was employed to determine the number of malaria-related deaths and OOP 
spending averted, the FRP provided and the government cost associated with universal 
public finance of selected malaria intervention across income quintiles in Ethiopia. 
The target for LLIN and IRS intervention was population residing in malaria at-risk areas 
that constituted 60% of the total population. All malaria cases reported in at-risk areas in 
2016 were eligible for ACT. Similarly, the target for a malaria vaccine was one birth 
cohort (born in 2016) which was followed for five years to capture the full effect of the 
vaccine. The target population was distributed equally through income quintiles for all 
interventions to assess the equity of the health policies. The number of malaria 
susceptible infants across income quintiles was approached for the vaccine through the 
distribution of total fertility rates. The input related to malaria prevalence distribution by 
income quintiles for at-risk populations was proxied by the gradient of malaria 
prevalence in the general population. The percentage of hospital admissions related to 
malaria was extracted from existing literature and disaggregated by population 
subgroups based on malaria prevalence across income quintiles (123). For both 
outpatient and inpatient cases, case fatality ratio (CFR) was derived from literature and 
assumed to be constant across quintiles. The baseline malaria-related deaths were then 
distributed across income quintiles for all interventions (except vaccine) (see Paper II, 




In the case of the vaccine, the total malaria deaths among children under-five was 
obtained by multiplying the number of deaths from malaria in the general population by 
the proportion of under-five malaria deaths (124, 125). In particular, the distribution of 
malaria-related deaths by income quintiles requires proxy inputs (such as prevalence, 
treatment coverage, child mortality and efficacy) that are associated with malaria-related 
deaths and differ across income quintiles except for efficacy measure (126). In addition, 
under-five deaths from malaria was disaggregated by age group, as the vaccines efficacy 
decreases over time (124, 125). During the follow-up period, a Weibull decay function 
was used to represent the waning effect of the malaria vaccine. The birth cohort received 
three doses of malaria vaccine within 6–9 months, with protection beginning at the age 
of 9 months (127).  
An incremental coverage of 10% has been chosen for all malaria interventions and is 
presumed to be achievable within 1 year or a short period. In addition, coverage of fully 
immunised children with a scale of 0 to 33% is considered for malaria vaccines (97). The 
costs incurred by the household and the healthcare system when an individual seeks 
outpatient/inpatient malaria care across income quintiles were extracted from previous 
studies conducted in the country (21, 128). 
3.3.2.2 Health benefits    
The health benefit was measured in terms of deaths averted. Firstly, the potential number 
of deaths that would have occurred in each income quintile at the existing coverage levels 
was estimated for each malaria intervention (2016). Secondly, using the data on malaria 
incidence, CFR, intervention efficacy and incremental coverage by income quintiles, and 
the magnitude and distribution of malaria deaths averted for each intervention after 
universal public finance were estimated (see Paper II, Additional appendix for details). 
3.3.2.3  Private expenditure averted  
In estimating private expenditures averted, universal public finance was assumed to 
remove before the policy co-payment (OOP spending) for treatment interventions and 




interventions. From the perspective of the households, the level of private expenditure 
averted (by income groups) on malaria care after the public finance of malaria 
interventions was estimated and reflects cost savings. Private OOP expenses averted 
depend on: target population, healthcare use, incremental coverage, OOP costs and 
effectiveness of preventive interventions (see detailed mathematical equation in Paper 
II, Additional appendix). 
3.3.2.4 Financial risk protection benefits 
In order to estimate CHE under the baseline and each policy intervention scenario, two 
methods were used. First, CHE was determined by comparing household total OOP 
expenses against a cut of value of 10% of total consumption. Alternatively, 40% of 
capacity to pay (i.e. total household non-food consumption) were used to define CHE 
for this particular study (22, 26). The annual household consumption as income proxy 
was obtained from the 2016 consumption and expenditure survey (129). Universal public 
finance would reduce the malaria incidence and related OOP spending, thus avoiding the 
occurrence of many CHE cases. Subsequently, for each malaria intervention, the FRP 
offered to households was quantified in terms of the cases of CHE averted, calculated as 
the difference in cases of CHE before and after universal public finance (see Additional 
Appendix for information in Paper II). 
3.3.2.5 Programme costs  
The programme costs were any government costs incurred while the four malaria 
interventions were being scaled-up through universal public financing. The intervention 
costs include net price and distribution costs for LLIN; insecticide costs, spray campaign 
activities, labour and capital costs for IRS; vaccine prices, supplies, training, 
transportation and waste management costs for the vaccine, and labour, medication and 
supplies for ACT. The total costs consider the target population, intervention coverage 
and unit cost of the interventions (see the detailed mathematical equation in Paper II, 
Additional appendix). Patients and the healthcare system costs were converted for the 
year 2016 using Ethiopia’s GDP deflator before analysis (130). A one-way sensitivity 




3.3.3 Paper-III. Mortality reduction and FRP benefits of expanded TB control in 
Ethiopia: findings from a modelling study. 
3.3.3.1 Model input and interventions 
In Paper-III, a compartmental transmission model (i.e. TIME Version 5.76 nested in the 
spectrum software package) was used to generate projection of TB incidence, prevalence 
and mortality for both drug-susceptible (DS-TB) and MDR-TB burden during the period 
from 2018-2035. The TIME model is used to project the epidemiological effect of TB 
interventions over time, and a detailed methodological overview is described in previous 
literature (131). The TIME model automatically incorporates TB impact measures from 
the WHO global database and HIV impact estimates from UNAIDS and population 
values from the UN Population Division. Estimates of prevalence were extracted from 
the national TB prevalence survey in Ethiopia. Key pathogenetic and epidemiological 
parameters were accessed from published literature and surveys. The programmatic and 
laboratory-related performances were extracted from country reports and expert opinion 
from the national TB programme. The baseline model was calibrated manually and fitted 
to TB prevalence, incidence and mortality with past trends from 2000-17. The baseline 
model was based on the existing TB performance in the country and assumed that the 
epidemiological and programmatic parameters were still at their current levels for 2018-
2035. 
In accordance with the post-2015 End TB strategy, and based on availability of required 
data for analysis, three TB prevention and control strategies were modelled in the 
intervention scenario and compared with the existing TB control performance (base-
case). The interventions include implementation of active case finding (Int1); enhanced 
implementation of DOTS for DS-TB (Int2), and improved MDR-TB diagnosis and 
treatment (Int3), most of which are currently being implemented in the country. The 
primary aim of these interventions was to find TB cases (Int1), link them to care and 
ensure successful treatment (Int2-3).  Int1 is primarily done through the involvement of 
health extension workers to educate, identify and refer presumptive TB cases for further 
evaluation through house-to-house visits, contact investigations and provision of proper 




on TB protocols, patient education, care and adherence counselling for drug-susceptible 
cases. Specifically, Int3 focuses on the implementation of robust case finding strategies 
such as Xpert for diagnosis, instituting an improved model of care, provision of effective 
treatment and adherence counseling for MDR-TB cases. Using the calibrated model, the 
impact of the three TB control interventions during the period (2018-2035) was 
projected. The increased coverage due to public financing was determined through 
consultation and discussion with national TB experts and assumed to be achieved by 
2025 (2030 for Int3). Linear scale-up was applied for all intervention coverage from 
2018-25 (2018-30 for Int3) and presumed constant values from 2025 onward (2030 
onwards for Int3). Several model parameters were affected following each intervention. 
For example, for enhanced MDR-TB care or Int3, three different model probabilities 
were mainly assumed to change (treatment success rate, linkage to care and drug 
susceptibility testing). The detailed inputs and assumed coverage due to universal public 
finance can be found in Paper III-Table 1 and 2. The projected outcomes, over 18 years, 
include: number of active TB cases, number of treated TB cases, total diagnostic test 
performed, the mean duration of diseases, number of TB-related deaths for base-cases 
and intervention scenarios. 
Evidence on TB prevalence disaggregated by quintile was not available in the country. 
The distribution of TB cases by quintile was estimated using a methodology described 
in the previously published study (132). Firstly, a set of five proxy factors (i.e. HIV, 
smoking, the prevalence of malnutrition, overcrowding and history of contact) that are 
associated with increased likelihood of contracting TB have been identified. Then, TB 
cases are distributed across income quintile based on two inputs: i) the importance of 
risk factor in increasing TB disease (i.e. relative risk of these risk factors) and ii) the risk 
factor prevalence obtained from the Ethiopian Demographic and Health Surveys (EDHS 
2016) (97, 133). Subsequently, the distribution of TB cases across income quintiles was 
made based on the prevalence and the relative weight assigned to each risk factor for TB 
(see Paper III: Supplementary Appendix). Probability of healthcare use across income 




3.3.3.2 Estimation of health benefits 
The reduction in TB-related deaths from enhanced coverage of Int1-3 across socio-
economic groups was assessed during the years 2018-35 (i.e. in line with End TB 
strategy target date). As there is no evidence of TB mortality by income quintile in 
Ethiopia, the total TB deaths at the base-case and intervention scenario (i.e. output from 
the TIME modelling) was distributed using a method outlined in previous literature 
(126). Specifically, the distribution of TB deaths by income quintiles for each year and 
cumulatively was estimated in 2018–35 by applying the coverage gradients of the 
probability of seeking TB care, mortality rate by quintile (i.e. a proxy for the probability 
of dying from TB) and the effectiveness of TB treatment (see Paper III: Supplementary 
Appendix for detail). In the absence of evidence regarding which proxy parameters 
represent more of the quantile share, an average based on the three proxies was calculated 
to obtain a single estimate of TB mortality in each of the five quintiles. Then, the number 
of deaths across income quintile for the base-case and intervention scenario was 
estimated. The total deaths averted is the difference between total deaths at baseline and 
under each policy intervention per quintile over 2018-2035. 
3.3.3.3 Estimation of FRP benefits  
Estimates of patient costs, both direct and indirect costs incurred by patients, were 
imputed from recently published Paper-I results (135). The patient cost data are 
disaggregated further by type of TB cases (i.e. DS- and MDR-TB care). Similarly, 
distribution of income is proxied using a simulated gamma distribution constructed from 
the gross domestic product per capita and the Gini coefficient of Ethiopia (116). All costs 
were expressed in 2019 United States dollars.  
Financial risk protection benefits from public financing mainly occurred from a 
reduction in TB cases and related costs (Int-1) that would have occurred without 
intervention, and from improved treatment and linkage to care (Int2-3) that reduce the 
lost to follow-up, duration of contagiousness, and secondary cases. The FRP was 
estimated using the number of cases of CHE averted. In this study, CHE (also called 




combined) exceeded 20% of household income (see Paper III: Supplementary Appendix 
for details) (118). In line with the literature, other thresholds for CHE that generally lies 
between 10-40% of total household expenditure were also explored in the scenario 
analysis. 
Cases of CHE incurred under the base-case and each intervention are calculated for each 
year and cumulatively in 2018–35. Cases of CHE averted by each intervention were 
calculated by subtracting the number of households incurring CHE in the intervention 
scenario from the base-case. 
3.3.3.4 Scenario analysis  
In this study, various scenarios were performed to check the robustness of the result in 
relation to the model parameters. In the sensitivity analysis, for deaths averted, the effect 
of varying parameters used to distribute TB-related mortality such as effectiveness of 
treatment, healthcare use, and mortality estimates were investigated. For CHE averted, 
the influence of varying prevalence of TB, threshold for CHE, healthcare use, and patient 
costs was examined. Data analyses were carried out using R-Studio (version 4.0.0).   
3.4  Ethical consideration 
Ethical approval for Paper-I was obtained from the National Committee for Medical and 
Health Research Ethics in Norway (2018/1647/REK) and from the Ethiopian Public 
Health Institute (EPHI-IRB-121-2018). Official letters bearing a request for 
collaboration were written to the Oromia and Afar Regional Health Bureaus. In 
collaboration with respective zonal health offices, the regions granted permission to 
undertake the TB study. All participants were informed about the purpose and expected 
outcome of the study, and informed consent was obtained before each interview. All the 
information collected through the study was kept confidential, and analysis was carried 
out without revealing the identity of individuals to ensure privacy. Papers II-III did not 
require ethical approval, as the studies depends on secondary data and findings from 





4 Summary of results  
4.1 Paper-I. Economic burden of HIV and TB. 
Socio-demographic and clinical characteristics 
The socio-demographic and clinical characteristics of HIV and TB study participants are 
summarised in Table 1 of Paper-I, but briefly, females account for 75% and 50% of the 
total HIV and TB study participants, respectively. More than two-thirds of the 
participants were between 25 and 44 years old for HIV and below 34 years for TB. The 
median household size was four (inter-quartile range (IQR), HIV: 3 to 5, IQR, TB: 3 to 
6). The average (standard deviation (SD)) annual household income/consumption for 
HIV was $ 1,188 ($ 1,288) and TB was $ 545 ($ 462). About 22% of HIV and 6% of TB 
participants had both outpatient and inpatient visits. During the study, only 2% of HIV 
and 6% of TB patients were enrolled in a community health insurance scheme. 
HIV and TB patient costs 
The mean (SD) cost of care for HIV was $ 78 ($ 170) per year and $ 115 ($ 118) per TB 
episode (with 4 times higher cost for drug-resistant TB). The major cost drivers were 
medical costs for HIV, while non-medical costs and productivity loss for TB. The total 
HIV and TB patient cost, on average, was equivalent to 7% and 21% of their annual 
income, respectively. The direct cost of HIV and TB accounted for 69% and 46% of the 
total cost, respectively. Medical costs accounted for 68% and 38% of HIV and TB direct 
costs, respectively (Figure 6). The total mean (SD) cost for hospitalisation episodes is 





Figure 6: Household direct medical, non-medical and indirect cost of HIV and TB care 
in Ethiopia (expressed in $). 
Incidence and inequality in financial risks 
The total mean (SD) cost also varies across socio-economic status, from the lowest to 
the highest income or consumption quintile ([HIV: ranges $ 53 ($ 97) to $ 133 ($ 262)], 
[TB: ranges $ 50 ($ 44) to $ 202 ($ 189)]). The concentration index of the total cost of 
HIV and TB care against the ranked living standards, starting with the poorest and 
finishing with the richest, was 0.175 and 0.251, respectively. Similarly, the concentration 
index for the share of OOP payment is -0.476 and -0.219, respectively. These indicate 
that, in absolute terms, the rich spend more on HIV and TB care, but in relative terms, 
the poor spend more as a share of total income or consumption. 
The incidence of CHE occurred in one-fifth (20%) of HIV households (43% of the 
poorest to 4% of the richest income quintile, p<0.001) and that of TB households was 
40% (where it reaches 58% in the poorest and 20% in the richest income quintile, 
p<0.001) (Figure 7). Furthermore, the incidence was considerably higher for inpatient 
HIV care (33%) and (94%) for inpatient TB care, for individuals co-infected with 
TB/HIV (48%), and for patients with MDR-TB (62%). 
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Figure 7: Box plot of OOP share, mean overshoot and mean positive overshoot at 10% 
threshold associated with HIV and TB care across income quintiles. 
In a multivariate analysis significant determinant factors for incurring CHE common to 
both HIV and TB disease were being hospitalised, having frequent health facility visits 
and living in the poor or poorest households. In addition, diagnosis at the private health 
facility, type of TB and co-infection were additional determinant factors for TB (see 
Paper I, Table 4). 
4.2 Paper-II. Health gains and financial risk protection of malaria interventions. 
Health benefits  
Increasing the coverage for ACT, LLINs, IRS and malaria vaccine by 10% through 
universal public finance accounted for 358, 188, 107 and 38 malaria deaths averted per 
year among at-risk population, respectively. In contrast to the other malaria interventions 





In addition, there are variations in the magnitude of deaths averted through income 
quintiles for all malaria interventions. For instance, ACT, LLINs, IRS and malaria 
vaccine save more lives among the poorest quintile (i.e. 30% of deaths averted), mainly 
attributed to the high prevalence of malaria and its risk factors in this group. Almost half 
of the deaths averted occurred in the lowest socio-economic groups (i.e. the poorest two 
quintiles). To consider the relative effectiveness of malaria interventions, the number of 
deaths averted per 1 million dollars spent was estimated, which differs greatly with 
malaria interventions, from less than 5 deaths averted for IRS to more than 60 deaths 
averted for the ACT (see Paper II, Additional appendix, Figs. S1-S3). 
Private expenditure averted  
The four malaria interventions (i.e. ACT, LLIN, IRS and malaria vaccination) would 
avert approximately $ 4,277,000, $ 214,000, $ 122,000 and $ 15,000 of private health 
expenditure, respectively. The gains in private expenditures were evenly distributed (i.e. 
flat) across income quintiles. The even trend of private expenditure averted across 
income quintile was a reflection of the uniform gradient of patient costs by income 
quintile, the downward trend in the distribution of the prevalence of malaria from poorest 
to richest, and the rise in the use of  healthcare from poorest to richest (Table 3). 
Financial risk protection  
The four malaria interventions led to a reduction in the number of CHEs. The largest 
proportion of cases of CHE averted per year was generated by ACT 440 (10% of the 
base-case), followed by LLINs 220 (5%), IRS 125 (3%) and vaccination against malaria 
accounted for 18 (2%). The majority of cases of CHE averted occurred in the poorest 
quintile and very few to nil were averted in the richest quintiles (Table 3).  
Table 3: Distribution of deaths averted, private expenditure averted and CHE averted by 
each malaria intervention per income quintile in Ethiopia. 
Intervention Outcome  Total  Q1 Q2 Q3 Q4 Q5 
Artemisinin-
based 
Deaths averted 358 107 71 82 50 47 
Private expenditure 
averted 






CHE averted 440 182 106 152            -               -    
Long-lasting 
Insecticidal  
Deaths averted 188 56 38 43 26 25 
Private expenditure 
averted 
214,000 48,310 42,380 44,600 39,460 39,140 
CHE averted 220 91 53 76           -                -    
Indoor residual 
spray 
Deaths averted 107 32 21 25 15 14 
Private expenditure 
averted 
122,000 27,540 24,150 25,420 22,490 22,310 
CHE averted 125 52 30 43          -               -    
Malaria Vaccine  Deaths averted 38 11 8 8 6 4 
Private expenditure 
averted 
15,000 4,880 3,660 2,560 2,280 1,220 
CHE averted             18 9 5 4          -                -    
Q1, poorest income quintile; Q5, richest income quintile.    
Government Expenditures 
A 10% incremental coverage of ACT, LLIN, IRS and the malaria vaccine through 
universal public finance costs the Government $5.7, 16.5, 32.6, and 5.1 million, 
respectively. The scale-up of the IRS was the most costly intervention, accounting for 
twice the expense of LLIN. 
4.3 Paper-III. Mortality reduction and FRP of expanded TB control. 
In this section, the projected numbers of deaths and cases of CHE averted were reported, 
as compared to the baseline (i.e. if the existing TB control programme performance 
remains the same during the period from 2018-35). Int1 was primarily presumed to 
increase the screening rate by 25% over the follow-up period, in addition to the effect on 
other parameters. Similarly, Int2 and Int3 were mainly assumed to improve the linkage 
and treatment success rates for DS-TB (to 95% in 2025) and MDR-TB (to 95% in 2030) 
from a varying baseline coverage according to HIV status. 
Health benefits  




In Ethiopia, TB-related deaths are projected to be 757,000 without intervention during 
2018-2035. The largest proportion of TB deaths were projected to occur in the poorest 
quintiles (40%) compared to the richest quintiles (6%). Similarly, at baseline, the 
estimated number of households that incurred TB related CHE was approximately 
601,000 over the same period. Catastrophic healthcare costs have occurred in all 
quintiles and the poorest quintile accounts for the largest percentage of the overall CHE 
(57%) compared to the richest quintile (2%). The bottom two income quintiles accounted 
for the largest proportion of cases of CHE (75%) compared to those in the richest two 
income quintiles (<10%), where the risk and prevalence of TB were higher in the former 
group (Figure 8). 
Deaths and cases of CHE averted with TB interventions 
Implementing active case finding (Int1) over the follow-up period would avert about 
206,000 TB deaths (i.e. 27% of the base-case total deaths) and 193,000 cases of CHE 
(i.e. 32% of the base case catastrophic cases). The enhanced implementation of DOTS 
(Int2) averts about 192,000 TB deaths (25% of the base-case total deaths) and 93,000 
cases of CHE (15% of the base-case catastrophic cases). The improvements in MDR-TB 
care (Int3) cumulatively avert around 6,300 TB deaths (up to 1% of the base-case total 
deaths) and 33,000 cases of CHE (up to 6% of all catastrophic cases incurred in the base-
case) (Figure 8). These findings also indicate the marked disparities in CHE risk and 




Q1: poorest income quintile; Q5: richest income quintile.    
Figure 8: Estimated number of households (in thousands) incurring TB-related deaths 
and CHE across income quintiles at a 20% threshold over 2018-2035, in Ethiopia. 
The trend of deaths and CHE averted increased overtime for active case finding (Int1) 
and enhanced DOTS implementation (Int2) with immediate gain to be realised, but that 
of improvement in MDR-TB care (Int3) was marginal (Figure 9 and 10). 
Deaths and cases of CHE averted across socio-economic groups  
The deaths and CHE averted from the universal public finance of TB interventions (Int1-
3) vary across socio-economic groups. The poorest quintile, as they are more likely to 
acquire TB despite their low care-seeking behaviour, accounted for the largest share of 
deaths and CHE averted. The implementation of active case finding (Int1) and enhanced 
implementation of DOTS (Int2) averted about 39% of deaths occurring in the poorest 
quintile compared to 6% in the richest quintile. In addition, the improvements in MDR-
TB care (Int3) would cumulatively lead to a 34% reduction in deaths that accrue to the 
poorest quintile, while only 10% in the richest quintile. More than half of the deaths 
averted by all TB interventions concentrated among the bottom two quintiles. 
Similarly, enhanced implementation of active case finding would avert a higher 
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4% in the richest quintile. Implementation of enhanced DOTS and improved MDR-TB 
care would each avert approximately 60-65% of cases of CHE in the poorest quintile 
compared to 0-1% in the richest quintile, respectively. In terms of FRP, households in 
the poorest two quintiles benefitted from all three TB interventions, where 70-85% of 
CHE cases were averted in this subgroup (Figures 9 & 10). 
 
Figure 9: Total number of deaths averted 
(in 1,000s) (9a) and incidence of CHE 
averted (in 1,000s) (9b) over 18 years 
among households in Ethiopia through 
scale-up of core TB interventions. 
 
 
Figure 10: Cumulative number of 
households per quintile with deaths 
averted (in 1,000s) (10a) and the number 
of CHEs averted (in 1,000s) (10b) 
through scale-up of core TB 
















5 Discussion  
Priority-setting decisions require a broad range of evidence from multiple policy 
dimensions. In this respect, the findings from the three studies provide valuable insights 
about the financial burden of diseases on households, and the benefit of universal public 
finance of health policies to mitigate adverse outcomes (e.g. premature deaths), 
inequalities and financial risks. Specifically, Paper-I has generated evidence on 
economic burden and CHE associated with seeking HIV and TB services. Papers II and 
III estimated the magnitude of health and non-health benefits of universal public finance 
of effective malaria and TB interventions. This section sequentially summarises the key 
findings of these Papers, the policy implications and discusses these findings with 
reference to existing literatures. Finally, the strengths and limitations of the studies are 
discussed. 
5.1 Main findings  
Paper-I shows the total patient cost of HIV is $ 78 per year and $ 115 per TB episode 
(where the cost for drug-resistant TB was four times higher). The direct patient costs of 
HIV and TB care are 69% and 46% of the total costs, respectively. The overall incidence 
of HIV-related CHE is 20% (i.e. 4% for the richest quintile and 43% for the poorest 
quintile) and that of TB was 40% (i.e. 20% for the richest quintile and 58% for the 
poorest quintile). The rate of CHE is higher for patients with TB/HIV co-infection, drug-
resistant TB and those who required hospital admission. Financial risk inequality was 
observed amongst the different income quintiles, with a 15-18 times higher financial 
burden among poorest relative to the richest.  
In Paper-II, a 10% increase in the coverage of the four malaria interventions (ACT, 
LLIN, IRS and malaria vaccination) through universal public finance averted 358, 188, 
107 and 38 premature deaths and 440, 220, 125 and 18 CHE cases per year among 
malaria at risk population, respectively. ACT and LLIN resulted in a substantial 
reduction in deaths and case of CHE. The highest health and FRP benefits occurred in 
the lowest income quintiles. For instance, the poorest two quintiles accounted for almost 
half of the deaths averted, compared to one-third in the richest two quintiles. ACT, LLIN, 
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IRS and malaria vaccine were estimated to have an incremental government cost of $ 
5.7, 16.5, 32.6, and 5.1 million, respectively. 
Paper-III indicates that implementing active case finding from 2018 to 2035 would lead 
to TB deaths and CHE reductions of 27% and 32%, respectively. Similarly, enhancing 
DOTS for DS-TB would avert 25% of deaths and 15% of CHE, and improvements in 
MDR-TB care would avert up to 1% and 6% of deaths and CHE over the same period, 
respectively. Both the health and financial risk benefits would be greatest for the poorest 
two quintiles. 
5.2 Interpretation and discussion of main findings  
5.2.1 Paper-I. Economic burden of HIV and TB   
In this study, on average, patients spend $ 78 per year for HIV care and $ 115 per TB 
episode. Previous studies from Ethiopia also show high OOP spending for HIV and TB 
care, with a mean cost of $ 141 per year for HIV and $ 177.3 per TB episode (25, 136). 
These findings also support previous literature in sub-Saharan Africa that found OOP is 
still the major source of healthcare payment at the point of use, although the direct 
comparison is challenging as cost measurements differ across the studies (1, 13). This 
finding would not be unprecedented in view of the greater demand-side financial barriers 
to accessing healthcare in the country. The 2016/17 Ethiopia Health Accounts (VII) 
survey report show that OOP spending as a share of total health expenditure is 31% 
(137). The contribution of OOP is slightly decreasing (i.e. by 6% from 2013/14), but the 
rate is still very high, given that more than a quarter of the country’s population live in 
poverty (100). Besides, OOP payment for healthcare is inequitable and is deemed 
regressive by nature, increasing the gap in health outcomes across social groups (138). 
This study also showed the economic burden of HIV and TB diseases is not homogenous 
across socioeconomic status, where both diseases represent a disproportionate burden 
for low-income groups. The relative costs of medical, non-medical and productivity loss 
in poor households increase their economic vulnerability by consuming a higher 
proportion of their annual income and savings (11, 136, 139).  
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This study indicates high level of OOP payment increases the likelihood of CHE in 
Ethiopia, where 20% of HIV and 40% of TB patients incurred CHE at 10% threshold of 
annual household income or consumption. This finding supports the results of previous 
studies from sub-Saharan Africa that documented HIV and TB patient costs are 
associated with high financial hardship (1, 13). In this study, 7% and 21% of annual 
household income/consumption is lost due to HIV and TB care, respectively, which is 
lower than the figures (i.e. 21% for HIV and 30% for TB) reported in previous studies 
from Ethiopia (25, 136). Consequently, more patients have experienced CHE in the 
previous studies. Such difference is primarily attributed to the change in the potential 
coverage of HIV services during the study periods. The previous study was held during 
the pilot implementation phase of HIV service (i.e. 2005), where the service provision 
was more centralised. As a result, patients face substantial costs due to delays in seeking 
care, travelling long distances and being seriously ill, compared to this study, where 
services are more decentralised and accessible (25). Similarly, the difference with the 
TB cost is mainly attributable to the expense of nutritional supplements incurred, where 
the cost is twice the value reported in this study (136). Moreover, more than half of 
patients with extra-pulmonary TB and MDR-TB had CHE, which was comparable to a 
study from India that found patients with extra-pulmonary TB encountered twice higher 
healthcare cost relative to those with pulmonary TB, and the majority of MDR-TB cases 
also experienced CHE (140). 
The proportion of households facing CHE from HIV and TB care varies substantially 
across different factors, one of which is socio-economic status, where the poorest 
households suffer the most. This finding confirms many of the studies conducted in sub-
Saharan Africa, including Ethiopia (26, 136, 141, 142) that found strong national health 
financing and social protection schemes are important in responding to the needs of this 
group. In addition to household socio-economic status, frequent visits to healthcare, 
hospitalisation episode, TB/HIV co-infection and seeking diagnostic care from private 
health facilities contribute to heightened vulnerability. This finding is similar to what 
was previously documented in the systematic review of patient costs in sub-Saharan 
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Africa where HIV co-infection, type of healthcare provider, and insurance schemes were 
listed as important determinants of CHE (13, 142). 
The finding also indicates that TB/HIV co-infected patients suffer from relatively high 
healthcare costs and CHE compared to individuals with TB or HIV infections alone, as 
previously reported (24, 143). The integration of HIV and TB services facilitates the 
provision  of a comprehensive package of service for patients through a one-stop-shop 
care model (144). However, TB/HIV integration is poorly implemented in several 
settings. Often the services are either not given at one-location or have strong referral 
linkages (145). For example, joint TB/HIV collaborative activities have been scaled-up 
in Ethiopia over the past decades. The TB service deliveries at health facilities is more 
decentralised than that of HIV services (15). This mismatch contributes to the provision 
of fragmented services, increases visits to health facilities, and affects the continuity of 
healthcare, resulting in increased costs of care for households and might even delay 
access to essential services. Integration could benefit patients more if it is focused on 
implementation experiences and addresses the prevailing problems of collaborative 
TB/HIV implementation (e.g. decentralisation of HIV services) in the country. 
Another determinant of CHE was the frequency of healthcare visits, which has a positive 
association with increased patient costs. The decrease in the HIV and TB health facility 
visits or improved patient scheduling systems has alleviated part of the economic burden 
and uptake barrier as revealed in previous studies (136, 139). However, if not 
accompanied by proper support, a decrease in the frequency of visits alone may have 
implications on retention in care and adherence to treatment with potential consequences 
on emergence of drug resistance (29). In this context, the community-based systems (i.e. 
health extension programme) is important for providing both preventive and curative 
services for vulnerable and rural communities in Ethiopia. The HIV and TB services 
provision through community-based systems is a cost-effective strategy that improves 
adherence and FRP in LMICs, including Ethiopia (146, 147). However, according to 
recent survey, the provision of clinical services such as HIV and TB under the existing 
health extension programme needs to be strengthened in terms of service delivery (e.g. 
availability of essential medicines, commodities), trained personnel and infrastructure, 
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etc. in order to increase the quality of care and meet the growing demand of the 
population (148).  
Insurance scheme enrolment is another determinant of CHE. Despite the comparatively 
low coverage of health insurance (i.e. 2% for HIV and 6% for TB), scheme members are 
protected from CHE as opposed to non-members (142, 149). The Government of 
Ethiopia had introduced a community health insurance system to withstand the economic 
shocks triggered by healthcare costs through enhancing the systems to pool risks for 
healthcare costs (13). However, the current coverage is not adequate to attain universal 
coverage of HIV and TB services and to eliminate the risk of CHE in Ethiopia. 
Households have poor resilience to withstand economic shocks and adopt various coping 
mechanisms in order to limit the economic consequences of healthcare costs. This study 
shows almost 24% of HIV and 68% of TB participants indicated the use of coping 
mechanism, from current income and savings, borrowing and selling assets to cover 
expenses and loss of earnings, although the coping strategies for both diseases were not 
similar. If these measures are ineffective, households may experience enormous declines 
in non-health consumptions, such as food, education, and housing, forcing households 
into poverty. The coping measures are not cost-free, protecting current consumption at 
the expense of future insecurity or welfare effect. In particular, the use of savings and 
sale of assets can reduce household economic prospects. Reducing the intake of food or 
taking children out of school will smooth consumption in the short term, but can 
adversely affect health and education prospects in the long-term (150). This is a 
particular concern for African countries where 30% of households cope with healthcare 
payments through borrowing and selling assets (151).  
In Ethiopia, like other African countries, HIV and TB services are exempted from fee at 
point of care or provided at a subsidised rate in public and private health facilities linked 
to the national programme, in order to improve equitable access to services and reduce 
financial risks (13-16). In an environment of “free” provision of HIV and TB services, 
households continue to face substantial expenses when seeking care. The current free-
of-charge programmes for both diseases in Ethiopia are an important milestone on their 
 63 
own, but do not fully avoid other major healthcare costs (e.g. basic laboratory tests, 
ancillary medications and hospitalisation, etc.) linked to these services. A high level of 
payment for HIV and TB care, on the one hand, could lead to CHE and drive households 
into poverty, and on the other hand, it forces households to make adverse economic 
choices, such as cutting back on basic necessities including food, shelter and education 
in order to finance their healthcare (152). Besides costs during treatment phase of HIV 
and TB services, high pre-treatment cost of HIV and TB services is not only reflected in 
economic terms, but can also deter or delay families from seeking the needed services 
(11, 25). 
In conclusion, the economic burden of HIV and TB services is context-specific. The 
difference in service delivery arrangements and health financing mechanisms may affect 
the populations and breadth of covered services and healthcare costs. While such services 
were meant to be provided free-of-charge at point of care, the exemptions were not 
adequate to cover other necessary costs and to provide adequate FRP. The provision of 
HIV and TB care needs to be person-centred and accompanied by effective diagnosis 
and community-based approaches to minimise patient non-medical costs. Furthermore, 
the integration of HIV and TB services with existing prepayment schemes (i.e. national 
health insurance, tax-based financing, or a mix of this mechanisms) in low-income 
countries including Ethiopia, helps to reduce patient costs, even though the strength of 
such systems depends on the socio-economic and political context. 
5.2.2 Paper-II. Public financing of malaria interventions  
In this study, the ECEA method was employed to evaluate the variation in health gains, 
private expenditure averted, and FRP across income quintile of universally publicly 
financed malaria interventions in Ethiopia. Universal public finance at 10% incremental 
coverage for key malaria interventions could bring major FRP benefits in addition to 
substantial health gains. This is supported with finding from previous study, where ACT 
provision for malaria treatment would avert 410 deaths and is comparable with this 
study’s estimates (i.e. 358 deaths averted) using similar incremental coverage (61). 
However, the extent of malaria-related deaths averted per year with each of the four 
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interventions fall far below the findings from the universal public finance of pneumonia, 
diarrhoea prevention and treatment interventions (153, 154). This can be attributed to the 
rapid decline in the morbidity and mortality of malaria, both globally and in Ethiopia, 
due to the scale-up of highly effective preventive and curative interventions, compared 
to other childhood diseases (106). Among the four malaria interventions, ACT and LLIN 
are the most effective interventions in reducing larger shares of malaria-related deaths 
and CHE cases per dollar spent. This is consistent with most CEA studies that have 
shown that malaria interventions, such as ACT and LLIN, are among the best purchases 
compared to other public health initiatives for malaria control (155). In contrast, the 
malaria vaccine would prevent the smallest number of deaths (i.e. 38) in children. This 
finding differs from the prior study of malaria vaccine (i.e. RTS,S vaccine) conducted in 
Zambia that found a large reduction in deaths and FRP benefits (134). Normalising the 
result using the same incremental coverage as the Zambia study would avert 
approximately 257 malaria-related deaths in children in this study (compared to 667). 
Similarly, standardising income on a monthly basis and adjusting incremental coverage 
would result in 1,723 cases of CHE averted in this study (compared to 4,411). This 
difference could be attributed to the high prevalence and deaths from malaria in children, 
which is 2-5 times higher in Zambia than in Ethiopia (134). Moreover, relative to 
pneumococcal and rotavirus vaccine, malaria vaccine has low health and FRP impacts, 
which is largely due to the lower vaccine efficacy (153, 154, 156). 
Approximately, one-third of deaths and CHE averted from all malaria interventions 
occurred in the poorest quintiles, relatively, due to the high burden of malaria among this 
group. A previous study of childhood pneumococcal vaccines and pneumonia treatment 
in Ethiopia also confirms the pro-poor distributional benefits, where universal public 
finance resulted in 30-40% of deaths averted in the poorest quintile. The distributional 
FRP benefits observed in this study are also consistent with a study held in Zambia, 
which found that universal public finance of the malaria vaccine provides FRP benefits 
for the first three income quintiles (134). Furthermore, equity consequences related to 
the health benefit and FRP of an intervention are a central concern of UHC. Malaria 
interventions would mainly benefit the poor, given the low health service coverage 
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among this population. The high prevalence of malaria among the poor contributes to 
unequal distributional benefits. This indicates that, despite pro-rich malaria intervention 
coverage, the poorest quintiles accrue higher health benefits. Public financing of malaria 
interventions enables countries to equitably distribute resources to optimise health 
outcomes across different subgroups of the population and reduce inequities. 
Alternatively, it is understood that malaria intervention would widen the existing health 
inequities if current pro-rich coverage continue.  
In this study, the gain in private expenditure averted is evenly distributed across income 
quintiles, which is inconsistent with results of previous ECEA of childhood pneumonia 
and diarrhoea prevention and treatment policies, which found the richest would acquire 
more reduction from private expenditure (153, 154). Unlike previous findings, this study 
shows that OOP expenses for malaria care do not vary between poor and rich households 
that neutralise the gain made in private expenditure averted across income groups (153, 
154). In addition, malaria preventive measures have resulted in patient cost savings 
across all income groups, as reported in the previous study (134). However, from the 
government perspective, a publicly financed malaria policy would increase net costs with 
little offset from averted malaria-related treatment costs from preventive interventions 
(134).  
In summary, the use of the ECEA method to estimate the impact of the universal public 
finance of various malaria related interventions could ensure and provide insight whether 
these interventions reach the intended population and offer the best value for money. The 
finding illustrated that the universal public finance of malaria interventions were 
important in improving health and protecting households from the cost of seeking care, 
particularly the poorest. It is critical for policymakers to consider which malaria 
interventions provide the greatest protection for families against health loss and financial 
risks, in addition to targeting the worse off. This would further guide decisions in 
selecting interventions to be included in the EHSP or HBP.  
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5.2.3 Paper-III. Impact on health and CHE of expanded TB control  
A modelling analysis of expanded TB control interventions was conducted to determine 
the health benefits and financial risks in terms of reduction in mortality and CHE in 
Ethiopia from 2018-2035. Although health gain may be the primary value, the 
assessment of the FRP of TB intervention is another important non-health outcome in 
places where ill health predisposes households to financial risks (2).  
In this study, substantial health and financial burdens were incurred by TB, affecting 
more than half a million families at baseline (with the existing coverage) during the 
follow-up period. Implementing active case finding over the period of 18 years would 
reduce about 206,000 (27% of the baseline) and 193,000 (32%) of TB deaths and cases 
of CHE, respectively. Similarly, enhancing DOTS for drug-susceptible TB would avert 
192,000 (25%) deaths and 93,000 (15%) cases of CHE; and improvements in MDR-TB 
care would avert up to 6,300 (1%) and 33,000 (6%) of deaths and cases of CHE, 
respectively. This finding is supported by previous studies in South Africa, where 
60,000-240,000 or 5-20% cases of CHE in the base cases were averted by intensified 
case findings. Similarly, improved DS-TB care would avert approximately 90,000-
220,000 or 7-19% cases of CHE, and improved MDR-TB care would avert 70,000-
220,000 or 6-18% of baseline CHE cases (157). Hence, improvements in the delivery of 
core TB interventions through public financing have the potential to reduce the deaths 
and CHE, thereby enhancing the health and FRP benefits. But the existing passive case 
finding failed to identify the predicted cases in areas where seeking TB care is poor and 
would yield substantial benefits through integration with active case finding strategies 
(158). Furthermore, DOTS is the single global strategy implemented for TB control and 
has led to a considerable reduction in morbidity and mortality related to TB diseases in 
endemic countries. Of particular concern, in places with high burden and weak systems, 
the widespread use of DOTS alone is not enough to rapidly reduce the TB transmission 
and associated economic consequences in recent years. TB remains a major public health 
problem in high-burden countries, where a substantial proportion of the population has 
been latently infected, creating a large reservoir of potential TB reactivation and 
continued transmission (159). Indeed, DOTs would continue to be the cornerstone of TB 
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management in high-burden countries like Ethiopia, but complementing with active case 
finding strategies is an important step towards sustained prevention and elimination of 
TB diseases (160). 
In this study, the universal public financing of TB health policies leads to higher health 
and FRP benefits for the poorest quintiles. For example, the public financing of active 
case findings would result in a more than seven-fold reduction in mortality and twelve-
fold reduction in CHE for the poorest quintiles compared to the richest quintiles. 
Similarly, improved implementation of DOTs results in a six-fold decrease in mortality 
and a fifty-five-fold decrease in CHE among the poorest quintiles compared to the richest 
quintiles. This finding corroborates with a previous study in India and South Africa, 
which found that the health and FRP benefits of TB policies were primarily concentrated 
among the worse-off populations, and none among the richest (70, 157). However, there 
are still substantial differences between socio-economic groups regarding access to 
healthcare and the economic burden of TB, indicating the need for policy reinforcement 
to ensure that all necessary services are given without financial hardship for the worse-
off. 
Although the health and FRP benefits of the interventions were substantial in absolute 
terms, most of the baseline deaths and CHE were not eliminated. This finding is 
supported by previous studies held in India and South Africa, where the reductions in 
deaths and catastrophic costs would fall below 20% of base-cases (70, 157). The impact 
would be influenced by the difference in coverage at the baseline level. For example, 
increasing DOTS coverage for DS-TB has a relatively modest impact as the baseline 
coverage reported is already high and close to the target to be achieved. 
Our finding aids policies and practices, and the public financing of TB interventions such 
as enhancing active case finding, and improvement in drug-susceptible TB care 
contributes to a reduction in mortality and CHE, thus improving health and FRP benefits 
for many patients in Ethiopia. Even if both benefits were high in absolute terms, the 
reductions in deaths and CHE are still not adequate. Hence, the enhanced implementation 
of TB prevention and control strategies in Ethiopia alone would not be sufficient to 
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achieve the target of ending TB and fully prevent CHE over the next decade (i.e. End 
TB strategy targets). Thus, not only the optimum implementation of available TB 
initiatives is essential, but also the introduction or expansion of viable social protection 
measures (e.g. sickness insurance, cash transfers, food assistance etc.) complemented by 
new diagnostic and treatment technologies are necessary to progress towards the End TB 
strategy targets in the country.   
5.3 Strengths and limitations 
In this sub-section, the strengths and limitations of Papers I-III are discussed. In Paper I, 
primary data sources were used from all (for HIV) and selected regions (for TB) of 
Ethiopia, and the strengths and limitation of this Paper is discussed separately. In Papers 
II and III modeling techniques based on large data sources, complemented by 
assumptions were used, and thus the strengths and limitations of both studies are 
discussed together. 
5.3.1 Validity  
5.3.1.1 Internal validity  
The internal validity of research refers to the magnitude to which the results reflect the 
truth in the study population (161). In Paper-I, cost data were collected retrospectively, 
which may introduce recall bias and influence the outcome of the study. The recall 
periods tend to vary by types of goods and services consumed, such that a shorter recall 
period is used for more frequently consumed goods or services such as outpatient 
services and food items. While a longer recall period is used for goods or services that 
are consumed less frequently such as non-food items, durable goods, incidents of 
hospitalisation. Shorter recall periods ease recollection and reduce bias, while longer 
recall periods are useful to capture several items incurred at different frequencies during 
the course of illness. However, it is always a challenge to ensure appropriate time to 
collect cost data in order to minimise recall bias; shorter recall might be affected by over-
reporting and assumptions to alleviate the error over the shorter durations, whereas the 
longer recall period would result less accurate estimates (162). Hence, the period of 
recall, shorter or longer, depends on the objective of the study and the type of prior event 
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(162). In this study, the recall period was chosen when participants receiving HIV and 
TB care had a better recall of their path to care. However, measuring financial burden 
related to chronic diseases such as HIV and TB through a cross-sectional survey might 
create uncertainties, even if this study provides an approximation of total cost per patient 
for a given period (i.e. annual or reported over the disease period). A longitudinal design 
may overcome these challenges but requires repeated visits and follow-up that entails 
additional resources, and is therefore beyond the scope of this study. Despite this 
limitation, the study captures all relevant cost data, including direct and indirect costs, 
using standard questionnaires. In addition, the cost of HIV and TB care was 
disaggregated by equity relevant parameters using a relatively larger sample compared 
to previous studies (1).   
There are various measures of living standards and understanding the potential 
limitations associated with these measures is important. In Paper-I, a direct measure of 
living standards such as income for HIV and consumption for TB was used. In LMICs, 
where home production of food is widespread and formal employment is less common, 
consumption is the preferred living standard measure instead of income (65). In this 
study, due to unavailability of data related to consumption for HIV participants, income 
has been used as a proxy of living standards measure. The use of income, unlike 
consumption, does not allow for the fact that households are able to minimise the 
variability of health spending overtime through borrowing and saving. Furthermore, it 
does not take into account home production. However, the majority of the HIV study 
participants (92%) were from urban areas and formally employed. In addition, data 
related to the coping mechanisms for HIV care were analysed and reported to minimise 
income-based limitations. In general, the choice between consumption and income 
matters more when measuring health inequities. Use of consumption includes borrowing 
to finance health spending, making these households appear relatively well-off and 
overstates household's living conditions, whereas income can understate the situation by 
making a household that is relatively well-off (with regard to consumption) appear to be 
relatively worse-off (65). 
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Models of economic evaluation, such as ECEA, have been used in Papers II and III, 
which require data from a wide range of sources and proxy inputs, as not all parameters 
are readily available or documented (68, 163). As a result, these national studies sought 
data from both primary and secondary sources, and uncertainties were inevitable. To 
acknowledge these effects, a one-way sensitivity analysis in Paper-II and different 
scenarios in Paper-III were conducted to check the robustness of the model results. In 
Paper-III, the interventions chosen (Int1 and Int2) were more effective in reducing TB-
related deaths and FRP, but the analysis did not include the program costs required to 
meet the targets. The estimation of these costs, in order to achieve the various levels of 
coverage across interventions, would better inform the decision on effective allocation 
of resources. Furthermore, the ECEA approach allows FRP inclusion on economic 
assessment of health policies that enables selection of interventions for benefit packages 
based on the extent of how much health and FRP purchased per dollar spent. However, 
the method does not have decision rules to weigh trade-offs in health benefits, equity and 
FRP domains that are left to policymakers to carefully assess the trade-offs along with 
interventions effectiveness and other moral obligations.  
Despite these constraints, the studies shed new light by producing data on the magnitude 
of financial burden, equity consequences and impact of universal public finance policies 
to protect households from adverse health and non-health consequences (i.e. financial 
hardship) that might need to be considered by policymakers to tailor suitable policy 
strategies. 
5.3.1.2 External validity   
External validity is the extent to which the research finding can be generalisable to the 
target populations or can be adapted to another context (164). In Paper-I, sampling of 
HIV survey participants consisted mainly of urban population and the TB survey was 
conducted in two purposely selected regions, restricting the representativeness of the 
finding to the whole population, even if probability sampling techniques were employed 
to recruit the patient samples in the survey. Ideally, the inclusion of both urban and rural 
populations in the HIV survey and of more geographic locations in the TB survey would 
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ensure wider representation of the findings. A modeling study, such as ECEA, was used 
in Papers II and III in order to prioritise TB and malaria policies in Ethiopia. The 
selection of appropriate policies would be influenced by the results of the model that in 
turn depend on the accuracy of the input parameters. The input parameters, such as 
epidemiologic, programmatic, clinical data and unit costs, synthesised in these Papers, 
were collected from various sources. In fact, local data inputs were used in these studies 
to minimise bias and ease the extrapolation to other settings (164). But, preferably, the 
collection and synthesis of such evidence or inputs should be performed in a reasonable 
manner, eliminating bias and optimising precision in the final result (165). The review 
of evidence in LMICs, like Ethiopia, is often a challenge due to the limited availability 
of data and resources. Therefore, such studies may involve the use of available data from 
both large and small-scale studies complemented by proxy inputs or assumptions that 
could lead to a trade-off in precision and possible bias (e.g. precise but biased estimation 
or vice versa). While this is not unprecedented for many economic evaluation studies, it 
would impact external validity of the findings (164, 165). In Papers II and III, the 
potential impact of these inputs or assumptions was accounted for by running different 
scenarios. The modelling used in these papers clearly articulates the intervention and 
comparators assessed, the perspective of analysis, rely on locally available data, and 
standard methods that facilitate the generalizability of the findings to other settings with 
similar characteristics in terms of disease epidemiology or baseline risks, intervention 












6 Concluding remarks  
In Ethiopia, the economic burden associated with HIV and TB services is enormous, 
with one-fifth and over one-third (40%) of households incurring CHE, respectively. The 
service exemption for these diseases was not sufficient to cover other necessary costs 
and to offer FRP. As a result, households have poor resilience to withstand economic 
shocks resulting from continuing expenditure on these diseases which jeopardise their 
welfare. 
Health expenditure on HIV and TB care takes a larger share of household income or 
consumption (7% for HIV and 21% for TB), contributing to CHE and poor health 
outcomes. Households with comorbidities, complications and repeated healthcare visits 
are more likely confronted with CHE relative to their counterparts. The healthcare costs 
caused by these diseases have the potential to divert the consumption of basic goods or 
be smoothed by the payment from savings, borrowing, and selling asset, which have an 
adverse effect on household welfare. In addition, spending on HIV and TB care is 
inequitable, where the poor spend higher proportion of their income/consumption while 
seeking care and are 15-18 times more likely to suffer from financial hardship. 
Therefore, targeted efforts to minimise healthcare payments among the poor could be 
much more affordable than attempts to eliminate all healthcare costs. Ultimately, 
ensuring that people are protected from the economic effects of these diseases would 
have to be a key priority of public health policies, in addition to improving the health of 
the population. 
Enhancing the coverage of existing or new strategies for malaria and TB control through 
universal public finance could save the lives of patients and bring higher FRP benefit, 
particularly among the poorest segment of the population. The universal public 
financing of malaria interventions could reduce up to 10% of baseline malaria deaths 
and CHE cases. Similarly, the universal public finance of TB interventions decreases 
about one-fourth and one-third of base-case TB-related deaths and CHE cases, 
respectively. In low-income countries like Ethiopia with severe resource constraints, 
policies such as ACT and LLINs for malaria, active case finding and DOTS for TB are 
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the most effective and cheapest ways to improve the lives of the general population, 
with meaningful benefits for the poorest in Ethiopia. However, the introduction of 
malaria vaccines alone does not provide substantial benefits, and the impact and 
feasibility of the vaccines need to be further explored in combination with other 
measures prior to wider use. Moreover, the substantial health and non-health benefits of 
publicly financing the interventions would provide policymakers with an important 

















7 Recommendations  
Person-centred, effective and focused strategies are essential to fight HIV, TB and 
malaria in Ethiopia. The availability of preventive and treatment strategies for HIV, TB, 
and malaria is an opportunity. However, national policies need to recognise the 
magnitude and distribution of economic consequences in terms of household income 
loss or reduction of consumption opportunities. Reviewing and expanding the free-of-
charge HIV and TB service package to include all the essential diagnostic and treatment 
services accompanied by the decentralisation of clinical services are therefore critical in 
reducing the economic burden faced by households. 
Furthermore, the high cost associated with HIV and TB care was an indication of a lack 
of adequate FRP policies, which requires innovative financial and social protection 
measures. One of the potential strategies for household protection against financial risks 
was the introduction of prepayments and pooling of funds. Community-based health 
insurance was scaled-up in the country to improve health service utilisation and ensure 
financial protections among households in the informal sectors. The development and 
integration of HIV and TB specific packages into the existing health insurance schemes 
are useful in ensuring financial protection for households. More importantly, the country 
needs to take explicit steps to ensure that public spending is a dominant source of health 
financing. As public spending for health grows, the population has better access to 
healthcare and FRP that foster the fair realisation of UHC in the country.  
In order to move towards equity, appropriate policy solutions that better protect poor 
households from financial risks should be designed (e.g. targeted approach such as 
establishing health equity funds for the poor to access full subsidised care or exemption 
of priority interventions through insurance schemes) (166). 
The investment return, in terms of health and FRP, related to the universal public finance 
of TB and malaria interventions highlights the priority interventions to be financed by 
the health sector in order to improve the health system performance and the realisation 
of UHC. Universal public finance allows the country to allocate resources equitably 
such that the benefits primarily accrue in the poorest quintile, but a strong effort is 
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required to reach and improve the coverage of high impact interventions among the 
populations that are relatively poor or most at-risk.  
7.1 Future research needs  
Cost and cost-effectiveness studies are evolving in LMICs, including Ethiopia, but more 
studies are required to analyse the health and non-health benefits of health policies to 
aid priority setting (6).  
It is useful to perform a longitudinal study with repeated data collection for chronic 
diseases such as HIV and TB in order to analyse the recovery mechanisms and the long-
term impact of CHE on the socio-economic status of households, workforce engagement 
and treatment outcomes (6). Measuring the trend of financial hardship and related 
inequalities, using national data, would help the country to track progress in protecting 
households against the cost of healthcare (67). In addition, integrating health service 
measures with financial burden and the worse-off effect would strengthen the economic 
case for affordable healthcare (6).   
Economic barriers are one of the main reasons for low health service coverage in 
Ethiopia, but other factors, such as geographic barriers, availability of quality services 
and health infrastructure may play a major role (61, 120). Hence, addressing the 
economic barriers alone does not guarantee the availability of health services, and future 
studies could consider other factors that may have an effect on the delivery of health 
services in the country. In addition, empirical evidence is needed to expand theoretical 
aspects of the ECEA on how to rank or aggregate the diverse health policy benefits in 
the areas of health, FRP and equity as well as methods to evaluate multiple equity 
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Strengths and limitations of this study
 ► This study will be of high value to policies aimed 
at universal health coverage for HIV and tuberculo-
sis (TB) care in Ethiopia due to the financial risk of 
seeking care.
 ► Patient costs from this study can provide empiri-
cal bases for national HIV and TB programmes for 
adopting public finance or health insurance- based 
financing strategies.
 ► The patient costs for outpatient and inpatient HIV 
and TB care are presented together with income and 
consumption levels of households.
 ► The cost measurements relied on a patient’s ability 
to remember, which increases risk of recall bias.
 ► The HIV sampling consisted primarily of urban pop-
ulation and the TB study was limited to specific re-
gions of the country, therefore, these samples are 
not necessarily nationally representative.
AbStrACt
Objectives HIV and tuberculosis (TB) are major global 
health threats and can result in household financial 
hardships. Here, we aim to estimate the household 
economic burden and the incidence of catastrophic health 
expenditures (CHE) incurred by HIV and TB care across 
income quintiles in Ethiopia.
Design A cross- sectional survey.
Setting 27 health facilities in Afar and Oromia regions for 
TB, and nationwide household survey for HIV.
Participants A total of 1006 and 787 individuals seeking 
HIV and TB care were enrolled, respectively.
Outcome measures The economic burden (ie, direct 
and indirect cost) of HIV and TB care was estimated. In 
addition, the CHE incidence and intensity were determined 
using direct costs exceeding 10% of the household income 
threshold.
results The mean (SD) age of HIV and TB patient was 
40 (10), and 30 (14) years, respectively. The mean (SD) 
patient cost of HIV was $78 ($170) per year and $115 
($118) per TB episode. Out of the total cost, the direct cost 
of HIV and TB constituted 69% and 46%, respectively. 
The mean (SD) indirect cost was $24 ($66) per year for 
HIV and $63 ($83) per TB episode. The incidence of CHE 
for HIV was 20%; ranges from 43% in the poorest to 4% 
in the richest income quintile (p<0.001). Similarly, for TB, 
the CHE incidence was 40% and ranged between 58% 
and 20% among the poorest and richest income quintiles, 
respectively (p<0.001). This figure was higher for drug- 
resistant TB (62%).
Conclusions HIV and TB are causes of substantial 
economic burden and CHE, inequitably, affecting those in 
the poorest income quintile. Broadening the health policies 
to encompass interventions that reduce the high cost 
of HIV and TB care, particularly for the poor, is urgently 
needed.
bACkgrOunD
HIV and tuberculosis (TB) are major global 
health threats that cause a large finan-
cial burden on vulnerable populations. 
Global efforts, in the past two decades, have 
improved access to lifesaving HIV and TB 
interventions.1–3 More than 72 million lives 
have been saved between 2000 and 2018.4 5 
Nevertheless, high disease burden, inequality 
in utilisation of healthcare and service quality 
issues still exist.1–3 Better understanding of 
factors that affect use of these services would 
help countries to achieve universal health 
coverage (UHC) of HIV and TB services.
The population in need for care is still 
large. Globally, 1.7 million people acquired 
HIV infection and 10 million new TB cases 
occurred in 2018. In the same period, more 
than 2 million people died from HIV and 
TB.4 6 In Ethiopia, the prevalence of HIV 
among adults was 1% (CI: 0.7% to 1.4%) 
and the incidence rate of TB was 151/100 
000 in 2018.4 6 In order to end HIV and TB, 
a comprehensive approach should include 
medical and non- medical interventions such 
as socio- economic support and poverty alle-
viation.7 8
Although many countries, including Ethi-
opia, offer ‘free’ HIV and TB services, the 
implemented policies do not adequately 
provide realistic financial risk protection. The 
health budget in Ethiopia is low ($33.2 per 
capita) and 31% of overall health financing 
is out of pocket payments (OOP).9 10 Hence, 
patient and their families, often face both 
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direct and indirect costs, which create financial burden on 
households.11 12 A systematic review showed that individ-
uals in low- income countries spend a mean direct cost of 
$155 per drug susceptible TB and $406 per drug- resistant 
TB (DR- TB). The productivity losses were two to three 
times higher than the direct costs of drug susceptible and 
resistant cases, respectively.13 Similarly, for HIV, spending 
ranges from $95 to $2672 in sub- Saharan Africa.12 Such 
high costs are related to catastrophic health expendi-
ture (CHE), which occurs when the OOP exceeds 10% 
of annual income14 15 or 40% of household non- food 
expenditure.16 In addition, OOP expenses for HIV and 
TB care may crowd out consumption of basic needs 
and leave vulnerable households in debt/impoverish-
ment.12 17 18 Furthermore, high levels of patient cost may 
affect access to care, and lead to poor treatment outcome 
and prolonged period with infection.12 14 19–21
Many factors may lead to CHE; exemptions of HIV and 
TB services often applies to limited aspects of the basic 
care package (eg, CD4, viral load, acid- fast bacilli and 
GeneXpert tests), treatment (eg, antiretroviral therapy 
(ART), anti- TB drugs). Patients pay for prediagnostic 
services, ancillary medications, some laboratory testing, 
imaging, adverse event monitoring, hospitalisation, 
transportation, food, lodging, etc.19 22–24 In addition, 
unavailability of diagnostic services in public health facil-
ities pushes patients to seek care from expensive private 
providers.22 Furthermore, low health insurance coverage 
(around 24% as of 2019), and repeated follow- up visits 
were important contributing financial risk factors.25 26 It 
is also imperative that HIV and TB programmes, needs 
to monitor household protection from CHE (ie, financial 
risk protection) and its distribution across income groups 
(equity), as OOP health spending places greater burdens 
on the poor.27 28
In Ethiopia, few studies have been evaluating the extent 
of patient cost due to seeking HIV and TB care. The costs 
related to severe forms of the diseases and assessments 
across income or consumption groups were lacking from 
the studies reviewed.22 23 29 Furthermore, none studied 
predictors of CHE.22 23 29 Because HIV and TB are chronic 
diseases and intimately linked, it is reasonable to look at 
them jointly. This paper aims to estimate the economic 
burden and incidence of CHE incurred by standard HIV 
and TB care across income or consumption quintile 
among Ethiopian households. Moreover, we will assess 
factors associated with CHE for HIV and TB.
MethODS
Study setting and population
In this study, a nationwide household survey for HIV10 
and a cross- sectional health facility based survey for TB, 
were used to estimate direct and indirect costs, and CHE.
Data for HIV were collected from mid- September 2016 
to mid- October 2016. The total estimated number of 
people living with HIV (PLHIV) was 722747 in Ethiopia. 
However, for TB, data were collected from December 
2018 to September 2019 in three zones (ie, zone 3 of Afar 
region, and Jimma and Adama special zones of Oromia 
region). The three zones were purposely selected and 
represents 4 million people mirroring the country’s 
geographical and socio- economic heterogeneity. The 
zones account for 10% and 13% of the TB cases in 
Oromia and Afar regions (and 6% of the national preva-
lence), respectively.
Sample size and sampling technique
For HIV, PLHIV associations were used as a sampling 
frame to select HIV participants, as there is no national 
registry of PLHIV. The association operates in major cities 
in all regions and its members were primarily residents 
in urban areas. The estimated sample size was 4200. The 
response rate ranges from 92% to 100% across regions. 
A two- stage stratified cluster- sampling method was 
employed. In stage one, a sample of 105 HIV associations 
from a total of 588 were randomly selected and allocated 
to each region using probability proportional to the size. 
In stage two, 40 HIV members from each sampled asso-
ciation, in total 4171, were randomly selected and inter-
viewed. Among the study participants (ie, 4171), 1006 
had HIV- related care during the data collection period 
and were considered in our analysis.
For TB, the sample size was calculated using two- 
population proportion formula with 80% power, 5% type 
I error, 95% CI and using 39%21 of households incur CHE 
among the richest income quartile; and to detect 15% 
point difference revealed 186 samples for each quartile. 
The final sample size with 10% non- response rate was 818 
(of which 7% were DR- TB). Systematic random sampling 
was employed to select 27 public health facilities from the 
three zones. The total sample size was distributed propor-
tional to the TB case load.30
Patient and public involvement
The research question of this study is in line with the 
Ethiopian tuberculosis research plan developed through 
multiple consultative processes involving broader stake-
holders including patient representatives. We plan to 
disseminate the research findings through the national 
TB research conferences involving researchers, policy-
makers, stakeholders and affected communities.
Data collection tools and quality assurance
The data collection was based on a structured question-
naire adapted from the United States Agency for Inter-
national Development (USAID) for HIV and the World 
Health Organization (WHO) patient costing tool for 
TB.31 32 The questionnaire captures sociodemographic 
variables, direct cost, indirect cost, productivity loss, 
assets, income, consumptions and coping- related infor-
mation. We complemented clinical information for TB 
through review of medical records.The questionnaire was 
translated into local languages, pretested and modified 
accordingly. Trained data collectors under close super-
vision undertook the face- to- face interview. TB patients 
 on N
ovem









pen: first published as 10.1136/bm




3Assebe LF, et al. BMJ Open 2020;10:e036892. doi:10.1136/bmjopen-2020-036892
Open access
with a minimum of 1 month on treatment were inter-
viewed consecutively and the expenses were reported 
retrospectively. This schedule of interview is based on 
WHO’s recommendation regarding the cost survey of TB 
patients.28 31 Whereas, for HIV, the expenditure in the 
past 4 weeks for outpatient and 6 months for inpatient 
care was gathered.
Patient cost
The costs of seeking standard HIV and TB care were 
estimated from a patient perspective. The expenditure 
related to routine care, HIV- related opportunistic infec-
tion and managing comorbidities was considered for HIV. 
Likewise, for TB episode, the expenditure in the pathway 
to care from onset of symptoms, diagnosis and comple-
tion of treatment was included.
Direct costs includes household expenditures for 
medical (ie, registration/consultation fees, laboratory 
tests, X- ray, medicines, hospital admission) and non- 
medical services (ie, special food/nutrition, transporta-
tion and guardian cost) net of reimbursement. Indirect 
costs constitute lost income following the disease episode. 
In order to estimate the indirect cost, patients were asked 
to estimate the time lost due to receiving and waiting for 
care, hospitalisation, transportation, lost working days 
and guardian time (TB). Then the total time lost was 
multiplied by an hourly wage rate, which was derived from 
monthly income/consumption by assuming 22 working 
days a month and 8 hours a day. For children less than 15 
years of age, non- medical direct and indirect TB cost was 
computed for the guardian. Total patient cost is the sum 
of all direct and indirect costs.
In order to annualise the cost, an average of four HIV 
outpatient visits and single TB episode outpatient visits 
was considered. The frequency of outpatient HIV visits 
per year was extrapolated on the basis of per capita 
healthcare visits an individual made over the last 1 month 
among all PLHIV interviewed. This proportion was annu-
alised to an approximately four visits per patient and year. 
The TB patient cost was extrapolated for the whole dura-
tion of TB episode based on an individual data reported 
retrospectively. All costs were gathered in local currency 
(Ethiopian Birr) and converted to US dollar ($) with the 
2019 exchange rate of $1=29.1468 Ethiopian Birr.33 For 
HIV, the cost was first converted to a reference period 
(2019) using Ethiopia’s consumer price index.34 Due to 
unavailability of data, we used household income (for 
HIV) and consumption aggregates (for TB) as a proxy 
for the household welfare measure and scaled to per 
adult equivalence (online supplementary appendix 1). 
In addition, participants were grouped into five- income/
consumption quintiles to reflect the socio- economic 
strata (online supplementary appendix 1).
An incidence of CHE occurs when direct costs (ie, OOP) 
exceed the 10% threshold of annual household income/
consumption.14 15 17 In addition to the 10% threshold, 
we carried out further analysis at 20% threshold of both 
OOP and total cost, and at 40% of non- food expenditure 
to allow for comparison.16 21 31 35 Furthermore, the distri-
bution of financial burden (measured as ratio of direct/
total costs to total household expenditure) across income 
quintiles was reported using headcount, overshoot 
and mean positive overshoot36 (online supplementary 
appendix 1).
Data analysis
Data was analysed using Stata V.16 software. The data was 
summarised using mean with SD or median with IQR due 
to skewed distribution. The cost was disaggregated by 
outpatient and inpatient care. A concentration index was 
used to assess health outcome measure inequality across 
income quintiles.36 37 Multivariate logistic regression was 
conducted to identify determinants of CHE by including 
significant variables in the univariate analysis. A stepwise 
regression approach was employed to develop the final 
model and an adjusted odds ratio (aOR) with 95% CI was 
reported. P value less than 0.05 declares statistical signif-
icance for each test. Multicollinearity was ruled out (vari-
ance inflation factor <5). Goodness of fit was checked by 
Hosmer- Lemeshow test.38
ethical consideration
Informed written consent was obtained from TB partic-
ipants. Oromia and Afar Regional Health Bureau, and 
respective zonal health offices provided permission to 
undertake the TB study.
reSultS
Out of the total 1006 HIV and 787 TB participants, 75% 
of HIV and 50% of TB were females (table 1). More than 
two- thirds of the study participants were in the age group 
between 25 to 44 years for HIV and 1 to 34 years for TB. 
The median family size was four (IQR, HIV: 3 to 5, IQR, 
TB: 3 to 6). The mean (SD) household annual income/
consumption per adult equivalence was $1188 ($1288) 
for HIV and $545 ($462) for TB. Seven per cent of TB 
patients were co- infected with HIV. Almost all (99%) of 
HIV and 91% of TB/HIV co- infected study participants 
were receiving ART. About 22% and 6% of HIV and TB 
patients had both outpatient and inpatient care, respec-
tively. The mean hospital stay was 11 days for HIV and 
10 days for TB. The mean (SD) time interval from first 
healthcare visit to TB diagnosis (health system delay) was 
14 (38) days and 85% of TB were diagnosed in public 
health facilities.
Patient cost of hIV and tb care
The total mean (SD) patient cost for HIV care was $78 
($170) per year and $115 ($118) for the entire duration 
of a TB episode (table 2). The mean (SD) direct cost was 
$54 ($144) for HIV and $53 ($59) for TB, which consti-
tutes 69% and 46% of the total cost, respectively. Medical 
costs contributed to 68% and 38% of the direct costs 
for HIV and TB, respectively. Diagnostics and medicine 
account for 39% of the total HIV cost. The mean (SD) 
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Table 1 Socio- demographic and clinical characteristics of 
HIV and TB study participants (Ethiopia)
Background 
characteristics
HIV (n=1006) TB (n=787)
N (%) N (%)
Gender
  Female 756 (75) 396 (50)
Age in years (mean, 
SD)
40 (10) 30 (14)
Age group
  <18 – 110 (14)
  18–24 14 (1) 190 (24)
  25–34 268 (27) 229 (29)
  35–44 435 (43) 117 (15)
  45–54 202 (20) 86 (11)
  55–64 58 (6) 32 (4)
  65+ 29 (3) 23 (3)
Marital status
  Single 38 (4) 309 (39)
  Married/living 
together
493 (49) 409 (52)
  Widowed 277 (27) 24 (3)
  Divorced 137 (14) 33 (4)
  Separated 61 (6) 11 (2)
Place of residence
  Urban 930 (92) 394 (50)
  Rural 76 (8) 393 (50)
Highest level of education
  Illiterate 290 (29) 257 (33)
  Elementary 457 (45) 334 (42)
  Secondary and 
higher
259 (26) 195 (25)
Family size
  ≤4 640 (64) 443 (56)
  >4 366 (36) 344 (44)
Annual household income/consumption
  Lowest 200 (20) 159 (20)
  Second 470 (21) 298 (20)
  Middle 797 (18) 443 (20)
  Fourth 1342 (20) 631 (20)
  Highest 3084 (21) 1198 (20)
ART status
  On ART 996 (99) 52 (91)
  Not on ART 10 (1) 5 (9)
Past history of illness*
  Yes 1006 (24) 61 (8)
  No 3165 (76) 726 (92)
Type of visit




HIV (n=1006) TB (n=787)
N (%) N (%)
  Inpatient 216 (22) 47 (6)
Number of visits per year/TB episode
  Outpatient 4428 (4 visits/
patient)
48 720 (70 visits/
patient)†





  Pulmonary TB – 507 (65)
  Extra- pulmonary 
TB
– 222 (28)
  Drug- resistant TB – 57 (7)
*HIV- related comorbidities (HIV), and history of TB (TB).
†The number of total visits per patient reaches 125 for outpatient 
and 135 for inpatient drug- resistant TB cases.
ART, antiretroviral therapy; TB, tuberculosis.
Table 1 Continued
indirect cost was $24 ($66) for HIV per year, and $63 
($83) per TB episode. The productivity loss related to TB 
follow- up visits accounts for 36% of the total cost.
The mean (SD) total cost was $63 ($165) for annual 
outpatient HIV care visit and $110 ($114) for the whole 
duration of outpatient TB care (table 2). Similarly, the 
mean (SD) total cost for each hospitalisation was $96 
($139) for HIV and $105 ($78) for TB. For patients 
having both outpatient and inpatient visits, the mean cost 
reaches $133 ($178) (p<0.001) for HIV and $ 217 ($157) 
(p<0.001) for TB.
For TB, the patient costs incurred prior to initiation of 
treatment are equal to the cost from initiation to comple-
tion of TB treatment (paired t- test >0.05). The mean (SD) 
total cost for those with TB/HIV co- infection reached 
$188 ($33). Similarly, the total cost of care significantly 
varies by type of TB, it was $104 ($107) for pulmonary, 
$140 ($138) for extra- pulmonary and $446 ($732) for 
DR- TB (Kruskal- Wallis test 41.1, p<0.001) (online supple-
mentary appendix table A1).
Coping costs
HIV and TB care results in adverse financial consequences 
for households. Nearly 24% of HIV and 68% of TB study 
participants have adopted coping mechanisms. Nine 
per cent of HIV and 4% of TB patients have borrowed 
money; while, 2% of HIV and 19% of TB patients sold 
their household assets. Furthermore, 12% of HIV patients 
relied on family assistance and 16% of TB patients used 
their savings to cope with the costs. Only 2% of HIV and 
6% of TB participants are covered by health insurance.
As shown in figure 1, the spikes in the Pen’s parade 
graph revealed that the healthcare costs of HIV and TB 
cause a large decrease in annual income/consumption 
for many of the households. The consumption drop for 
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Table 2 Distribution of household direct, indirect and total cost of HIV and TB care across main cost category in Ethiopia 
(expressed in $)
Cost category ($)








(per single visit) Total
(I) Direct medical cost
Consultation fee
  Mean (SD) 6 (15) 1 (5) 6 (15) 2 (5) 11 (16) 3 (7)
  Median (IQR) 0 (0–6) 0 (0–1) 0 (0–5) 1 (0–2) 7 (1–14) 1 (0–2)
Investigation cost
  Mean (SD) 14 (45) 9 (19) 15 (47) 8 (13) 14 (16) 9 (15)
  Median (IQR) 0 (0–11) 0 (0–9) 1 (0–12) 4 (0–12) 7 (3–18) 5 (0–13)
Drug cost*
  Mean (SD) 12 (40) 22 (63) 16 (48) 7 (14) 16 (21) 8 (16)
  Median (IQR) 0 (0–10) 4 (0–19) 1 (0–13) 1 (0–10) 8 (3–20) 2 (0–10)
Subtotal
  Mean (SD) 32 (88) 32 (77) 37 (98) 17 (24) 40 (37) 20 (30)
  Median (IQR) 4 (0–34) 8 (0–32) 6 (0–38) 10 (1–22) 30 (16–45) 11 (1–25)
(II) Direct non- medical cost
Transportation fee
  Mean (SD) 11 (55) 19 (34) 13 (53) 8 (10) 7 (7) 8 (10)
  Median (IQR) 2 (0–8) 6 (0–20) 3 (0–9) 5 (2–11) 7 (3–9) 5 (2–11)
Food/accommodation
  Mean (SD) 3 (50) 10 (30) 5 (48) 23 (29) 28 (34) 25 (31)
  Median (IQR) 0 0 (0–5) 0 15 (7–27) 16 (7–38) 16 (7–29)
Subtotal
  Mean (SD) 14 (80) 29 (49) 17 (76) 31 (34) 35 (36) 33 (37)
  Median (IQR) 2 (0–8) 10 (0–38) 3 (0–10) 21 (11–38) 20 (9–44) 21 (12–40)
Total direct cost
  Mean (SD) 46 (142) 60 (113) 54 (144) 48 (50) 75 (68) 53 (59)
  Median (IQR) 12 (1–45) 22 (4–74) 15 (2–57) 35 (17–61) 54 (26–94) 36 (18–64)
(III) Indirect cost
Foregone income before treatment†
  Mean (SD) 0 0 0 11 (28) 0 11 (26)
  Median (IQR) 0 0 0 0 (0–5) 0 0 (0–3)
Foregone income during treatment
  Mean (SD) 11 (44) 22 (41) 16 (50) 11 (26) 12 (31) 10 (26)
  Median (IQR) 0 8 (3–19) 0 (0–8) 0 (0–4) 0 0 (0–3)
Time loss related cost
  Mean (SD) 6 (19) 14 (52) 8 (30) 42 (59) 18 (24) 42 (58)
  Median (IQR) 2 (1–4) 2 (1–7) 2 (1–5) 27 (14–49) 8 (5–22) 27 (14–49)
Subtotal
  Mean (SD) 17 (54) 35 (75) 24 (66) 62 (84) 30 (37) 63 (83)
  Median (IQR) 3 (1–8) 13 (5–32) 4 (2–17) 36 (17–77) 9 (5–39) 36 (17–78)
(IV) Total cost
  Mean (SD) 63 (165) 96 (139) 78 (170) 110 (114) 105 (78) 115 (118)
  Median (IQR) 20 (5–63) 52 (25–109) 27 (7–80) 79 (46–140) 87(39-158) 81 (47–150)
*Drug other than anti- retroviral and anti- TB drugs.
†Not captured in HIV survey.
 on N
ovem









pen: first published as 10.1136/bm




6 Assebe LF, et al. BMJ Open 2020;10:e036892. doi:10.1136/bmjopen-2020-036892
Open access 
Figure 1 Pen’s parade of household annual income/
consumption gross and net of payments for HIV (a) and TB 
care (b) (Ethiopia). TB,tuberculosis.
Table 3 Mean (median) HIV and TB patient costs per year across income quintiles in Ethiopia (expressed in $)
Disease category Income quintiles
Cost type













HIV Poorest 45 (92) 14 (2–48) 8 (15) 2 (1–7) 53 (97) 20 (3–61)
Poor 55 (170) 13 (0–52) 10 (19) 3 (1–9) 65 (173) 22 (4–65)
Middle 50 (118) 19 (3–49) 16 (30) 3 (2–16) 66 (136) 32 (7–65)
Rich 47 (89) 15 (3–57) 25 (51) 4 (3–20) 71 (111) 27 (7–81)
Richest 73 (206) 19 (3–79) 60 (124) 14 (5–59) 133 (262) 60 (12–132)
P value* 0.358 <0.001 <0.001
TB Poorest 31 (35) 23 (7–41) 19 (20) 11 (6–24) 50 (44) 36 (20–66)
Poor 44 (48) 27 (15–54) 36 (32) 27 (13–45) 79 (65) 60 (38–96)
Middle 49 (53) 36 (17–61) 57 (46) 40 (22–82) 106 (79) 82 (57–137)
Rich 61 (48) 49 (28–84) 79 (63) 58 (27–117) 140 (96) 118 (68–181)
Richest 78 (86) 54 (34–99) 124 (145) 70 (40–163) 202 (189) 148 (88–260)
P value* <0.001 <0.001 <0.001
*Kruskal- Wallis test.
TB, tuberculosis.
TB is more pronounced than the income drop for HIV 
(figure 1).
As shown in table 3, there are inequalities in OOP 
costs among HIV and TB participants. The total cost rises 
steadily across the income quintiles and is concentrated 
among the richer quintiles (ie, the richer the quintile, the 
higher the cost). From the lowest to the highest income/
consumption quintile, the mean (median) total cost of 
HIV increases from $53 ($20) to $133 ($60), with signif-
icant difference among income quintiles (Kruskal- Wallis 
test 44.7, p<0.001), and for TB the cost increases from $50 
($36) to $202 ($148) (Kruskal- Wallis test 206.5, p<0.001). 
In general, the median cost (both direct and indirect) 
seems to be a bit higher for TB patients as compared to 
that of HIV patients.
Incidence and intensity of Che
At the 10% threshold, the overall CHE incidence of HIV 
was 20% (197 households); with 43% of the poorest and 
4% of the richest household experiencing CHE (χ2 for 
trend −10.58, p<0.001). The incidence is 33% for individ-
uals with inpatient HIV care. The corresponding level of 
TB was 40% (291 households); with 58% and 20% of the 
poorest and richest income quintile experienced CHE, 
respectively (χ2 for trend −6.79, p<0.001) (table 4). The 
incidence was much higher for those with TB/HIV co- in-
fection (48%), DR- TB (62%) and was almost universal 
(94%) for hospitalised TB patients. At the 20% threshold 
of total expenses, 48% (353 households) of TB house-
holds experienced catastrophic total costs (figure 2)
(online supplementary appendix table A2).
In our study, for example, the mean overshoot of 
TB- related CHE was 6.3% (range: 1.9% to 15.3%). 
On average, households spent 6.3% beyond the 10% 
threshold for TB care. However, the average positive 
overshoot among households that experienced CHE 
was 15.8% (range: 9.2% to 26.6%). Thus, on average, 
households that experienced CHE spent 25.8% (10% 
threshold+mean positive overshoot) of their total annual 
consumption for TB care (figure 2)(online supplemen-
tary appendix table A2).
Inequality in financial risk
In addition, as shown in figure 3, inequality in finan-
cial risk across income/consumption groups exists. 
The concentration curves for HIV and TB care costs lie 
 on N
ovem









pen: first published as 10.1136/bm




7Assebe LF, et al. BMJ Open 2020;10:e036892. doi:10.1136/bmjopen-2020-036892
Open access
Table 4 Multivariate logistic regression model of 
determinants of CHE for TB and HIV care at a 10% 
threshold of household income/consumption (Ethiopia)
Variable aOR (95% CI) P value
TB
Frequency of visits* 2.4 (1.9 to 3.1) <0.001
Hospitalisation
  No Ref.
  Yes 30.6 (4.8 to 199.8) 0.001
Income quintiles
  Richest Ref.
  Rich† 4.1 (2.1 to 7.8) <0.001
  Middle 4.9 (2.5 to 9.4) <0.001
  Poor 7.0 (3.6 to13.7) <0.001
  Poorest 14.6 (7.5 to 28.3) <0.001
Place of diagnosis
  Government Ref.
  Private 2.6 (1.5 to 4.3) <0.001
TB/HIV co- infection
  No Ref.
  Yes 3.2 (1.6 to 6.2) 0.001
Insurance (ie, CBHI)
  Yes Ref.
  No 2.7 (1.1 to 6.7) 0.038
Type of TB
  Bacteriologically- confirmed 
TB
Ref.
  Clinically- diagnosed TB 1.6 (1.0 to 2.8) 0.075
  Extra- pulmonary TB† 2.6 (1.8 to 4.0) <0.001
HIV
Frequency of visits per year* 1.07 (1.003 to 1.1) 0.04
Hospitalisation
  No Ref.
  Yes 3.3 (2.2 to 4.9) <0.001
Income quintiles
  Richest Ref.
  Rich 2.5 (1.1 to 5.8) 0.025
  Middle 4.5 (2.1 to 9.8) <0.001
  Poor 9.4 (4.5 to 19.5) <0.001
  Poorest 18.4 (8.9 to 37.7) <0.001
*Variable treated as continuous.
†Overall test is significant.
aOR, adjusted OR; CBHI, community- based health insurance; 
CHE, catastrophic health expenditures; TB, tuberculosis.
below the 45° line of equality, which shows a greater 
concentration of the costs among the rich. However, 
the financial burden is higher among the poor—the 
concentration curves for HIV and TB care expenditure 
in relation to income/consumption lie above the 45° 
line of equality.
Determinants of Che
In the multivariate analysis (table 4), three variables were 
independently associated with HIV related CHE: hospital-
ised patients (aOR: 3.3, 95% CI: 2.2 to 4.9), being poorest 
(aOR: 18.4, 95% CI: 8.9 to 37.7) and poor (aOR: 9.4, 95% 
CI: 4.5 to 19.5) were associated with catastrophic HIV 
care expenditures. Moreover, every additional visit for 
HIV care increases the odds of CHE by 7% (aOR: 1.07, 
95% CI: 1.003 to 1.1).
Seven variables were significantly associated with 
TB- related CHE (table 4): private facility diagnosis (aOR: 
2.6, 95% CI: 1.52 to 4.33), extra- pulmonary TB (aOR: 2.6, 
95% CI: 1.77 to 3.95), hospitalised patients (aOR: 30.6, 
95% CI: 4.77 to 199.83), being poorest (aOR: 14.6, 95% 
CI: 7.49 to 28.26) and TB/HIV co- infection (aOR: 3.2, 
95% CI: 1.63 to 6.15) were very likely to have TB- related 
CHE as compared with their counterparts after adjusting 
for other variables. Every additional visit for TB diag-
nosis increases the odds of experiencing CHE by 2.4 
times (aOR: 2.4, 95% CI: 1.92 to 3.05). Households with 
a health insurance scheme have protection from CHE 
(aOR 2.7; 95% CI 1.06 to 6.73).
DISCuSSIOn
In this study, we tried to estimate the OOP, total cost, 
incidence and determinants of CHE among individuals 
seeking HIV and TB care. This could provide valuable 
insight into the level of financial risk protection that a 
health system offers to its population.
hIV care costs and Che
In Ethiopia, where ART is given free- of- charge, PLHIV 
had to pay a total of $78 per year for HIV care ($19.5 per 
visit). The total HIV patient cost was equivalent to 7% of 
their annual income. As HIV requires lifelong care, such 
costs have a devastating impact on affected households. 
Our estimate was lower than the level and rate found in 
Cameroon 17%,39 Ethiopia 21%,23 Nepal 28.5%40 and 
South Africa (30%).41 These variations might arise from 
different study settings;39 40 high expenses of additional 
food and time loss.41 Similarly, more centralised HIV 
service delivery, delays in seeking care and long distance 
travel to access services may explain the difference with 
the previous study from Ethiopia. Additionally, the annual 
income in this study was twice that of the latter study.23 
However, a study on outpatient HIV care in Nigeria 
reported one- fourth of the cost in this study ($21.76).42
In our study, the average direct OOP expenditure for 
HIV care was $54 (ie, 69% of the total cost) and compa-
rable with that of the previous studies from Lao, Ethiopia 
and Nepal.19 23 40 Diagnostics, medicines and transpor-
tation costs constitute the largest share, and may pose a 
serious challenge to the success of the HIV programme. 
This calls for public financing policies (ie, free of charge 
diagnosis and treatment of HIV- related comorbidities 
for vulnerable groups) in the next steps of UHC expan-
sion. The productivity loss found here was one- half of 
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Figure 2 Interval plot (with 95% CI for the mean) of incidence and intensity of HIV and TB- related catastrophic health 
expenditures (CHE) across income quintiles, using 10% threshold (Ethiopia). CI, confidence interval, TB, tuberculosis.
that of the previous studies in Ethiopia and Nepal,23 40 
but one- fourth of that of Lao study.19 The difference in 
productivity losses with previous Ethiopian study could be 
attributed to a more centralised provision of HIV services 
and backlog of patients with advanced HIV diseases, 
unlike this study. The total costs of HIV care increases 
as income rises. The equity ratios (Q1:Q5, 0.39) showed 
higher expenditure among the richest income quintile, 
which is consistent with a study from southeast Nigeria.43
In our study, about a fifth (20%) of patients seeking 
HIV care experienced CHE. A study from India also 
depicts similar findings.44 However, the rate is lower than 
that of a study from Cameroon.39 Furthermore, the inci-
dence of HIV- related CHE remained relatively high; in 
particular, where poorest households suffer more. Similar 
socio- economic inequality was observed in previous 
studies,42 43 highlighting the importance of rendering 
equitable access to all in need of HIV care, particularly for 
the poor.39 Consistent with previous studies, being poor 
is associated with higher CHE.19 45 In addition, the poor 
were pushed further beyond the CHE threshold than the 
better off. This is of great concern, as health shocks are 
slightly managed by the poor through reduction of basic 
requirements to compensate for HIV care. Similar to 
previous studies, being hospitalised was a stronger deter-
minant of CHE.19 42
tb care costs and Che
In our study, patients with TB incurred a total cost of $115 
per episode and represents 21% of the annual household 
income, comparable to a study in South Africa (22%).46 
However, the total cost was less than the figure reported 
by previous studies in Ethiopia,22 29 but twice higher than 
the finding from southern Ethiopia.47 The variation in 
cost from previous studies arises from high expenditure 
on nutritional supplements ($72 vs $25),29 lower level of 
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Figure 3 Concentrations curves and index (I) for direct, 
indirect, total cost and share of OOP to income/consumption 
for (a) HIV and (b) TB services in Ethiopia. OOP,out- of- pocket 
payment; TB, tuberculosis.
seeking diagnostic care from public health facilities (64% 
vs 85%), high rates of clinically diagnosed cases (49% vs 
24%), diagnostic delays result in longer losses of working 
days,22 only direct cost captured.47 The average patient costs 
of DR- TB care were four times higher than drug- susceptible 
TB care. However, the DR- TB cost was three times lower 
than findings from another Ethiopian study.48 Still the 
devastating nature of DR- TB may put patients at special risk 
of CHE. The lower costs is mainly due to decentralisation 
of DR- TB services in recent years and the introduction of 
shorter multidrug- resistant TB treatment regimen (ie, 71% 
the study participants took 9- month to 12- month regimen).
In this study, one- half of the mean TB cost was incurred 
prior to initiation of treatment, which was consistent with 
many previous studies.11 21 22 49 50 This is mostly due to 
payment while demanding for proper diagnosis of TB.21 In 
addition to the financial burden of high pretreatment costs, 
it will be a barrier to complete the diagnostic process, and 
to timely access treatment and care. These emphasise the 
need for early case finding with rapid and point of care TB 
diagnostics, involvement of private care providers and insti-
tuting effective referral and linkage.47
The direct patient costs incurred constitute 46% of the 
total, comparable with findings from elsewhere (36%)51 
and systematic review results (40%).11 However, the propor-
tion was higher than the finding from southwestern Ethi-
opia (29%) and lower than the report from central Ethiopia 
(71%).22 29 Consistent with previous studies, non- medical 
and indirect costs represent a large share of the TB cost, 
while medical cost represent less than 20%.11 22 41 There-
fore, ensuring the expansion of TB service package through 
the effective integration of a health insurance scheme and 
decentralisation of services can reduce the direct costs.
A higher percentage of households incurs CHE for TB 
care (40%), which was comparable with studies from Fiji 
(40%), Ghana (47.6%), China (53%), Philippines (35%) 
and lower than reported rates from Ethiopia (63%), 
Nigeria (65%) and Benin (72%).29 49 50 52–54 However, CHE 
for TB care was higher in this study compared with findings 
in studies from India (21%) and Malaysia (6%).51 55 This 
variation might arise from cost estimation method, study 
setting, health system and socio- economic differences. The 
TB- related CHE was higher than the reported rate for HIV. 
The main reasons for this are the differences in treatment 
duration, follow- up frequency and care access between HIV 
and TB. TB patients experience a very onerous set of direct 
and indirect costs during diagnostic and intensive phase of 
directly observed short course therapy (ie, more intense 
for retreatment, extra- pulmonary and DR- TB cases). After 
treatment completion and possible sputum conversion, TB 
patients are less likely to face additional costs. Even though 
the annual cost of HIV care is lower, PLHIV faces these costs 
over its lifetime because HIV infection is a chronic disease 
that needs lifelong treatment. The comparison of incidence 
and intensity of CHE for TB and HIV is also complicated by 
the use of income for HIV and consumption for TB- related 
computations. In developing countries, income is a poor 
self- reported estimator of welfare due to more common 
informal employment, seasonal agricultural activities and 
widespread reluctance to disclose income.15 Therefore, 
income could understate the welfare of the household, 
whereas using consumption may overstate the condition of 
the household because of the use of dissaving/borrowing 
to smooth consumption over time.56
The mean overshoot for TB was 6.3% and the mean posi-
tive overshoot was 15.3%, both were similar with finding 
from Benin (7.8% and 14.8%) and Nigeria (6.0% and 
9.3%).50 52 TB, inequitably, imposes a greater burden of 
CHE on the poor households. Even though poor house-
holds tend to spend less, a higher share of their income is 
spent on seeking TB care.12 29 46 50 52 In addition, the excess 
CHE beyond the threshold was inequitably high among the 
poor. This finding is also in line with other studies.29 50 52 
Similar to other studies, hospitalisation, income status and 
TB/HIV coinfection were among the key determinants of 
TB- related CHE.28 49 50 52 55 In addition, even if the health 
insurance coverage (ie, community- based health insurance) 
was low and is limited to medical costs, we found protective 
effect of the scheme against CHE.57 However, health insur-
ance per se does not alleviate the major TB costs.
Study limitation and strengths
This study has some limitations. First, the cost measure-
ments relied on patient’s ability to remember, which 
increases risk of recall bias. However, we reduced the recall 
bias by interviewing participants who sought HIV and TB 
care within the past 1 month, when patients have a better 
recollection of their pathway to care.28 31 Second, HIV 
costs may be overestimated when aggregated over a 1- year 
period. Third, our findings may not be representative of 
all patients with TB in Ethiopia, as the study is limited to 
specific regions of the country. Similarly, the PLHIV associ-
ations operate in high HIV prevalence urban areas, where 
members of these associations may not be representative of 
both rural and non- members. Moreover, undetected HIV 
and TB cases not seeking care were not addressed. Despite 
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these limitations, we used a standard tool and method to 
conduct the study. We believe that our study will be of high 
value to inform policy, at national and subnational levels, 
related to financial risk protection of both diseases, which is 
central in achieving UHC.
Policy implications
Despite OOP exemption of HIV and TB services in Ethi-
opia, we found that there is a large gap between the actual 
level of financial protection provided and the ideal goal. 
Our findings highlight important policy implications. 
First, more patient- centred care with effective diagnostics, 
appointment spacing for stable patients and community- 
based treatment are required to improve the delivery of 
HIV and TB services. Second, strategies are required to 
ensure social and financial risk protection for the house-
holds affected by HIV and TB. This requires effective 
integration of HIV and TB services with social and finan-
cial protection schemes, including the provision of travel 
vouchers, nutritional support and paid sick leaves through 
multisectoral collaboration.
COnCluSIOn
HIV and TB affected individuals and their households in 
Ethiopia face substantial costs in seeking care despite ‘free 
medical services’. The incidence of CHE related to HIV and 
TB care was high in all income quintiles, though more so 
in the poorest households. Policymakers should introduce 
patient- centred care; expand social and financial risk protec-
tion measures to minimise the high patient cost of HIV and 
TB care, particularly among vulnerable populations.
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Supplementary appendix 1 
The financial burden of HIV and TB among patients in Ethiopia: a cross-sectional 
survey 
 
Lelisa Fekadu1*, Eyerusalem Negussie2, Abdulrahman Jbaily3, Mieraf Taddesse Tolla3, Kjell 
Arne Johansson1 
S1. Consumption construction 
In this study, income (for HIV) and consumption as proxy for income (for tuberculosis) were 
used as household welfare measure. The consumption aggregates for tuberculosis (TB) was 
constructed using the overall value of the food (purchased food, home produced food) items, 
non-food items, and housing information collected at different recall periods (ranging from 1 
to 12 months depending on how frequently the item purchased). Then, all reported expenditures 
on food items, non-food items, and housing were converted to a month period, then added up 
and multiplied by 12 to create annual consumption for each household. 
The income (for HIV) and consumption (for TB) measures were also adjusted for family size 
and demographic composition to reflect economy of scale. We constructed per adult 
equivalence through dividing household income/consumption expenditure by an adult 
equivalent scale. Adult equivalent values (AE) were calculated using 𝐴𝐸 = (𝐴 + 𝛼𝐾)𝜃 for 
HIV, where 𝐴 stands for number of adults, 𝐾 is the number of children in the household, 𝛼 is 
the cost of a child relative to an adult (0.33) and 𝜃 is the degree of economies of scale (0.9) (1). 
Whereas for TB, due to the unavailability of child data, we calculated using 𝐴𝐸 = ℎ𝑠𝑖𝑧𝑒𝛽 , 
where “ℎ𝑠𝑖𝑧𝑒” is the actual household size and β was set to be 0.56 (2). Using per adult 
equivalence income (HIV) and consumption (TB) values, we grouped all households into five 
income quintiles of equal size. 
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S2.  Incidence and intensity of catastrophic health expenditure (CHE) 
S2.1. Measuring incidence of CHE (Headcount) 
Catastrophic health expenditure (headcount, H) occurs when household OOP health spending 
exceeds a predefined threshold (10%) of household income/consumption. Furthermore, we 
conducted analysis at 20% threshold of both OOP and total cost (new definition of catastrophic 
cost recommended for TB), and at 40% of non-food expenditure (i.e. net of basic subsistence 
expenditure).     
The CHE headcount is calculated using the equation 
𝐻 = 1𝑁 ∑ 𝐸𝑖𝑁𝑖=1  ,  
Where,    𝐸𝑖 = 1  if  𝑇𝑖𝑋𝑖  or 𝑇𝑖(𝑋𝑖−𝐹𝐸𝑖) > 𝑧  and 0 otherwise. 
Here, N equals the total sample size, 𝑇𝑖  is the OOP health spending of household 𝑖,  𝑋𝑖 is the 
total expenditure of household 𝑖, 𝐹𝐸𝑖 is the food expenditure of household 𝑖 and 𝑧 is the 
specified threshold. 
S2.2. Measuring intensity of CHE  
The intensity is measured using overshoot (O) and mean positive overshoot (MPO). 
S2.2.1. Overshoot  
The overshoot measures the extent of average expenditure exceeding the given threshold in the 
entire sample. The overshoot is calculated using the equation   
𝑂 = 1𝑁 ∑(𝐸𝑖 (𝑇𝑖𝑋𝑖) − 𝑧)𝑁𝑖=1  
S2.2.2. Mean positive overshoot  
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The mean positive overshoot measures the extent of an average expenditure exceeding the 
threshold among households experiencing CHE, and is calculated by: 
𝑀𝑃𝑂 =  𝑂𝐻  
Table A1. Mean (median) patient costs per TB case across three types of TB (Ethiopia) 
expressed in $. 
 
* kruskal wallis test p-value <0.001 
¥    CHE at 10% threshold ranged from 33% to 57% for pulmonary and extra-pulmonary TB, respectively. 
Table A2. Incidence and intensity of CHE for HIV and TB across different income quintiles 
and threshold, 2019, Ethiopia 
Disease  Measure Of CHE Threshold Average Income Quantile 
Q1 Q2 Q3 Q4 Q5 
HIV Out-of-pocket HIV spending: as a share of annual income  
Head count (CHE incidence) %  10% 20 43 27 15 10 4 
Overshoot % 10% 7.6 26.2 7.5 2.7 0.9 0.9 
Mean positive overshoot % 10% 39.1 61.8 28.2 18.3 9.9 17.8 
Out-of-pocket HIV spending: as a share of annual income     
Head count (CHE incidence) %  20% 11 30 14 6 3 1 
Overshoot % 20% 6.2 22.5 5.6 1.7 0.5 0.6 
Mean positive overshoot % 20% 58.0 74.9 38.6 28.2 18.2 122.0 
Total HIV spending: as a share of annual income 
Head count (CHE incidence) %  20% 15 38 18 11 6 3 
Overshoot % 20% 7.2 25.4 6.4 2.5 0.8 0.8 
Mean positive overshoot % 20% 48.6 67.8 36.2 23.6 15.0 27.7 
Out-of-pocket HIV spending: as a share of total non-food expenditure 
Head count (CHE incidence) %  40% 11 31 15 7 3 1 
Overshoot % 40% 13.1 47.4 11.8 3.6 1.0 1.2 
Mean positive overshoot % 40%  116.3 153.0  79.5 55.4  39.7 128 
TB Out-of-pocket TB spending: as a share of annual income 
Head count (CHE incidence) %  10% 40 58 48 38 35 20 
Overshoot % 10% 6.3 15.8 7.5 4.1 2.7 1.9 




Type of  TB 
Pulmonary¥ Extra-pulmonary TB¥ Drug resistant-TB 
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR) 
Poorest  46 (43) 32 (13-62) 60 (45) 46 (32-75) 295 (290) 139 (65-607) 
Poor  67 (44) 56 (34-85) 107 (90) 83 (49-136) 159 (85) 153 (68-199) 
Middle  102 (80) 75 (48-137) 115 (74) 94 (72-131) 205 (175) 156 (86-250) 
Rich  133 (99) 102 (65-176) 155 (86) 133 (79-212) 534 (671) 291 (131-669) 
Richest  175 (165) 121 (78-216) 262 (226) 212 (112-294) 971 (1356) 610 (201-821) 
Total*  104 (107) 73 (41-135) 140 (138) 96 (58-180) 446 (732) 191 (107-607) 
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Out-of-pocket TB spending: as a share of annual income    
Head count (CHE incidence) %  20% 17 38 23 10 8 6 
Overshoot % 20%  3.7 10.7 4.1 1.9 0.7 0.8 
Mean positive overshoot % 20% 21.3 27.8 17.7 18.7 8.8 15.2 
Total TB spending: as a share of annual income 
Head count (CHE incidence) % 20% 48 60 53 48 46 36 
Overshoot % 20% 10.0 18.6 11.0 8.0 6.7 4.4 
Mean positive overshoot % 20% 20.0 31.1 20.9 16.7 14.7 12.3 
Out-of-pocket HIV spending: as a share of total non-food expenditure    
Head count (CHE incidence) %  40% 37 50 43 39 33 19 
Overshoot % 40% 29.2 73.0 27.5 18.6 14.9 11.6 
Mean positive overshoot % 40% 78.7 146 63.6 47.7 44.7 59.5 

























Supplementary material BMJ Open
 doi: 10.1136/bmjopen-2020-036892:e036892. 10 2020;BMJ Open, et al. Assebe LF
5 
 
 References  
1. Deaton A, Zaidi S. Guidelines for constructing consumption aggregates for welfare analysis. 2002. 
2. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household catastrophic health 















Supplementary material BMJ Open
 doi: 10.1136/bmjopen-2020-036892:e036892. 10 2020;BMJ Open, et al. Assebe LF
 
  Paper II 
 

Assebe et al. Malar J           (2020) 19:41  
https://doi.org/10.1186/s12936-020-3103-5
RESEARCH
Health gains and financial risk protection 
afforded by public financing of selected 
malaria interventions in Ethiopia: an extended 
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Abstract 
Background: Malaria is a public health burden and a major cause for morbidity and mortality in Ethiopia. Malaria 
also places a substantial financial burden on families and Ethiopia’s national economy. Economic evaluations, with 
evidence on equity and financial risk protection (FRP), are therefore essential to support decision-making for policy-
makers to identify best buys amongst possible malaria interventions. The aim of this study is to estimate the expected 
health and FRP benefits of universal public financing of key malaria interventions in Ethiopia.
Methods: Using extended cost-effectiveness analysis (ECEA), the potential health and FRP benefits were estimated, 
and their distributions across socio-economic groups, of publicly financing a 10% coverage increase in artemisinin-
based combination therapy (ACT), long-lasting insecticide-treated bed nets (LLIN), indoor residual spraying (IRS), and 
malaria vaccine (hypothetical).
Results: ACT, LLIN, IRS, and vaccine would avert 358, 188, 107 and 38 deaths, respectively, each year at a net govern-
ment cost of $5.7, 16.5, 32.6, and 5.1 million, respectively. The annual cost of implementing IRS would be two times 
higher than that of the LLIN interventions, and would be the main driver of the total costs. The averted deaths would 
be mainly concentrated in the poorest two income quintiles. The four interventions would eliminate about $4,627,800 
of private health expenditures, and the poorest income quintiles would see the greatest FRP benefits. ACT and LLINs 
would have the largest impact on malaria-related deaths averted and FRP benefits.
Conclusions: ACT, LLIN, IRS, and vaccine interventions would bring large health and financial benefits to the poorest 
households in Ethiopia.
Keywords: Malaria, Ethiopia, Equity, Financial risk protection, Extended cost-effectiveness analysis
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Background
Malaria prevention and control has been prioritized over 
the past decade in many national health sector plans. 
As a result, remarkable progress was made worldwide 
in reducing incidence and mortality from malaria [1, 
2]. Due to the expansion of effective strategies, between 
2001 and 2013, malaria incidence has dropped by 30% [1, 
2]. Despite such progress, malaria remains a major public 
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development of many countries [1, 2]. Nearly one-half of 
the world population lives in malaria-endemic countries 
[3]. In 2016 alone, there were an estimated 216 million 
cases and 445,000 deaths attributable to malaria world-
wide [4]. Sub-Saharan Africa accounts for 90% of both 
cases and deaths due to malaria [4]. Malaria control is 
unequally distributed across socioeconomic groups and 
the rates of insecticide- and drug-resistance are increas-
ing. Further scale-up of cost-effective malaria interven-
tions with sustainable financing mechanisms is therefore 
urgently needed [5].
Ethiopia has made notable progress towards malaria 
control [6, 7]. Nationally, the prevalence of malaria has 
declined from 5 to 3% over 2010–2015 [5, 8, 9]. During 
the same period, malaria-related deaths were reduced 
by 40% [5]. Scale-up of effective anti-malaria interven-
tions at the primary health care level and improved com-
munity engagement were major contributing factors to 
this progress [10]. There is little evidence from Ethio-
pia about other factors that might have contributed to 
malaria decline (e.g. climate change, housing structures 
and urbanization). However, despite significant progress, 
much remains to be done in the fight against malaria in 
Ethiopia, where about 2.6 million cases and 5000 deaths 
were estimated for the year 2016 [4]. Additionally, the 
2015 malaria indicator survey shows that only 40% of the 
population at risk correctly use insecticide-treated bed 
nets [9].
Malaria prevention and control are major priorities for 
Ethiopia’s health sector transformation plan (HSTP) [11]. 
The primary strategies include rolling out long-lasting 
insecticide-treated bed nets (LLIN) and insecticide resid-
ual spray (IRS) for at-risk population [10, 12]. Similarly, 
artemisinin-based combination therapy (ACT) is recom-
mended as first-line treatment of uncomplicated malaria 
[10, 12]. Ethiopia has committed to end malaria by 2030 
and adopted global malaria control and elimination strat-
egies [12]. As the country moves towards elimination 
by 2030, tests that are more sensitive will be required to 
detect subclinical malaria infection to prevent disease 
transmission [13]. A malaria vaccine (i.e. RTS,S/AS01) 
could help curb the malaria burden. However, the effi-
cacy of the vaccine is partial and presents rapid waning 
immunity [14, 15].
Malaria is endemic in many regions of Ethiopia with 
marked seasonal and geographic variation. Nearly 60% 
of the total population reside in high-risk areas [10, 12]. 
In addition to its public health impact, malaria imposes 
a large financial burden on households, consuming on 
average 7% of household income [16, 17]. Marginalized 
and economically vulnerable populations are also at a 
higher risk of acquiring malaria and of experiencing fatal 
consequences because of limited health care access and 
the inability to pay for it [1, 18, 19]. Malaria spending is 
estimated to cost Ethiopia about $200 million annually 
or 10% of its total health expenditure [20]. Hence, reduc-
ing malaria disease burden has the potential to improve 
socioeconomic development [21].
The recent attention to universal health coverage 
(UHC) has provided context to explore mechanisms that 
would expand access to malaria prevention and treat-
ment services in Ethiopia [22]. This would also help 
address the high rate (33%) of out-of-pocket (OOP) pay-
ments [20]. Given that a quarter of the Ethiopian popu-
lation lives below the national poverty line [23], OOP 
malaria treatment costs can be an important barrier to 
access effective treatment and in pushing households into 
impoverishment in Ethiopia. Accounting for non-health 
benefits is essential to reduce health inequalities and 
contribute to the objectives of UHC [22]. Financial risk 
protection (FRP) is an important policy objective and can 
improve access to all needed quality health services with-
out financial hardship [24, 25].
In this paper, the aim is to estimate the potential health, 
FRP, and equity benefits of universal public finance of 
scaling up selected malaria prevention and treatment 
interventions in Ethiopia [26]. This will support poli-
cymakers in jointly considering health gains, FRP and 
equity benefits in resource allocation related decisions.
Methods
Using extended cost-effectiveness analysis (ECEA), we 
consider the costs and health impact of malaria inter-
ventions across population subgroups and estimate the 
FRP impact on households in Ethiopia [26]. Building on 
a recent ECEA of malaria vaccine [28], and using a static 
disease model, are quantified, across socioeconomic 
groups (i.e. income quintiles), for each of four malaria 
interventions (ACT, LLIN, IRS, and malaria vaccine): the 
number of malaria-related deaths and OOP expenditures 
averted; the corresponding household FRP provided; and 
the implementation costs. Furthermore, ECEA is also 
applied across malaria transmission intensities to account 
for geographic variation of malaria (see Additional file 1: 
Appendix Table S2).
Malaria interventions
Large scale use of LLINs is a key strategy to reduce 
malaria burden [29]. A meta-analysis showed that LLIN 
was effective in both reducing malaria cases (by 50%) and 
malaria deaths (by 18%) [27]. IRS can eliminate malaria 
vectors by applying a residual insecticide to the internal 
walls and ceilings of homes [2, 30], and its use has been 
shown to decrease plasmodium falciparum malaria by 
29% [31]. A complete cure can be expected in 95% of 
falciparum malaria cases treated with ACT [32]. The 
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proportion of Plasmodium falciparum malaria in Ethio-
pia totals about 80–90% of all malaria cases [9]. Lastly, a 
recent clinical trial showed a 26% reduction in the num-
ber of episodes and hospital admissions, in children 
under 2  years of age, following three doses of malaria 
vaccine (currently under development) [14].
Health benefits
Population at risk of malaria (accounting for 60% of total 
population—defined as areas with annual incidence > 0 
per 1000 population) is the target population for LLIN 
and IRS (Table  1) [12]. Similarly, the estimated number 
of annual malaria cases and birth cohorts born in at-risk 
areas were the target populations for ACT and vaccine, 
respectively [12, 14]. Target populations were split into 
income quintiles for LLIN, IRS, and ACT interventions. 
As for the vaccine, quintile-specific total fertility rates 
were applied in order to differentiate between the num-
ber of susceptible individuals per income quintile (see 
Additional file  1: Appendix). For each intervention, in 
order to calculate malaria prevalence by at-risk popula-
tion per income quintile, first the relative risk of malaria 
prevalence by income quintile is estimated for the gen-
eral population [9, 10]. These stratified relative risks were 
multiplied by average malaria prevalence, in order to split 
prevalence rates across income quintiles for populations 
at risk (see Additional file 1: Appendix) [9, 10].
The baseline coverage (before introduction of universal 
public financing) was 40% for LLIN and 29% for IRS and 
their respective coverage by income quintile was sourced 
from the 2016 malaria indicator survey (MIS) (Table  1) 
[9]. LLIN use, rather than its possession, was selected as 
a proxy parameter because the actual use of LLIN reflects 
behavioural change [33]. The percentage for whom care 
was sought among children who had fever in the past 
2  weeks was used as a proxy for probability of seeking 
malaria care and baseline ACT coverage (35%) [34, 35]. A 
10% incremental coverage across quintiles was assumed 
for each intervention. For the vaccine, in addition to the 
10% incremental increase in coverage, a scenario with 
coverage scale-up from 0 to 33% was also considered 
(since this is the national coverage level of the basic child 
immunization programme) [34].
Before intervention, 2.6 million cases and 5000 deaths 
attributed to malaria were assumed to occur annually in 
Ethiopia [4]. On average, 1% of all malaria cases would 
be hospitalized, according to the integrated disease sur-
veillance database [36, 37]. Severe and mild cases were 
treated as inpatient and outpatient cases, respectively. 
Deaths averted by each intervention were calculated 
as a product of disease incidence, case fatality ratio, 
intervention efficacy and incremental coverage (see 
Additional file 1: Appendix). 
Financial consequences for households
Both inpatient and outpatient care of malaria can impose 
an economic burden to individual households. Direct 
medical, non-medical, and indirect costs were extracted 
from two previously published studies [18, 42]. Before 
universal public finance (UPF) of each intervention, indi-
viduals seeking malaria care would pay about $6 and $66 
out-of-pocket (OOP) costs for outpatient and inpatient 
treatment, respectively [18, 42]. Even if there were no 
OOP payments for preventive interventions, the three 
malaria preventive interventions (i.e. LLIN, IRS, vaccine) 
would lower the risk of malaria and thus household OOP 
expenditures related to malaria treatment. The amount of 
OOP expenditures averted per income quintile was quan-
tified, before and after UPF. OOP expenditures averted 
depended on: target population, incremental coverage, 
health care use, OOP payments, and preventive interven-
tion effectiveness (see Additional file 1: Appendix).
Financial risk protection benefits
The financial risk faced by households depends on the 
malaria burden, intervention coverage, and probability 
of seeking treatment. Annual consumption expenditures 
were extracted from the Ethiopian Household Income 
Consumption and Expenditure and Welfare Monitor-
ing Survey as a proxy for income [48]. In this study, a 
case of catastrophic health expenditures (CHE) was 
counted when total OOP spending for malaria treatment 
exceeded 10% of total household consumption expendi-
tures or 40% of capacity to pay (i.e. non-food total house-
hold consumption) [49, 50]. UPF introduction would 
avert a number of CHE cases following the reduction in 
incidence of OOP expenditures.
Intervention costs
The cost of each intervention was estimated from the 
health system perspective. Average unit cost estimates 
for preventive (LLIN, IRS, and vaccine) and curative 
(ACT) interventions were obtained from published stud-
ies (Table  1) [44–47]. The unit cost for LLIN included 
net price and delivery cost. Similarly, for IRS, insecticide 
cost accounted for 50%, spray campaign operations and 
labour for 26%, capital cost for 23% and other commodi-
ties accounted for 1% [44, 46, 47]. The average unit cost 
per fully vaccinated child included vaccine price, and sup-
plies accounted for 84%, and the remaining costs (16%) 
included training, transportation, waste management 
[45]. Unit cost of ACT comprised of human resources at 
58%, drug and pharmaceutical supplies at 25% and rest 
was indirect costs [43]. Patient and health system costs 
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Table 1 Extended cost-effectiveness analysis input parameters for  public financing of  selected malaria prevention 
and treatment interventions in Ethiopia
a Q1 stands for poorest income quintile,  Q5 for richest income quintile, and A for average
b Average unit cost estimate for inpatient visit
Parameter Value References
Epidemiology
 Population at risk of malaria (2016) 61,504,000 [12, 38]
 Population for malaria vaccine (2016 birth cohort) 1,984,000 Authors’ calculation [34, 38]
 Crude birth and child mortality rate, per 1000 population 32, 20 [34]
 Total fertility rate,  Q1–Q5;  A
a 6.4, 5.6, 4.9, 4.3, 2.6; 4.6 [34]
 Average household size 4.2 [38]
 Number of malaria deaths in the general population, population at risk, 
and children
5000; 3767; 1790 [4, 39]
 Prevalence of malaria in population at risk,  Q1–Q5; A 4.6; 3.1; 3.6; 2.2; 2.1; 3.1% [9, 10]
 Prevalence of malaria in children,  Q1–Q5; A 5, 3.3, 2.9, 2, 1.7, 3.1% [9]
 Probability of seeking malaria care,  Q1–Q5; A 23.8, 30.4, 33.0, 42.3, 50.5; 35.3% [34]
 Case fatality ratio for malaria outpatient and inpatient cases 0.19; 0.65% [3, 4]
 Proportion of malaria-related hospital admissions, Q1–Q5 1.00, 0.90, 0.96, 0.87, 0.83; 0.91% [36, 37]
 Effectiveness of LLIN 50% [27, 40]
 Effectiveness of indoor residual spraying (IRS) 29% [31]









 LLIN coverage before intervention,  Q1–Q5, A 26, 36, 42, 47, 44; 40% [9]
 LLIN coverage after intervention,  Q1–Q5, A 36, 46, 52, 57, 54; 50% [12] Authors’ assumption
 IRS coverage before intervention,  Q1–Q5, A 35, 35, 36, 28, 11; 29% [9]
 IRS coverage after intervention,  Q1–Q5, A 45, 45, 46, 38, 21; 39% [12] Authors’ assumption
 Malaria vaccine coverage before intervention,  Q1–Q5, A 0 [15]
 Malaria vaccine coverage after intervention,  Q1–Q5, A 10, 10, 10, 10, 10; 10% Authors’ assumption
 Malaria vaccine coverage after intervention,  Q1–Q5, A (fully immunized 
coverage)
19, 31, 30, 40, 58; 33% [34]
 ACT coverage before intervention,  Q1–Q5, A 24, 30, 33, 42, 51; 35% [34]
 ACT coverage after intervention,  Q1–Q5, A 34, 40, 43, 52, 61; 45% Authors’ assumption
Costs (2016 $)
 Out-of-pocket outpatient costs,  Q1–Q5, A $6.4, 6.8, 5.5, 6.6, 5.7; 6.2 [42]
 Out-of-pocket inpatient costs $65.9 [18]
 Unit cost of malaria treatment outpatient visit $7.3 [43]
 Unit cost of malaria treatment inpatient  visitb $31.6 [43]
 Unit cost of LLIN $5.4 [44]
 Unit cost per vaccinated child (3 doses) $26.0 [45]
 IRS unit cost per person protected $5.3 [46, 47]
 Household consumption expenditure  Q1–Q5, A $227, 369, 499, 671, 1422; 638 [48]
 Share of food in total consumption expenditure  Q1–Q5, A 48, 54, 51, 51, 58, 54% [23]
 GDP per capita 2016 $713 [38]
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were extracted from the literature and converted for the 
year 2016 using Ethiopia’s gross domestic product (GDP) 
deflator [38]. The total costs considered: target popula-
tion, intervention coverage and intervention unit cost.
Sensitivity analyses
The robustness of the findings were tested by using one-
way sensitivity analyses. Specifically, the value of malaria 
prevalence, case fatality ratio, intervention effectiveness, 
health services utilization, and intervention unit cost 
were varied by ± 20%, one at a time, to evaluate the inter-
ventions impact on the deaths and CHE averted, across 
income quintiles.
Results
Deaths and cases of CHE averted by malaria interventions
Increasing coverage (by 10%) of ACT, LLIN, IRS and 
vaccine among the population at risk would avert 358, 
188, 107 and 38 deaths per year in Ethiopia, respectively. 
The four interventions would also avert 440 (i.e. 10% of 
the baseline CHE), 220 (5%), 125 (3%) and 18 (2%) CHE 
cases annually, respectively. Among the interventions, 
LLIN and ACT would have the largest number of deaths 
averted and CHE cases averted. In addition, ACT and 
LLIN would avert $4,277,000 and $214,000 of OOP 
expenditure, respectively (Table 2).
Distribution of deaths and CHE cases averted by malaria 
intervention
All four interventions would save larger numbers of lives 
among the poor, due to the fact that the poor would face 
a higher malaria prevalence and associated risk factors. 
For example, ACT would avert twice as many deaths in 
the poorest income quintile as compared to the richest 
quintile (Fig. 1). 50% of the deaths averted would be con-
centrated in the poorest two quintiles. The distribution of 
deaths averted (by LLIN, IRS and ACT), from poorest to 
richest quintiles, would be 30, 20, 23, 14 and 13%, respec-
tively. Similarly, the distribution of deaths averted by the 
malaria vaccine would be 30, 22, 21, 16, and 11%, respec-
tively (Fig. 1).
For each intervention, the gradient in private OOP 
expenditures averted would be flat across quintiles 
Table 2 Total government costs, household out-of-pocket (OOP) expenditures averted, deaths averted, and catastrophic 
health expenditure (CHE) cases averted from  universal public finance of  selected malaria interventions at  10% 
incremental coverage, in Ethiopia




Deaths averted Cases 
of CHE 
averted
Artemisinin-based combination 5,721,000 4,277,000 358 440
Long-lasting insecticide-treated bed nets 16,489,000 214,000 188 220
Indoor residual spray 32,644,600 122,000 107 125








Q1 Q2 Q3 Q4 Q5
Income Quintile
Deaths Averted
Artemisinin-based combination treatment (ACT) Long-lasting Insecticidal bed nets












Fig. 1 Distribution of deaths averted by each malaria intervention per income quintile in Ethiopia
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as malaria prevalence would decrease with increas-
ing income, but the probability of seeking malaria care 
would increase as income goes up (Table  3). Therefore, 
the gains in private expenditures would be evenly dis-
tributed across income quintiles. Across the first three 
income quintiles, a greater number of CHE cases would 
be averted and the largest benefits would be among the 
poorest income quintile (Fig. 2).
The annual policy costs of UPF for 10% incremental 
coverage of ACT, LLIN, IRS and vaccine would be $5.7, 
16.5, 32.6, and 5.1 million, respectively. Similarly, due to 
declines in malaria cases through preventive interven-
tions, $241,000, $137,000 and $16,000 of government 
expenditures on malaria treatment would be averted 
annually by LLIN, IRS and malaria vaccine, respectively.
Most of these government savings would be observed 
within quintile one to three and LLINs would contribute 
to more than half of these savings. The rollout of malaria 
vaccines at 10% incremental coverage, under the rou-
tine immunization program in the country, would cost 
around $5 million and avert 38 deaths and reach $17 mil-
lion and avert about 120 deaths with 33% coverage.
Deaths and cases of CHE averted per million spent
The health benefits per $1 million invested on ACT, 
LLIN, IRS, and vaccine interventions would be 63, 11, 
3, and 7 lives, respectively. Similarly, they would reduce 
OOP expenditures by $1,560,000, 13,000, 3700 and 2800, 
respectively; with varying numbers of CHE cases averted 
by income quintile (see Additional file 1: Appendix, Figs. 
S1–S3).
Sensitivity analyses
The results of our univariate sensitivity analyses are 
described in Table 4 (and Additional file 1: Tables S3–S6). 
Generally, the distribution of health gains is highly prone 
to variations in malaria prevalence, case fatality ratio and 
intervention efficacy. The distributions in OOP expen-
ditures averted and CHE cases averted would be more 
sensitive to malaria prevalence, health care utilization, 
Table 3 Out-of-pocket private expenditures averted (in 2016 USD) per  income quintile for  all malaria interventions 
in Ethiopia
Q1; poorest quintile, Q5; richest quintile
Interventions Income group
Q1 Q2 Q3 Q4 Q5
Artemisinin-based combination 966,209 847,472 891,970 789,078 782,701
Long-lasting insecticide-treated bed nets 48,310 42,374 44,598 39,454 39,135
Indoor residual spray 27,537 24,153 25,421 22,489 22,307

























Artemisinin-based combination treatment (ACT) Long-lasting Insecticidal bed nets
Indoor residual spray Malaria Vaccine
Catastrophic health expenditure (CHE) averted
Fig. 2 Distribution of financial risk protection benefits (cases of CHE averted at 10% threshold) for each intervention per income quintile in Ethiopia
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probability of seeking inpatient care, intervention efficacy 
and OOP expenditures.
Discussion
In this paper, the health and financial benefits of UPF for 
malaria interventions were estimated across Ethiopian 
households at all income levels. Overall, all four interven-
tions showed substantial benefits, with ACT and LLIN 
accounting for the larger shares of malaria-related deaths 
and CHE cases averted.
All the interventions showed a greater number of 
deaths averted among the poorest 40% of the popula-
tion, averted similar OOP expenditures across all income 
groups, and relatively higher FRP benefits for the poor-
est 40%. Even if the poor had lower access for care and 
higher baseline malaria risk, for each of the intervention 
greater benefits would go toward the poor. This suggests 
that the malaria interventions analysed in this paper ben-
efit the worse-off and poor populations in remote areas 
of Ethiopia, who suffer the disease risk at most. Given the 
relatively lower malaria burden, the four malaria inter-
ventions would avert fewer deaths annually, as compared 
to, other interventions addressing childhood diarrhoea 
and pneumonia for example [51, 52]. Rapid decline of 
malaria deaths in Ethiopia over the last two decades and 
a relatively lower prevalence were the main reasons [6]. 
Among the four interventions, LLIN and ACT were the 
two strategies with the highest impact on malaria mor-
tality. In contrast, the malaria vaccine would prevent 
the smallest number of deaths averted (i.e. 38 per year) 
as compared to the other interventions. This is largely 
because the vaccine would be relatively less efficacious 
[14, 41]: only 2% of malaria-related child deaths would be 
prevented from the vaccine in this study.
Even though the rich had more access to health ser-
vices and less malaria burden, the private OOP sav-
ings would be similar across all income quintiles. This 
might be due to the fact that the poor and rich are 
Table 4 Sensitivity analyses on  the  impact on  deaths and  catastrophic health expenditure (CHE) cases averted 
when  long-lasting insecticide-treated bed nets (LLIN) input parameters vary across  income quintiles (Q1 = poorest; 
Q5 = richest), (low to high shows when input parameters are decreased or increased by 20%, respectively)
Sensitivity analysis LLIN Q1 Q2 Q3 Q4 Q5
Low High Low High Low High Low High Low High
Prevalence of malaria
 Deaths averted 45 68 30 45 35 53 21 32 20 30
 Private expenditures averted 38,710 58,070 33,900 58,070 36,090 50,850 31,830 54,130 31,810 47,720
 Cases of CHE averted 73 109 42 64 61 92 0 0 0 0
Malaria case fatality ratio
 Deaths averted 46 67 30 45 35 52 21 31 20 30
 Private expenditures averted 48,310 48,310 42,370 42,370 44,600 44,600 39,450 39,450 39,135 39,135
 Cases of CHE averted 91 91 53 53 76 76 0 0 0 0
Health services utilization
 Deaths averted 56 56 38 38 43 43 26 26 25 25
 Private expenditures averted 38,970 58,460 33,450 50,180 35,680 53,520 31,340 47,010 31,620 47,430
 Cases of CHE averted 73 110 42 63 61 91 0 0 0 0
Probability of inpatient visit
 Deaths averted 56 57 37 38 43 44 26 26 25 25
 Private expenditures averted 47,230 49,390 41,750 43,000 43,680 45,500 39,020 39,890 38,660 39,610
 Cases of CHE averted 73 109 42 64 61 91 0 0 0 0
Efficacy
 Deaths averted 45 68 30 45 35 52 21 32 20 30
 Private expenditures averted 38,650 57,970 33,900 50,850 35,680 53,520 31,560 47,350 31,310 46,960
 Cases of CHE averted 73 109 42 64 61 91 0 0 0 0
Cost inputs
 Government costs 2,625,170 3,963,500 2,632,890 3,971,210 2,621,860 3,960,190 2,634,170 3,972,500 2,628,660 3,966,990
OOP outpatient costs
 Deaths averted 56 56 38 38 43 43 26 26 25 25
 Private expenditures averted 39,850 56,770 34,600 50,150 36,680 52,520 32,040 46,860 31,820 46,450
 Cases of CHE averted 91 91 53 53 76 76 0 0 0 0
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spending similar OOP expenditures for malaria care. 
In absolute terms, the gains in private OOP expen-
ditures could be lower as compared to findings from 
other Ethiopian ECEAs [51–53]. This might be due to 
less OOP payments for malaria care as compared to 
the other diseases. As for the FRP benefits, LLIN and 
ACT prevented a higher number of CHE cases, and for 
all interventions, the greatest number of CHE cases 
averted would occur in the poorest income quintile. In 
addition, the annual cost of implementing IRS at a 10% 
incremental coverage for the at-risk population was 
about $33 million, 2 times higher than that of the LLIN 
intervention. This corresponds to more than 16% of 
malaria-related health care spending in Ethiopia [20]. 
Lastly, though ACT, LLIN, IRS, and malaria vaccine are 
critical for malaria control and elimination, these inter-
ventions would need to be combined with other inter-
ventions, such as behavioural change, correct use and 
implementation, to yield full impact.
Nevertheless, the analysis presented here has several 
limitations. First, the disease model was static and did 
not address the dynamics of malaria transmission. Sec-
ond, because of the unavailability of key input param-
eters by socioeconomic group, proxy input parameters 
were used. For example, the percentage who sought 
treatment for fever in the past 2  weeks was used as a 
proxy indicator for seeking malaria care. This might 
have overestimated malaria cases as there are other 
causes of fever among individuals (besides malaria). 
The Ethiopian 2016 DHS, the Malaria indicator survey 
and the ACT malaria consortium guidance on health 
equity analysis use health care utilisation due to fever in 
the past 2 weeks as a proxy for seeking care for malaria 
[9, 34, 35]. Third, due to the lack of disaggregated data, 
constant rates for case fatality ratio, intervention effec-
tiveness, and inpatient cost inputs were assumed across 
quintiles. Fourth, unit costs for the vaccine were not 
specific to Ethiopia. However, despite the limitations, 
the analysis is crucial as the findings could assist poli-
cymakers decide on which health interventions to roll-
out to reduce malaria disease burden affecting 60% of 
the Ethiopian population [9].
The ECEA can also answer some of the equity con-
cerns by providing valuable information on how malaria 
prevention or treatment strategies would decrease both 
malaria burden and financial risk incurred by households 
across various socioeconomic groups in Ethiopia. This 
study shows that malaria interventions could improve 
FRP across all income groups, especially among the bot-
tom income groups in Ethiopia. Furthermore, this analy-
sis can help reorienting malaria interventions to target 
elimination across selected segments of the population, 
especially among the poor.
Conclusions
All four malaria interventions would save more lives 
among the poor than among the rich. Preventing and 
treating malaria provides substantial health benefits and 
FRP, especially among poor Ethiopians. ACT and LLINs 
would generate the largest impact on malaria-related 
deaths averted and FRP benefits. Improving health equity 
and reducing poverty are major objectives of the Sustain-
able Development Goals, and the findings of the study 
presented here would provide insight for policymakers 
on how to prioritize malaria interventions for targeted 
population groups including the poorest.
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1. Introduction  
This appendix describes the assumptions underlying the methodology used, and presents 
supplementary tables, figures, and sensitivity analyses used for the extended cost-effectiveness 
analysis (ECEA) of universal public finance (UPF) of selected malaria preventive and curative 
interventions. The methodology for the four malaria interventions is described under section 2 
and builds on a previous ECEA of malaria vaccine in Zambia [1]. 
 
1.1. Description of model inputs and assumptions for all the interventions  
The population at risk of malaria (about 60% of the total Ethiopian population) is the target 
population for long-lasting insecticide-treated bednets (LLIN) and indoor residual spraying 
(IRS); for artemisinin combination therapy (ACT), the target population is the estimated number 
of annual malaria cases of 2016. For malaria vaccine, the target population is the Ethiopian 2016 
birth cohort (i.e. calculated as a product of crude birth rate by the size of the at-risk population) 
in at-risk areas followed over five years to capture the potential full impact of the vaccine. Each 
target population was evenly distributed across income quintiles for LLIN, IRS and ACT 
interventions. For the vaccine, quintile-specific total fertility rates were applied in order to 
differentiate the number of susceptible infants across income quintiles [2]. 
For each intervention, to distribute the prevalence of malaria for the at-risk population across 
income quintiles, we used the average malaria prevalence across socioeconomic groups with two 





Survey and the proportion of clinical malaria cases (i.e. 0.5%) from Ethiopia’s Federal Ministry 
of Health (FMOH) malaria review report [3,4].  
In order to calculate malaria prevalence by at-risk population per income quintile, we first 
estimated the relative risk of malaria prevalence by income quintile, and then multiplied it with 
the prevalence of malaria for the at-risk population. The distribution of malaria cases into 
outpatient and inpatient categories followed the share of malaria-related hospital admissions and 
was further disaggregated by income quintile with the distribution of malaria prevalence across 
income quintiles [5,6].    
Case fatality ratios (CFR) for both outpatient and inpatient cases were extracted from the World 
Health Organization (WHO) 2015 and 2016 malaria reports, which were assumed to be similar 
across quintiles [7,8]. Then, for all the interventions (except vaccine), we distributed the baseline 
malaria-related deaths by income quintile through the product of outpatient and inpatient CFR by 
the number of outpatient and inpatient malaria cases, respectively.  
Regarding malaria vaccine, at baseline, among the total malaria deaths, 48% of deaths would 
occur among under-five children [9]. The total number of malaria deaths was multiplied by this 
proportion in order to obtain the number of malaria deaths among under-five children [8,9]. 
Furthermore, malaria deaths were disaggregated by age group, as vaccine efficacy would wane 
with time since vaccination [8,9]. We used proxy measures (prevalence, treatment coverage, 
efficacy and child mortality) to distribute the malaria-related deaths by income quintile [10]. We 





 , (1) 
where 5𝑞08 is under-five mortality in income quintile j, 𝑎𝐶𝑂𝑉8	is	malaria treatment coverage in 
income group j as provided by EDHS 2016 [2], and 𝐸𝑓𝑓 is treatment effectiveness (assumed 
constant across quintiles for simplicity) [11]. The risk index in equation (1) (i.e. 𝑅C) is estimated 
as an average of three proxy measures: probability of being infected with malaria, malaria 
treatment seeking and a proxy for the relative probability of dying from childhood illness. This 
approach enables us to distribute the baseline child deaths due to malaria in each quintile. In 





the five-year time horizon: E(t) = 𝑒'	𝑒𝑥𝑝	
J+KL(M)∗(OPOQ)R
SR
T, where E0 is initial efficacy against 
infection (91.1% following third dose), L is half-life protection, K is the decay shape, and (𝑡 −
𝑡') is the time since vaccination [12]. The birth cohort would receive three vaccine doses over 6, 
7.5 and 9 months, where vaccine would offer protection starting at age 9 months. UPF would 
yield a 10% incremental coverage across quintiles for all four interventions. 
 
2. ECEA of malaria interventions  
For the three preventive (LLIN, IRS and vaccine) and one curative (ACT) malaria intervention, 
we divide the population into five income groups j, and we denote 𝑦8  the average individual 
consumption expenditures per income quintile. 𝑝XL,8 denotes the proportion of inpatient malaria 
cases, and 𝑝Z[\,8 denotes the proportion of outpatient malaria cases in income quintile j ; and 
health care utilization is denoted 𝑢8 . 𝑂𝑂𝑃XL,8 are the OOP costs of inpatient visit for malaria, and 
𝑂𝑂𝑃Z[\,8 are the OOP costs of outpatient visit for malaria among income group j ; 𝑂𝑂𝑃\Z\,K,8 is 
the total OOP costs in income quintile j. 𝐶XL,_Z`,8	and  𝐶Z[\,_Z`,8 are the government costs for 
inpatient and outpatient visit for malaria disease treatment in income group j. The intervention 
has an effectiveness Eff; the incremental coverage achieved by the program is		𝐶𝑜𝑣8.  
 
2.1. Estimation of health benefits (i.e. deaths averted) 
The number of deaths averted by the intervention in income group j was expressed with a simple 
static model: 
𝐷,`,8 =	)Eff	 ∗ 	𝐶𝑜𝑣8 ∗ 	𝐷82               ,                        (2) 
where 𝐷8 is the annual number of malaria-related deaths (among under-fives or among all age 
groups) in income quintile j  before the program, and 𝐶𝑜𝑣8 is incremental coverage. 
 
2.2. Consequences for household expenditures  
We estimated the private expenditures averted in each income quintile j for both preventive 
interventions (vaccine, LLIN, IRS) and curative interventions (ACT) potentially rolled out in 
Ethiopia. For preventive interventions, the private expenditures averted by public finance in each 
income quintile j would be computed as: 





where 𝑛8 is the annual number of malaria cases (among under-fives or among all age groups) in 
income quintile j before the program. 
For curative interventions (i.e. ACT), the private expenditures averted by publicly finance in 
each income quintile j would be computed as: 
PE,`,8 = 𝑢8 ∗ [𝑝XL,8 ∗ 𝑂𝑂𝑃XL,8 + 𝑝Z[\,8 ∗ 𝑂𝑂𝑃Z[\,8] ∗ 𝑛8				,    (4) 
where 𝑛8 is the annual number of malaria cases (among under-fives or among all age groups) in 
income quintile j before the program, as before-the-program out-of-pocket (OOP) costs are 
removed by public finance. 
 
	2.3. Estimation of financial risk protection benefits    
A case of catastrophic health expenditure (CHE) before intervention (𝐶𝐻𝐸') is counted when 
OOP spending for malaria care (𝑂𝑂𝑃XL,8 or 𝑂𝑂𝑃Z[\,8 above) is higher than a specified threshold 
(Th =10%) defined in comparison with consumption expenditures per quintile (i.e. yj). Then, 
𝐶𝐻𝐸'   among those who utilized care occur when 𝑂𝑂𝑃XL,8	or 𝑂𝑂𝑃Z[\,8	> Th* yj.  
For preventive interventions (vaccine, IRS, LLIN), the introduction of public finance would 
avert the following number of CHE cases per income quintile j: 
𝐶𝐻𝐸,`,8 = 𝐶𝑜𝑣8 	∗ 	Eff	 ∗ 	𝐶𝐻𝐸'          .        (5) 
For curative interventions (ACT), the introduction of public finance would avert the following 
number of CHE cases per income quintile: 𝐶𝑜𝑣8 	∗ 	𝐶𝐻𝐸' .         
Cases of CHE were estimated using either a threshold of annual income or a capacity to pay 
approach (Table S1). For capacity to pay, we extracted the proportion of food expenditure (FEj) 
per income quintile j. Then, we calculated the absolute value of subsistence expenditure (SEj) in 
quintile j as SEj = (1- FEj)*yj. Capacity to pay was calculated as yj – SEj [13,14]. 
 
2.4. Quantification of the total costs of the program  
From the government perspective, the total costs incurred for the vaccine program are, per 
income quintile: 
        𝑇𝐶/,l,8 = 𝐶𝑜𝑣8 ∗ 𝐶`,l ∗ 𝑃𝑜𝑝𝑗       ,      (6)   





where 𝐶`,l stands for both the costs of the vaccine (3 doses) and program implementation, 
𝐶𝑜𝑣8 is vaccine coverage per quintile, and 𝑃𝑜𝑝𝑗 is the target population per quintile. The 
healthcare costs of malaria treatment averted by vaccine for the government (per quintile j) are:  
 𝑇𝐶n-,8 = Eff ∗ 𝐶𝑜𝑣8 ∗	𝑢𝑗 ∗ [(	𝑝XL,8 ∗ 𝐶XL,_Z`,8 	+ 𝑝Z[\,8 ∗ 𝐶Z[\,_Z`,8)] ∗ 𝑛8	 ,   (7)                      
where 𝑛8 is the annual number of malaria cases (among under-fives or among all age groups) in 
income group j before program. Hence, from the government perspective, the net incremental 
costs incurred are:    
             𝑇𝐶 = 𝑇𝐶/,l,8 − 𝑇𝐶n-,opq`,8                          .     (8) 
From the government perspective, the total incremental costs incurred for LLIN/IRS program 
are, per income quintile: 
𝑇𝐶opq`,8 = 𝐶𝑜𝑣8 ∗ 𝑐_Z` ∗ 𝑃𝑜𝑝𝑗              ,    (9) 
where cgov is the unit costs of LLIN/IRS intervention, 𝑃𝑜𝑝𝑗 is the target population per quintile, 
and 𝐶𝑜𝑣8 is incremental coverage (10%). The total LLIN cost is adjusted by one half, 
corresponding to one net per two people within a household.  
The healthcare costs of malaria treatment averted by LLIN/IRS intervention for the 
government (per quintile j) are:  
 𝑇𝐶n-,opq`,8 = Eff ∗ 𝐶𝑜𝑣8 ∗ 𝑢𝑗 ∗ [(	𝑝XL,8 ∗ 𝐶XL,_Z`,8 + 𝑝Z[\,8 ∗ 𝐶Z[\,_Z`,8)] ∗ 𝑛8	     ,   (10)                   
where  𝑛8 is the annual number of malaria cases (among under-fives or among all age groups) in 
income quintile j before program, and 𝐶𝑜𝑣8 is incremental coverage (10%). Hence, from the 
government perspective, the net incremental costs incurred are:    
             𝑇𝐶 = 𝑇𝐶opq`,8 − 𝑇𝐶n-,opq`,8                      .     (10) 
From the government perspective, for ACT, the incremental government expenditure per quintile 
are given by: 
𝑇𝐶l[pq,8 = 𝐶𝑜𝑣8 ∗ 𝑛8 ∗ 	 )𝑝XL,8 ∗ 𝐶XL,_Z`,8 + 𝑝Z[\,8 ∗ 𝐶Z[\,_Z`,82 + )	𝑝XL,8 ∗ 𝑂𝑂𝑃XL,8 + 𝑝Z[\,8 ∗
𝑂𝑂𝑃Z[\,82 ∗ 𝑢8 ∗ 𝑛8	      ,    (11) 
where 𝑛8 is the annual number of malaria cases (among under-fives or among all age groups) in 
income quintile j before program; 𝑢8 is healthcare utilization before program, and 𝐶𝑜𝑣8 is the 






3. Additional tables and figures 
  
Table S1. Cases of catastrophic health expenditure averted, for public finance of malaria 
interventions after a 10% increase in coverage, in Ethiopia. 




Cases of catastrophic 
health expenditures 
averted (40% 
capacity to pay) 
Artemisinin-based combination  440 182 
Long-lasting insecticide-treated bednets 220 91 
Indoor residual spray 125 52 
Malaria vaccine  18 9 
 
Annual parasite incidence (API) corresponds to the total number of positive confirmed cases per 
1000 population per year [15]. The API level for a specific geographic area is used to classify the 
districts into control (i.e. API ≥ 10), optimization (i.e. 5 < API < 10), pre-elimination and 
elimination phases (i.e. 0 < API < 5). As shown in Table S2, the health impact of all malaria 
interventions in the control phase would be substantial, however in other phases selected 
interventions would yield more benefit. 
 
Table S2: Extended cost-effectiveness analysis results for each intervention per malaria 
transmission intensity: deaths averted, out-of-pocket (OOP) expenditures averted, and cases of 
catastrophic health expenditures (CHE) averted. 
Intervention  Outcome  0<API< 5 (Pre-
elimination 
/Elimination) 
5 ≥ API < 10 
(Optimization 
phase) 
API  ≥ 10 
(Control 
phase) 
LLINs Deaths averted 4 14 102 
OOP expenditures averted 3,696 16,262 106,213 
Cases of CHE averted 7 20 179 
IRS Deaths averted 2 8 58 
OOP expenditures averted 2,107 9,269 60,541 
Cases of CHE averted 4 11 102 
Malaria 
vaccine 
Deaths averted 0 1 10 
OOP expenditures averted 300 1,321 8,627 
Cases of CHE averted 2 10 88 
ACT Deaths averted 8 27 194 
OOP expenditures averted 73,913  325,232  2,124,255  









Figure S1. Distribution of deaths averted and financial risk protection afforded per US$1 million 






Figure S2. Distribution of financial risk protection afforded per US$1 million government 
expenditures for each of malaria intervention per income quintile (Q1 is poorest and Q5 is 





















Malaria deaths averted per US$1 million spent
Artemisinin-based combination treatment (ACT) Long-lasting Insecticidal bed nets












Catastrophic costs averted per US$1 million spent 
Artemisinin-based combination treatment (ACT) Long-lasting Insecticidal bed nets





Figure S3. Private expenditure averted (in USD) and malaria deaths averted, per $1 million net 
government expenditures, per income quintile, by malaria preventive intervention in Ethiopia. 































































































4. Sensitivity analyses 
Table S3: Sensitivity analysis of deaths averted and cases of catastrophic health expenditures (CHE) when IRS model 
input parameters were varied across income quintiles (Q1 = poorest; Q5 = richest), (low to high shows when model input 
parameters are decreased/increased, respectively).  
Sensitivity analysis IRS Q1 Q2 Q3 Q4 Q5 
Low High Low High Low High Low High Low High 
Prevalence of malaria 
Deaths averted 26 39 17 26 20 30 12 18 12 17 
Private  
expenditures averted ($1,000s) 
22  33  19  29 21 31 18  27  18 27 
CHE cases averted 42 62 24 36 35 52 0 0 0 0 
Malaria case fatality ratio 
Death averted 26 38 17 26 20 29 12 18 11 17 
Private  
expenditures averted ($1,000s) 
28 28 24 24  25  25  22  22  22  22  
CHE cases averted 52 52 30 30 43 43 0 0 0 0 
Health care use 
Death averted 32 32 21 21 25 25 15 15 14 14 
Private  
expenditures averted ($1,000s) 
22  33  19  29 20  31 18 27 18 27 
CHE cases averted 42 63 24 36 35 52 0 0 0 0 
Probability of inpatient visit 
Death averted 32 32 21 22 25 25 15 15 14 14 
Private  
expenditures averted ($1,000s) 
33 34 28  29  30 31  27 27 27 27  
CHE cases averted 50 75 29 43 41 62 0 0 0 0 
Efficacy 
Death averted 26 38 17 26 20 30 12 18 11 17 
Private  
expenditures averted ($1,000s) 
22 33  19  29 20  31 18 27 18 27  
CHE cases averted 42 62 24 36 35 52 0 0 0 0 
Cost inputs /IRS 
Government costs  
for the policy ($1,000s) 
5216  7838 5220 7842 5214 7836 5221 7843 5218  7840 
OOP outpatient /IRS 
Death averted 32 32 21 21 25 25 15 15 14 14 
Private  
expenditures averted ($1,000s) 
23 32 20 29 21 30 19 27 18 26 






Table S4: Sensitivity analysis of deaths averted and cases of catastrophic health expenditures (CHE) averted when 
malaria vaccine model input parameters were varied across income quintiles (Q1 = poorest; Q5 = richest), (low to 
high shows when the model input parameters are decreased or increased, respectively). 
Sensitivity analysis vaccine Q1 Q2 Q3 Q4 Q5 
Low High Low High Low High Low High Low High 
Prevalence of malaria 
Deaths averted 9 11 7 8 6 8 5 6 3 4 
Private expenditures averted 3 900 5 850 2 930 4 390 2 040 3 070 1 820 2 730 972 1 460 
CHE cases averted 7 11 4 5 3 5 0 0 0 0 
Malaria case fatality ratio 
Deaths averted 9 11 7 8 6 8 5 6 3 4 
Private expenditures averted 4 880 4 880 3 660 3 660 2 560 2 560 2 280 2 280 1 210 1 210 
CHE cases averted 9 9 5 5 4 4 0 0 0 0 
Health care use 
Deaths averted 11 11 8 8 8 8 6 6 4 4 
Private expenditures averted 3 940 5 900 2 890 4 330 2 050 3 070 1 810 2 710 981 1 470 
CHE cases averted 5 14 2 7 2 7 0 0 0 0 
Probability of inpatient visit 
Deaths averted 11 11 8 8 8 8 6 6 4 4 
Private expenditures averted 4 770 4 990 3 610 3 710 2 500 2 610 2 250 2 300 1 200 1 230 
CHE cases averted 7 11 4 5 3 5 0 0 0 0 
Efficacy 
Death averted 9 14 7 10 6 10 5 7 3 5 
Private expenditures averted 3 900 5 850 2 930 4 390 2 050 3 070 1 820 2 730 970 1 460 
CHE cases averted 7 11 4 5 3 5 0 0 0 0 
Cost inputs /vaccine 






















OOP outpatient /vaccine 
Deaths averted 11 11 8 8 8 8 6 6 4 4 
Private expenditures averted 4 020 5 730 2 990 4 330 2 100 3 010 1 850 2 710 990 1 440 











Table S5: Sensitivity analysis of death averted and cases of catastrophic health expenditures (CHE) averted when 
ACT model input parameters were varied across income quintiles (Q1 = poorest; Q5 = richest), (low to high shows 
when the model input parameters are decreased or increased, respectively). 
Sensitivity analysis ACT  Q1 Q2 Q3 Q4 Q5 
Low High Low High Low High Low High Low High 
Prevalence of malaria 
Deaths averted 86 128 57 86 67 100 40 60 38 58 
Private expenditures averted 
($1,000s) 
774 1161 678 10167 722 10823 6367 955 6367 954 
Cases of CHE averted 146 219 85 127 123 184 0 0 0 0 
Malaria case fatality ratio 
Deaths averted 86 127 58 85 66 98 40 60 38 57 
Private expenditures averted 
($1,000s) 
966  966  847 847 892 892 789 789 783 783 
Cases CHE averted 182 182 106 106 152 152 0 0 0 0 
Health care use 
Deaths averted 107 107 71 71 82 82 50 50 47 47 
Private expenditures averted 
($1,000s) 
779 1169 669  1004 714 1070 627 940 632 949 
Cases CHE averted 147 220 84 125 121 182 0 0 0 0 
Probability of inpatient visit 
Deaths averted 106 108 71 72 82 83 50 50 47 47 
Private expenditures averted 
($1,000s) 
945 988 835 860  874  910 78 798 773 792 
Cases of CHE averted 146 219 85 127 121 182 0 0 0 0 
Efficacy 
Deaths averted 86 113 57 75 66 87 40 53 38 50 
Private expenditures averted 
($1,000s) 
966  966 847 847 892 892 789  789  783 783 
Cases of CHE averted 182 182 106 106 152 152 0 0 0 0 
Cost inputs /ACT/ 
Government costs for  
the treatment (outpatient cost 
varied) ($1,000s) 
1316 1479 1079 1189 1160 1286  950 1028 935 1009 
Government costs for  
the treatment (inpatient cost 
varied) ($1,000s) 
1394  144 1133 1138 1221  1227 989 991 92 974 
OOP outpatient /ACT/ 
Deaths averted 107 107 71 71 82 82 50 50 47 47 
Private expenditures averted 
($1,000s) 
797 1135  692 1003 734 1050  641 937   636  929  









Table S6: Sensitivity analysis of deaths averted when all deaths occurring in the general population is assumed to 
occur in population at risk (i.e. high case scenario, 5,000 and base case scenario, 3,767) at baseline. 
Sensitivity 
analysis 
Intervention Scenario Average Q1 Q2 Q3 Q4 Q5 
ACT Base case 358 107 71 82 50 47 
High case 475 141 95 109 67 63 
LLIN Base case 188 56 38 43 26 25 
High case 250 74 50 57 35 33 
IRS Base case 107 32 21 25 15 14 
High case 143 42 28 33 20 19 
Vaccine 
Base case 38 11 8 8 6 4 
High case 51 15 11 11 8 6 
As shown in the above table if all malaria related deaths were attributed to population at risk, the death averted 
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Tool to estimate patients’ costs 
 
 
Questionnaire number:             ___________ 
Patient registration number in facility unit TB/MDR TB register :   ____________ 
Date of Interview 
(dd/mm/yy) 
      Zone Woreda 





      
Type of Facility 
(Circle) 
 1. Health Centre                       2. Primary/General/Specialized Hospital    
 3. Private Health facility (clinics, hospital)       4.Other (specify)  _________ 
Informed consent:  
Good Morning/Good Afternoon. My name is _________________. I am working for a research 
team from University of Bergen, Department of Global Public Health and Primary Care. We are 
conducting a study on “Cost of tuberculosis to patients and their family during pre-treatment and 
treatment period”. The study would help to estimate the economic cost of tuberculosis at patient 
and household level, which in turn inform the design of appropriate strategies to address the 
problem by health policy decision makers both at the local and national level. 
It is important for you to understand that your participation in this study is completely voluntary. 
We would be really grateful if you would agree to participate in this study as your response is very 
crucial to look at the cost of tuberculosis, but you have full right not to participate in this study. If 
you decline, there will be no consequence for you and you will receive whatever care and treatment 
you need at the health facility as usual. And also, there is no payment or reward for your 
participation in this study.   
If you choose to participate in this study you need to know that you may withdraw from the study 
at any stage without giving any explanation for your withdrawal. We would like to assure you that 
your personal identifications will not be written on the questionnaire and your answers will be kept 
confidential. In addition, socio-demographic and clinical information will be gathered from your 
records and will be kept strictly confidential. At some point I will ask you about your personal 
income and the income of your household. We will NOT provide this information to any authorities 
and your response will be kept confidential, also not after the end of the study. 
The interview will take 30 minutes.  
If you want to ask questions for clarification about the study later on; you can contact Mr. Lelisa 
Fekadu, by phone numbers 0910-102673 and Dr. Getachew addis, by phone numbers 0944 123110. 
Do you want to participate? (Circle)   Yes   /   No 
If Yes: Thank you!      If No: Is there a reason why not?    







Patient Information (to be filled in by Interviewer with the help of patient interview and register; fill in 
also if interview is refused for non-response analysis ),  (Circle and fill response)    
1. Gender                                1. Male                           2. Female 
2. Age of the patient:  ___________ years 
3. What is the highest level of 
education did you complete? 
 1. Illiterate            2. Read and write                3. Primary              
 4. Secondary         5. Diploma/certificate        6.  First degree 
and above                     7.  Other (specify)___________________ 
4. Current Marital Status 
1. Single                     2. Married/Living together        
3. Divorced                4. Separated                    5. Widowed 
5. Occupation   
  
 
1. Civil Servant           2.Housewife                        3. Farmer  
4. Laborer                   5.Trader/Merchant              6. Housemaid 
7. Student                8. No occupation/dependent on household 
9. Other (Specify) ____________ 
6. Place of residence 
1. Urban                   2. Rural                       
3. Pastoral                4. Other (specify) ____________ 
7. Type of TB or DR TB  
1. Pulmonary, bacteriologically confirmed-TB 
2. Pulmonary, clinically diagnosed TB 
3. Extra-pulmonary TB 
4. Pulmonary, bacteriologically confirmed  MDR-TB 
5. Pulmonary, clinically diagnosed MDR-TB 
6. Extra-pulmonary  MDR-TB 
7. Pre- XDR/XDR TB 
8. Date of TB/DR TB diagnosis (dd/mm/yy)    _____/_____/_____ 
9. Type of bacteriological TB test 
used for diagnosis and its result 
1. Smear microscopy: not done, done-positive, done negative 
2. X-pert MTB/RIF: not done, done-positive, done negative 
3. Culture: not done, done-positive, done negative 
10. Place of TB/DR TB diagnosis 
1. Public Hospital      2. Health Center       3. Private hospital/clinic                             
4. NGO clinic            5. Other (Specify)__________________ 
11. Start date of current TB/DR TB 
treatment (dd/mm/yy)    _____/_____/_____ 
12. Currently in intensive or 




2. Continuation phase, _____weeks of phase completed 
13. Total duration of planned 
treatment  ________months intensive________months continuation 
14. HIV status  
(Only if indicated on register) 
1. HIV-Positive on ART   2. HIV-Positive not on ART                                 
3. Negative                     4. Not tested/Unknown         5. declined 
15. Interviewee 
1. Patient    2. DOT supporter / guardian  
3.Other(specify)________ 
NB: If the patient is under 15 years – for children, all questions concerning costs, time spent, 
income, and income loss before and during TB treatment concern cost for the guardian. 
Previous Treatment (for TB  or DR TB re-treatment cases only) 
16. a) Have you ever had TB treatment before? 
 If No, go to 17. 
1. Yes (mm/yy treatment ended) 
_____/_____          
2. No   
If yes, how many times __________ 
b) If Yes: Have you completed your last/recent TB 
treatment?   
  1. Yes                   2. No 
c) If No: why not? 
1. Lack of money for treatment costs          2. Drug side effects                   3. Moved               
4. Distance to facility                                  5. Other (specify): _________________________ 
Pre-diagnostic and diagnostic costs 
17. What symptoms did you experience that led you to seek treatment for your current illness? How 
long did you experience these symptoms before you went to seek treatment? 
  
i. Cough               1. Yes   ______ day’s     2. No       ii. Night sweats    1. Yes ________ days    2. No   
iii. Coughing up blood 1. Yes ______days      2.  No   iv.Weight loss   1.  Yes _________ days       2. No 
v. Other (specify)      1. Yes   ___________________, _______ days         2. No   
18. Time interval it takes between the date of presentation to a health care provider and the 
initiation of anti-TB treatment _________________ days   
19. Besides yourself, does anyone else of your household receive treatment for TB?  If yes, fill 
separate questionnaire for the household member affected with TB at the end. [Link the household 
with this patient questionnaire with similar code]. 
                                                           1. Yes                              2. No 
20.  Which of the following types of facilities did you seek care or advice for symptoms of the 
current illness before TB/DR TB treatment?  Check all that apply and Circle first place of visit.  
 
 1. Health post           2. Health Centre                   3. Primary/General/Specialized Hospital     
 4. Private Health facility (clinics, hospital)         5. Pharmacy, drug store     









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cost during current TB/MDR-TB treatment   
NB: This period for MDR TB starts when the patient is put on effective MDR TB regimen, period before this 
will be captured on ‘Pre-diagnostic and diagnostic Costs’ above 
22. Where do you take your TB drugs (DOT) and how many times do you go to the health facility for 
these service per month? 
(If the patient has visited two different DOT places, tick the current place and report costs only for that place) 
22a) During intensive phase  
1. Health center / hospital ________times per month    2. Home       
3. Health post _______times per month       
4. Work place_________times per month    5. Other_______ 
If the patient is in intensive phase now and DOT is at home or self-administered, go to 27. 
 
22b) During continuation phase (Please skip to 23 if the patient is currently in intensive phase) 
 
1. Health center / hospital ________times per month    2. Home       
3. Health post _______times per month       
4. Work place_________times per month    5. Other_______ 
 If the patient is in continuation phase now and DOT is at home or self-administered, go to 27.         
23.  From your home to the DOT place, how long does it take you to get there (one way)  
____ hours walking         ______ hours with transport       other:__________ 
24. How long does one of these visits take on average, including time on the road and waiting time (total 
turnaround time)? ____________Hours 
25. What was the cost of transport (return from health facility, other travel costs) for the last DOT 
visit, in total for you? ______________ 
26. How much did you spend on food and drinks for the last DOT visit (on the road, while waiting, 
lunch etc.), in total for you?   __________ If No, go to 27 




Filled if household member picks up drugs for either bringing to DOT provider (e.g. family member, DOT at 
home) or self-administered treatment. 
27. How often do you travel to the health facility / health post for picking up your TB drugs? 
      ______Times / month 
28.  How long does it take you to get there (one way)  
____ hours walking         ______ hours with transport       other:__________ 
29. How long does one of these visits take on average, including time on the road and waiting time (total 
turnaround time)? __________hours 
30. What was the cost of transport (return from health facility, other travel costs) last time you picked 
up drugs, in total for you? ____________   
31. How much did you spend on food and drinks for last time you picked up drugs (on the road, while 
waiting, lunch etc.), in total for you?  ______________ If No, go to 32. 
32. a) Do you have to pay administration fees when picking up your TB drugs?    1. Yes        2. No 
    If No, go to 33.             b) If yes, how much?  __________ 
 
Cost related to medical follow-up (see the doctor or nurse, have tests, check-up, visit for side-effect, doesn’t 
include  DOT visits or visits to pick up drugs) 
33. a) Did you ever have to go to the health facility in addition to your 
regular visits for TB-related medical follow-up visits since the 
beginning of treatment? If No, go to 34.  
 
    b) If yes, how many times have you made visit so far? 
 
    c) If yes, did you have to pay any additional costs any time during 
the entire period? 
    d) If so, what kind of costs and how much?      
Administrative  fees_______   Sputum test  _______ X-ray______  TB 
Drugs ______ Other Drugs______ transport/(return)________ 
Other(specify)__________ 










e) How long does the last medical outpatient visit take on average, including time on the road,   



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































37. a) Does any family/friend/DOT supporter accompany you on any visits 
or go in your place (i.e. pre-diagnosis/diagnosis visits, DOT visit, visit to pick 
up drugs, medical follow-up visits and hospitalization) to health facility? If 
No, go to 38. 
1. Yes       2. No 
b) If yes, on how many visits has your family/friend/DOT supporter 
accompanied you or gone in your place? Record pre-diagnosis/diagnosis 
visits and treatment visits separately 
Pre-diagnosis/diagnosis costs per visit including hospitalization during this 
period:  
Transport ________ Food __________  Accommodation ________ Total 
pre/diag: _______ 
Costs during treatment per visit (i.e. treatment visit, medical follow-up visits and 
hospitalization):  








If hospitalized, how many 
days did he/she stay with 
you, while in health 
facility? ___________ 
c) How much does your friend/family/DOT supporter earn per day?   
 
1. ___________ 
2. Doesn’t earn 
d) Did anyone in your household drop out of school or interrupt schooling 
to assist the household because of your TB illness? 
1. Yes, _________ 
persons,  
Duration of drop out 
_________ 
2. No 
e) Does someone stay home specifically to take care of you?  If No, go to 38.    1. Yes                2. No 
f) If Yes: for how long?   ________________days 
g) Did they quit their income-earning job to stay home and care for you?        1. Yes                2. No 
 
     Other Costs Food Supplements 
38. a) Do you buy any supplements for your diet because of the TB illness, 
for example vitamins, meat, energy drinks, soft drinks, fruits? If No, go to 
39. 
      1. Yes          2. No 
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    b)  How much did you spend on these items in the last month approximately? ____________ 
 
     Other Illnesses 
39.  a) Do you have any chronic illness for which you are receiving 
treatment? If No, go to 40. 
b) If yes: which?  _______________________________ 
      1. Yes          2. No 
c) Are there any additional costs for you because of this other illness 
besides the costs that you have already mentioned? 
      1. Yes          2. No 
d) If yes: How much are these additional costs on average per month? 
Tests:_______________ Drugs: ___________Transport:______________  
Food: _______________ Other: ___________ 
Total:    ____________ 
 
Coping Costs (filled for DOT, Pick up, medical follow up, guardian, food supplement, other illness section) 
40.  How did you finance/cover the expenses for these visits 
Circle relevant source(s) and state the amount. Multiple answers are possible. 




2.Own saving (cash or bank deposit) _________ 
3.Assets/livestock  sale______ 
4.Borrowed_________ 
5. Insurance (CBHI)________ 
6. Other(specify) _______________ 





2. Own saving (cash or bank deposit) _________ 
3.Assets/livestock  sale______ 
4.Borrowed_________ 
5. Insurance (CBHI)________ 
6. Other(specify) _______________ 
c) In the continuation treatment phase? Apply for 
patients in continuation phase 
 
1.Current income________ 
2. Own saving (cash or bank deposit) _________ 
3.Assets/livestock  sale______ 
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4.Borrowed_________ 
5. Insurance (CBHI)________ 
6. Other(specify) _______________ 
d) In total (In case the detail by treatment phase is not 
available, request the total) 
1.Current income________ 
2. Own saving (cash or bank deposit) _________ 
3.Assets/livestock  sale______ 
4.Borrowed_________ 
5. Insurance (CBHI)________ 
6. Other(specify) _______________ 
41. Has the TB illness affected your social or private 
life in any way? (More than one answer is allowed) 
1. No 
2. Food insecurity 
3. Divorce or Separated from 
spouse/partner 
4. Loss of Job 
5. Social exclusion 
6. Other(specify) _______________ 
 
 Household expenditures and income 
42. On average how much does your household spend on the following items? 
a. Food and supplies (e.g. raw ingredients, any semi-cooked/cooked/food/snack/sweets bought, alcohol, 
cigarette etc.). Per month  ____________ 
Raw ingredients :- CEREALS (Enjera (teff), Wheat, Barley, Maize, Sorghum, Millet), TUBERS and STEMS (Potato, 
Kocho/ Bula), Fruits and Vegetables (including relish and leaves), others (Meat, Milk, Cheese, Eggs, Sugar, Salt, Pasta, 
Macaroni and Biscuits, Oils/fats/butter) STIMULANTS (Coffee,chat,tea) etc.  
b. Do you consume any of the home produced food or goods (eg. Teff, wheat, maize, sorgum, fruits, 
vegetables, milk, milk products etc.)   1. Yes     2. No      If yes, specify 
____________________________ 
c. If you were to buy the same food from the market, how much would it cost on an average per month? 
________________ 
d. Utilities (electricity, water, telephone (both landline and mobile) Per month  ___________ 
e. House/land/shop  rent per month: ________ 
f. Soup/OMO, firewood, candles, charcoal, kerosene per month. ________ 
g. Education (School for children or self) per term (3 months) _______ 
h. Health care (for the household) per term (3 months) _______ 
i. Clothes/shoes per year  _______ 
j. Transport cost per month _________ 
k. Goods and utensils (kitchen equipment (cooking pots, linens (sheets, towels, blankets) furniture etc.) 
household use. Per year _______ 
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l. Replacements of household appliances (stove, inverter, fridge, food processor, lanterns, fuel and 
maintenance of car etc.) Per year _________ 
m. Other cost per year (describe e.g. contributions, Edir, recreations) ____________ 
43. How much do you estimate was the average income of your household per month BEFORE the TB 
illness?   
1. Income patient: ________ 2. Income of head household _______ 3. Income of household ________ 
 4. Welfare payments and government assistance _________ 5. Other:________ 6.Total: __________ 
44.    How much do you estimate is the average income of your household per month NOW?   
1. Income patient: ________2. Income of head household _______ 3. Income of household ________ 
 4. Welfare payments and government assistance _________ 5. Other:________ 6.Total: __________ 
45. a) Do you have any other source of income [house rent, shop, restaurants, dairy, agriculture, rental 
from agricultural land and animals, car, money sent from relative etc?]  
                                                 1. Yes                  2. No   
 45b) If yes, what is the six month average income from these sources ____________ 
46. a) Do you receive per month in allowances or gratuities, cash transfer including in-kind payments 
such as uniform, housing, food item, and transport that were not included in the salary you just 
reported?  
                                                1. Yes                  2. No  
46b) If yes, what is the average allowance from these sources per month ____________? 
47. Approximately how many working days of income have you lost due to your TB illness overall? 
_________working days before diagnosis of TB (but due to TB disease) 
_________working days after TB diagnosis 
 
48. Asset and socio-economic indicators  
   A1) What are the main walls made of in the dwelling where your household lives?  
             1.   No walls                                     2. Bamboo/wood with mud                       3. Cement 
             4.   Corrugated iron                          5. Other (Specify) _____________ 
 A2) What is the main material of the roof in the dwelling where your household lives?  
 1. Thatch/leaf                           2. Rustic Mat/Plastic Sheets                 3. Corrugated Iron    
 4. Cement/Concrete                 5. Other (Specify) ___________ 
A3) What is the main material of the floor in the dwelling where your household lives?  
1. mud/dung                         2. Bamboo/reed                 3. Wood planks                     4. Cement                                 
5. Ceramic                            6. Brick tiles                      5. Other (Specify) ___________ 
A4) How many rooms are there in your dwelling? ___________ Number of rooms used for 
Sleeping? ____________ 
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A5) Family size _____________ 
A6) Does this household own any livestock or poultry?                  1. Yes               2. No 
A7) If yes to A6, how many of the following are owned by the household  
 Number of  Goats __________Sheep __________milk cow, oxen, bulls __________ 
Donkey/Horse/Mule_________Camel ________ Chicken or Poultry _________ Other(specify)__________ 
A8) What kind of toilet does most members of your household use?   
1. Flush toilet                   2. Improved pit latrine               3. Public toilet       4. Open field  
5. Not improved toilet      6. Neighbours’                          7. Other (Specify)____________ 
A9) What kind of fuel does your household usually use for cooking? (More than one response is possible)    
           1. Electricity           2. Animal dung               3. Bio-gas                 4. Kerosene             5.Wood   
           6. Coal, lignite, peat                                       7. Charcoal                 8. Other (specify)____________ 
A10) Ask the availability of the following assets 
 1. Is there a radio in the household?                                                     1. Yes               2. No 
 2. Is there a bicycle in the household?                                                  1. Yes               2. No 
 3. Is there a motorbike in the household?                                             1. Yes               2. No 
 4. Is there a car or mini-truck/bajaj in the household?                          1. Yes               2. No 
 5. Is there a cell phone in the household?                                             1. Yes               2. No 
 6. Do you have landline telephone in household?                                1. Yes               2. No 
 7. Is there a refrigerator in the household?                                            1. Yes               2. No 
 8. Is there a television in the household?                                               1. Yes               2. No 
 9. Is there electricity in the household?                                                  1. Yes               2. No 
10. Is there a table in the household?                                                      1. Yes               2. No 
11. Is there a chair in the household?                                                      1. Yes               2. No 
12. Is there a bed in the household?                                                        1. Yes               2. No 
A11) What is the main source of water for drinking for your household?  
 1. Pipeline               2. Public                         3. Protected well             4. Unprotected well  
 5. River                   6. Spring protected        7. Unprotected spring       8. Other (specify) ___________ 
A12) Does any member of household own any agriculture land?       1. Yes               2. No 
If Yes how many hectares do you own? __________________  
 
 13 
49. If the government could provide you with some service to ease the burden of TB on you 
and your household, what would you prefer to have? State options, choose one 
1. Transport vouchers          2. Food vouchers          3. More efficient service          
4. Other (specify): _______________ 
 
We would like to know the cost of the TB illness on the welfare of your household; that is, we 
would like to put a value on the TB illness which includes pain and suffering. 
Therefore, we would like to know how much it would be worth to you if you could avoid 
becoming ill with TB in the first place. Note that we don’t ask what you actually can, but 
what you would be willing pay if you had an unlimited amount of money. 
50. How much would you be willing to pay for not becoming ill with TB in the first place? 
1. Under 500         2. Between 500 and 1000            3. Over 1000             4. Other (specify) ________ 
51. What if the price you had to pay to avoid or prevent TB in the first place is higher than the amount 
you have said above, will you be willing to pay?    1. Yes               2. No 
52.    What if the price you had to pay to avoid or prevent TB in the first place is lower than the amount 
you have said above, will you be willing to pay?     1. Yes               2. No 
53. Say, if due to inflation or an unforeseen economic situation, the price for TB services increased 
tremendously, what is the maximum amount you are very certain to pay bearing in mind your average 
monthly income. ______________ 
54. If you are not willing to pay any amount at all, what might be the possible reasons?  
 1. Do not believe my TB is curable.  
 2. Do not have money   
 3. Do not like the TB services   
 4. My health is not getting any better 
 
Thank you for your cooperation! Is there anything you would like to ask or say? 
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